# Patent

## Title
Solid phase synthesis of oligonucleotides using carbonate protecting groups

## Abstract

The sequences of 5' ESTs derived from mRNAs encoding secreted proteins are disclosed. The 5' ESTs may be to obtain cDNAs and genomic DNAs corresponding to the 5' ESTs. The 5' ESTs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. Upstream regulatory sequences may also be otained using the 5' ESTs. The 5' ESTs may also be used to design expression vectors and secretion vectors.

## Background
The 50,000-100,000 genes scattered along the human chromosomes offer tremendous promise for the understanding, diagnosis, and treatment of human diseases. In addition, probes capable of specifically hybridizing to loci distributed throughout the human genome find applications in the construction of high resolution chromosome maps and in the identification of individuals.

In the past, the characterization of even a single human gene was a painstaking process, requiring years of effort. Recent developments in the areas of cloning vectors, DNA sequencing, and computer technology have merged to greatly accelerate the rate at which human genes can be isolated, sequenced, mapped, and characterized. Cloning vectors such as yeast artificial chromosomes (YACs) and bacterial artificial chromosomes (BACs) are able to accept DNA inserts ranging from 300 to 1000 kilobases (kb) or 100-400 kb in length respectively, thereby facilitating the manipulation and ordering of DNA sequences distributed over great distances on the human chromosomes. Automated DNA sequencing machines permit the rapid sequencing of human genes. Bioinformatics software enables the comparison of nucleic acid and protein sequences, thereby assisting in the characterization of human gene products.

Currently, two different approaches are being pursued for identifying and characterizing the genes distributed along the human genome. In one approach, large fragments of genomic DNA are isolated, cloned, and sequenced. Potential open reading frames in these genomic sequences are identified using bio-informatics software. However, this approach entails sequencing large stretches of human DNA which do not encode proteins in order to find the protein encoding sequences scattered throughout the genome. In addition to requiring extensive sequencing, the bio-informatics software may mischaracterize the genomic sequences obtained. Thus, the software may produce false positives in which non-coding DNA is mischaracterized as coding DNA or false negatives in which coding DNA is mislabeled as non-coding DNA.

An alternative approach takes a more direct route to identifying and characterizing human genes. In this approach, complementary DNAs (cDNAs) are synthesized from isolated messenger RNAs (mRNAs) which encode human proteins. Using this approach, sequencing is only performed on DNA which is derived from protein coding portions of the genome. Often, only short stretches of the cDNAs are sequenced to obtain sequences called expressed sequence tags (ESTs).

In the past, these short EST sequences were often obtained from oligo-dT primed cDNA libraries. Accordingly, they mainly corresponded to the 3' untranslated region of the mRNA. In part, the prevalence of EST sequences derived from the 3' end of the mRNA is a result of the fact that typical techniques for obtaining cDNAs, are not well suited for isolating cDNA sequences derived from the 5' ends of mRNAs. (Adams et al., Nature 377:174, 1996, Hillier et al., Genome Res. 6:807-828, 1996).

In addition, in those reported instances where longer cDNA sequences have been obtained, the reported sequences typically correspond to coding sequences and do not include the full 5' untranslated region of the mRNA from which the cDNA is derived. Such incomplete sequences may not include the first exon of the mRNA, particularly in situations where the first exon is short. Furthermore, they may not include some exons, often short ones, which are located upstream of splicing sites. Thus, there is a need to obtain sequences derived from the 5' ends of mRNAs.

While many sequences derived from human chromosomes have practical applications, approaches based on the identification and characterization of those chromosomal sequences which encode a protein product are particularly relevant to diagnostic and therapeutic uses. Of the 50,000-100,000 protein coding genes, those genes encoding proteins which are secreted from the cell in which they are synthesized, as well as the secreted proteins themselves, are particularly valuable as potential therapeutic agents. Such proteins are often involved in cell to cell communication and may be responsible for producing a clinically relevant response in their target cells.

In fact, several secretory proteins, including tissue plasminogen activator, G-CSF, GM-CSF, erythropoietin, human growth hormone, insulin, interferon-.alpha., interferon-.beta., interferon-.gamma., and interleukin-2, are currently in clinical use. These proteins are used to treat a wide range of conditions, including acute myocardial infarction, acute ischemic stroke, anemia, diabetes, growth hormone deficiency, hepatitis, kidney carcinoma, chemotherapy induced neutropenia and multiple sclerosis. Thus, there is a need for the identification and characterization of secreted proteins.

In addition to being therapeutically useful themselves, secretory proteins include short peptides, called signal peptides, at their amino termini which direct their secretion. These signal peptides are encoded by the signal sequences located at the 5' ends of the coding sequences of genes encoding secreted proteins. Because these signal peptides will direct the extracellular secretion of any protein to which they are operably linked, the signal sequences may be exploited to direct the efficient secretion of any protein by operably linking the signal sequences to a gene encoding the protein for which secretion is desired. This may prove beneficial in gene therapy strategies in which it is desired to deliver a particular gene product to cells other than the cell in which it is produced. Signal sequences encoding signal peptides also find application in simplifying protein purification techniques. In such applications, the extracellular secretion of the desired protein greatly facilitates purification by reducing the number of undesired proteins from which the desired protein must be selected. Thus, there exists a need to identify and characterize the 5' portions of the genes for secretory proteins which encode signal peptides.

Public information on the number of human genes for which the promoters and upstream regulatory regions have been identified and characterized is quite limited. In part, this may be due to the difficulty of isolating such regulatory sequences. Upstream regulatory sequences such as transcription factor binding sites are typically too short to be utilized as probes for isolating promoters from human genomic libraries. Recently, some approaches have been developed to isolate human promoters. One of them consists of making a CpG island library (Cross, S. H. et al., Purification of CpG Islands using a Methylated DNA Binding Column, Nature Genetics 6: 236-244 (1994)). The second consists of isolating human genomic DNA sequences containing SpeI binding sites by the use of SpeI binding protein. (Mortlock et al., Genome Res. 6:327-335, 1996). Both of these approaches have their limits due to a lack of specificity or of comprehensiveness.

The present 5' ESTs may be used to efficiently identify and isolate upstream regulatory regions which control the location, developmental stage, rate, and quantity of protein synthesis, as well as the stability of the mRNA. (Theil, BioFactors 4:87-93, 1993). Once identified and characterized, these regulatory regions may be utilized in gene therapy or protein purification schemes to obtain the desired amount and locations of protein synthesis or to inhibit, reduce, or prevent the synthesis of undesirable gene products.

In addition, the 5' ends of secretory protein genes may include sequences useful as probes for chromosome mapping and the identification of individuals. Thus, there is a need to identify and characterize the sequences upstream of the 5' coding sequences of genes encoding secretory proteins.

The present invention relates to purified, isolated, or recombinant ESTs which include sequences derived from the authentic 5' ends of their corresponding mRNAs. The term "corresponding mRNA" refers to the mRNA which was the template for the cDNA synthesis which produced the 5' EST. These sequences will be referred to hereinafter as "5' ESTs." As used herein, the term "purified" does not require absolute purity; rather, it is intended as a relative definition. Individual 5' EST clones isolated from a cDNA library have been conventionally purified to electrophoretic homogeneity. The sequences obtained from these clones could not be obtained directly either from the library or from total human DNA. The cDNA clones are not naturally occurring as such, but rather are obtained via manipulation of a partially purified naturally occurring substance (messenger RNA). The conversion of mRNA into a cDNA library involves the creation of a synthetic substance (cDNA) and pure individual cDNA clones can be isolated from the synthetic library by clonal selection. Thus, creating a cDNA library from messenger RNA and subsequently isolating individual clones from that library results in an approximately 10.sup.4 -10.sup.6 fold purification of the native message. Purification of starting material or natural material to at least one order of magnitude, preferably two or three orders, and more preferably four or five orders of magnitude is expressly contemplated.

As used herein, the term "isolated" requires that the material be removed from its original environment (e.g., the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide present in a living animal is not isolated, but the same polynucleotide, separated from some or all of the coexisting materials in the natural system, is isolated.

As used herein, the term "recombinant" means that the 5' EST is adjacent to "backbone" nucleic acid to which it is not adjacent in its natural environment. Additionally, to be "enriched" the 5' ESTs will represent 5% or more of the number of nucleic acid inserts in a population of nucleic acid backbone molecules. Backbone molecules according to the present invention include nucleic acids such as expression vectors, self-replicating nucleic acids, viruses, integrating nucleic acids, and other vectors or nucleic acids used to maintain or manipulate a nucleic acid insert of interest. Preferably, the enriched 5' ESTs represent 15% or more of the number of nucleic acid inserts in the population of recombinant backbone molecules. More preferably, the enriched 5' ESTs represent 50% or more of the number of nucleic acid inserts in the population of recombinant backbone molecules. In a highly preferred embodiment, the enriched 5' ESTs represent 90% or more of the number of nucleic acid inserts in the population of recombinant backbone molecules.

"Stringent", "moderate," and "low" nybridization conditions are as defined in Example 29.

Unless otherwise indicated, a "complementary" sequence is fully complementary.

Thus, 5' ESTs in cDNA libraries in which -one or more 5' ESTs make up 5% or more of the number of nucleic acid inserts in the backbone molecules are "enriched recombinant 5' ESTs" as defined herein. Likewise, 5' ESTs in a population of plasmids in which one or more 5' EST of the present invention have been inserted such that they represent 5% or more of the number of inserts in the plasmid backbone are "enriched recombinant 5' ESTs" as defined herein. However, 5' ESTs in cDNA libraries in which 5' ESTs constitute less than 5% of the number of nucleic acid inserts in the population of backbone molecules, such as libraries in which backbone molecules having a 5' EST insert are extremely rare, are not "enriched recombinant 5' ESTs."

In particular, the present invention relates to 5' ESTs which are derived from genes encoding secreted proteins. Such 5' ESTs include nucleic acid sequences, called signal sequences, which encode signal peptides which direct the extracellular secretion of the proteins encoded by the genes from which the 5' ESTs are derived. Generally, the signal peptides are located at the amino termini of secreted proteins.

Secreted proteins are translated by ribosomes associated with the "rough" endoplasmic reticulum. Generally, secreted proteins are co-translationally transferred to the membrane of the endoplasmic reticulum. Association of the ribosome with the endoplasmic reticulum during translation of secreted proteins is mediated by the signal peptide. The signal peptide is typically cleaved following its co-translational entry into the endoplasmic reticulum. After delivery to the endoplasmic reticulum, secreted proteins may proceed through the Golgi apparatus. In the Golgi apparatus, the proteins may undergo post-translational modification before entering secretory vesicles which transport them across the cell membrane.

The 5' ESTs of the present invention have several important applications. For example, they may be used to obtain cDNA clones which include the full protein coding sequences of the corresponding gene products, including the authentic translation start sites derived from the 5' ends of the coding sequences of the mRNAs from which the 5' ESTs are derived. These cDNAs will be referred to hereinafter as "full length cDNAs." These cDNAs may also include DNA derived from mRNA sequences upstream of the translation start site. The full length cDNA sequences may be used to express the proteins corresponding to the 5' ESTs. As discussed above, secreted proteins are therapeutically important. Thus, the proteins expressed from the cDNAs may be useful in treating or controlling a variety of human conditions. The 5' ESTs may also be used to obtain the corresponding genomic DNA. The term "corresponding genomic DNA" refers to the genomic DNA which encodes the mRNA from which the 5' EST was derived.

The 5' ESTs (or cDNAs or genomic DNAs obtained therefrom) may be used in forensic procedures to identify individuals or in diagnostic procedures to identify individuals having genetic diseases resulting from abnormal expression of the genes corresponding to the 5' ESTs. In addition, the present invention is useful for constructing a high resolution map of the human chromosomes.

The present invention also relates to secretion vectors capable of directing the secretion of a protein of interest. Such vectors may be used in gene therapy strategies in which it is desired to produce a gene product in one cell which is to be delivered to another location in the body. Secretion vectors may also facilitate the purification of desired proteins.

The present invention also relates to expression vectors capable of directing the expression of an inserted gene in a desired spatial or temporal manner or at a desired level. Such vectors may include sequences upstream of the 5' ESTs, such as promoters or upstream regulatory sequences.

Finally, the present invention may also be used for gene therapy to control or treat genetic diseases. Signal peptides may also be fused to heterologous proteins to direct their extracellular secretion.

Bacterial clones containing Bluescipt plasmids having inserts containing the 5' ESTs of the present invention (SEQ ID NO:s 38-270 are presently stored at 80.degree. C. in 4% (v/v) glycerol in the inventor's laboratories under the designations listed next to the SEQ ID NOs in Table II). The inserts may be recovered from the deposited materials by growing the appropriate clones on a suitable medium. The Bluescript DNA can then be isolated using plasmid isolation procedures familiar to those skilled in the art such as alkaline lysis minipreps or large scale alkaline lysis plasmid isolation procedures. If desired the plasmid DNA may be further enriched by centrifugation on a cesium chloride gradient, size exclusion chromatography, or anion exchange chromatography. The plasmid DNA obtained using these procedures may then be manipulated using standard cloning techniques familiar to those skilled in the art. Alternatively, a PCR can be done with primers designed at both ends of the EST insertion. The PCR product which corresponds to the 5' EST can then be manipulated using standard cloning techniques familiar to those skilled in the art.

One aspect of the present invention is a purified or isolated nucleic acid having the sequence of one of SEQ ID NOs: 38-270 or having a sequence complementary thereto. In one embodiment, the nucleic acid is recombinant.

Another aspect of the present invention is a purified or isolated nucleic acid comprising at least 10 consecutive bases of the sequence of one of SEQ ID NOs: 38-270 or one of the sequences complementary thereto.

Yet another aspect of the present invention is a purified or isolated nucleic acid comprising at least 15 consecutive bases of one of the sequences of SEQ ID NOs: 38-270 or one of the sequences complementary thereto. In one embodiment, the nucleic acid is recombinant.

A further aspect of the present invention is a purified or isolated nucleic acid of at least 15 bases capable of hybridizing under stringent conditions to the sequence of one of SEQ ID NOs: 38-270 or one of the sequences complementary to the sequences of SEQ ID NOs: 38-270. In one emodiment, the nucleic acid is recombinant.

Another aspect of the present invention is a purified or isolated nucleic acid encoding a human gene product, said human gene product having a sequence partially encoded by one of the sequences of SEQ ID NO: 38-270.

Still another aspect of the present invention is a method of making a cDNA encoding a human secretory protein, said human secretory protein being partially encoded by one of SEQ ID NOs 38-270, comprising the steps of contacting a collection of mRNA molecules from human cells with a primer comprising at least 15 consecutive nucleotides of a sequence complementary to one of SEQ ID NOs: 38-270; hybridizing said primer to an mRNA in said collection that encodes said protein; reverse transcribing said hybridized primer to make a first cDNA strand from said mRNA; making a second cDNA strand complementary to said first cDNA strand; and isolating the resulting cDNA encoding said protein comprising said first cDNA strand and said second cDNA strand.

Another aspect of the invention is an isolated or purified cDNA encoding a human secretory protein, said human secretory protein comprising the protein encoded by one of SEQ ID NOs 38-270 or a fragment thereof of at least 10 amino acids, said cDNA being obtainable by the method described in the preceding paragraph. In one embodiment, the cDNA comprises the full protein coding sequence of said protein which sequence is partially included in one of the sequences of SEQ ID NOs: 38-270.

Another aspect of the present invention is a method of making a cDNA encoding a human secretory protein that is partially encoded by one of SEQ ID NOs 38-270, comprising the steps of obtaining a cDNA comprising one of the sequences of SEQ ID NOs: 38-270; contacting said cDNA with a detectable probe comprising at least 15 consecutive nucleotides of said sequence of SEQ ID NO: 38-270 or a sequence complementary thereto under conditions which permit said probe to hybridize to said cDNA; identifying a cDNA which hybridizes to said detectable probe; and isolating said cDNA which hybridizes to said probe.

Another aspect of the present invention is an isolated or purified cDNA encoding a human secretory protein, said human secretory protein comprising the protein encoded by one of SEQ ID NOs 38-270 or a fragment thereof of at least 10 amino acids, said cDNA being obtainable by the method described in the preceding paragraph. In one embodiment, the cDNA comprises the full protein coding sequence partially included in one of the sequences of SEQ ID NOs: 38-270.

Another aspect of the present invention is a method of making a cDNA comprising the sequence of SEQ ID NOs: 38-270, comprising the steps of contacting a collection of mRNA molecules from human cells with a first primer capable of hybridizing to the polyA tail of said mRNA; hybridizing said first primer to said polyA tail; reverse transcribing said mRNA to make a first cDNA strand; making a second cDNA strand complementary to said first cDNA strand using at least one primer comprising at least 15 nucleotides of one of the sequences of SEQ ID NOs 38-270; and isolating the resulting cDNA comprising said first cDNA strand and said second cDNA strand.

Another aspect of the present invention is an isolated or purified cDNA encoding a human secretory protein, said human secretory protein comprising the protein encoded by one of SEQ ID NOs 38-270 or a fragment thereof of at least 10 amino acids, said cDNA being obtainable by the method described in the preceding paragraph. In one embodiment, the cDNA comprises the full protein coding sequence partially included in one of the sequences of SEQ ID NOs: 38-270.

In one embodiment of the method described in the paragraph two paragraphs above, the second cDNA strand is made by contacting said first cDNA strand with a first pair of primers, said first pair of primers comprising a second primer comprising at least 15 consecutive nucleotides of one of the sequences of SEQ ID NOs 38-270 and a third primer having a sequence therein which is included within the sequence of said first primer; performing a first polymerase chain reaction with said first pair of nested primers to generate a first PCR product; contacting said first PCR product with a second pair of primers, said second pair of primers comprising a fourth primer, said fourth primer comprising at least 15 consecutive nucleotides of said sequence of one of SEQ ID NO:s 38-270, and a fifth primer, said fourth and fifth primers being capable of hybridizing to sequences within said first PCR product; and performing a second polymerase chain reaction, thereby generating a second PCR product.

One aspect of the present invention is an isolated or purified cDNA encoding a human secretory protein, said human secretory protein comprising the protein encoded by one of SEQ ID NOs 38-270, or a fragment thereof of at least 10 amino acids, said cDNA being obtainable by the method of the preceding paragraph. In one embodiment, the cDNA comprises the full protein coding sequence partially included in one of the sequences of SEQ ID NOs: 38-270.

Another aspect of the present invention is the method described four paragraphs above in which the second cDNA strand is made by contacting said first cDNA strand with a second primer comprising at least 15 consecutive nucleotides of the sequences of SEQ ID NOs: 38-270; hybridizing said second primer to said first strand cDNA; and extending said hybridized second primer to generate said second cDNA strand.

Another aspect of the present invention is an isolated or purified cDNA encoding a human secretory protein, said human secretory protein comprising the protein partially encoded by one of SEQ ID NOs 38-270 or comprising a fragment thereof of at least 10 amino acids, said cDNA being obtainable by the method described in the preceding paragraph. In one embodiment, the cDNA comprises the full protein coding sequence partially included in of one of the sequences of SEQ ID NOs: 38-270.

Another aspect of the present invention is a method of making a protein comprising one of the sequences of SEQ ID NO: 271-503, comprising the steps of obtaining a cDNA encoding the full protein sequence partially included in one of the sequences of sequence of SEQ ID NO: 38-270; inserting said cDNA in an expression vector such that said cDNA is operably linked to a promoter; introducing said expression vector into a host cell whereby said host cell produces the protein encoded by said cDNA; and isolating said protein.

Another aspect of the present invention is an isolated protein obtainable by the method described in the preceding paragraph.

Another aspect of the present invention is a method of obtaining a promoter DNA comprising the steps of obtaining DNAs located upstream of the nucleic acids of SEQ ID NO: 38-270 or the sequences complementary thereto; screening said upstream DNAs to identify a promoter capable of directing transcription initiation; and isolating said DNA comprising said identified promoter. In one embodiment, the obtaining step comprises chromosome walking from said nucleic acids of SEQ ID NO: 38-270 or sequences complementary thereto. In another embodiment, the screening step comprises inserting said upstream sequences into a promoter reporter vector. In another embodiment, the screening step comprises identifying motifs in said upstream DNAs which are transcription factor binding sites or transcription start sites.

Another aspect of the present invention is an isolated promoter obtainable by the method described above.

Another aspect of the present invention is an isolated or purified protein comprising one of the sequences of SEQ ID NO: 271-503.

Another aspect of the present invention is the inclusion of at least one of the sequences of SEQ ID NOs: 38-270, or one of the sequences complementary to the sequences of SEQ ID NOs: 38-270, or a fragment thereof of at least 15 consecutive nucleotides in an array of discrete ESTs or fragments thereof of at least 15 nucleotides in length. In one embodiment, the array includes at least two of the sequences of SEQ ID NOs: 38-270, the sequences complementary to the sequences of SEQ ID NOs: 38-270, or fragments thereof of at least 15 consecutive nucleotides. In another embodiment, the array includes at least five of the sequences of SEQ ID NOs: 38-270, the sequences complementary to the sequences of SEQ ID NOs: 38-270, or fragments thereof of at least 15 consecutive nucleotides.

Another aspect of the present invention is a promoter having a sequence selected from the group consisting of SEQ ID NOs: 31, 34, and 37.

FIG. 1 is a summary of the procedure for obtaining cDNAs which have been selected to include the 5' ends of the mRNAs from which they are derived.

FIG. 2 is an analysis of the 43 amino terminal amino acids of all human SwissProt proteins to determine the frequency of false positives and false negatives using the techniques for signal peptide identification described herein.

FIG. 3 shows the distribution of von Heijne scores for 5' ESTs in each of the categories described herein and the probability that these 5' ESTs encode a signal peptide.

FIG. 4 shows the distribution of 5' ESTs in each category and the number of 5' ESTs in each category having a given minimum von Heijne's score.

FIG. 5 shows the tissues from which the mRNAs corresponding to the 5' ESTs in each of the categories described herein were obtained.

FIG. 6 provides a schematic description of the promoters isolated and the way they are assembled with the corresponding 5' tags.

FIG. 7 describes the transcription factor binding sites present in each of these promoters.

A. Chemical Methods for Obtaining mRNAs having Intact 5' Ends

In order to obtain the 5' ESTs of the present invention, mRNAs having intact 5' ends must be obtained. Currently, there are two approaches for obtaining such mRNAs. One of these approaches is a chemical modification method involving derivatization of the 5' ends of the mRNAs and selection of the derivatized mRNAs.

The 5' ends of eucaryotic mRNAs possess a structure referred to as a "cap" which comprises a guanosine methylated at the 7 position. The cap is joined to the first transcribed base of the mRNA by a 5',5'-triphosphate bond. In some instances, the 5' guanosine is methylated in both the 2 and 7 positions. Rarely, the 5' guanosine is trimethylated at the 2, 7 and 7 positions.

In the chemical method for obtaining mRNAs having intact 5' ends, the 5' cap is specifically derivatized and coupled to a reactive group on an immobilizing substrate. This specific derivatization is based on the fact that only the ribose linked to the methylated guanosine at the 5' end of the mRNA and the ribose linked to the base at the 3' terminus of the mRNA, possess 2',3'-cis diols. Optionally, where the 3' terminal ribose has a 2',3'-cis diol, the 2',3'-cis diol at the 3' end may be chemically modified, substituted, converted, or eliminated, leaving only the ribose linked to the methylated guanosine at the 5' end of the mRNA with a 2',3'-cis diol.

A variety of techniques are available for eliminating the 2',3'-cis diol on the 3' terminal ribose. For example, controlled alkaline hydrolysis may be used to generate mRNA fragments in which the 3' terminal ribose is a 3'-phosphate, 2'-phosphate or (2',3')-cyclophosphate. Thereafter, the fragment which includes the original 3' ribose may be eliminated from the mixture through chromatography on an oligo-dT column. Alternatively, a base which lacks the 2',3'-cis diol may be added to the 3' end of the mRNA using an RNA ligase such as T4 RNA ligase. Example 1 below describes a method for ligation of pCp to the 3' end of messenger RNA.

1 .mu.g of RNA was incubated in a final reaction medium of 10 .mu.l in the presence of 5 U of T.sub.4 phage RNA ligase in the buffer provided by the manufacturer (Gibco-BRL), 40 U of the RNase inhibitor RNasin (Promega) and, 2 .mu.l of .sup.32 pCp (Amersham #PB 10208).

The incubation was performed at 37.degree. C. for 2 hours or overnight at 7-8.degree. C.

Following modification or elimination of the 2',3'-cis diol at the 3' ribose, the 2',3'-cis diol present at the 5' end of the mRNA may be oxidized using reagents such as NaBH.sub.4, NaBH.sub.3 CN, or sodium periodate, thereby converting the 2',3'-cis diol to a dialdehyde. Example 2 describes the oxidation of the 2',3'-cis diol at the 5' end of the mRNA with sodium periodate.

0.1 OD unit of either a capped oligoribonucleotide of 47 nucleotides (including the cap) or an uncapped oligoribonucleotide of 46 nucleotides were treated as follows. The oligoribonucleotides were produced by in vitro transcription using the transcription kit "AmpliScribe T7" (Epicentre Technologies). As indicated below, the DNA template for the RNA transcript contained a single cytosine. To synthesize the uncapped RNA, all four NTPs were included in the in vitro transcription reaction. To obtain the capped RNA, GTP was replaced by an analogue of the cap, m7G(5')ppp(5')G. This compound, recognized by polymerase, was incorporated into the 5' end of the nascent transcript during the step of initiation of transcription but was not capable of incorporation during the extension step. Consequently, the resulting RNA contained a cap at its 5' end. The sequences of the oligoribonucleotides produced by the in vitro transcription reaction were:

The oligoribonucleotides were dissolved in 9 .mu.l of acetate buffer (0.1 M sodium acetate, pH 5.2) and 3 .mu.l of freshly prepared 0.1 M sodium periodate solution. The mixture was incubated for 1 hour in the dark at 4.degree. C. or room temperature. Thereafter, the reaction was stopped by adding 4 .mu.l of 10% ethylene glycol. The product was ethanol precipitated, resuspended in 10 .mu.l or more of water or appropriate buffer and dialyzed against water.

The resulting aldehyde groups may then be coupled to molecules having a reactive amine group, such as hydrazine, carbazide, thiocarbazide or semicarbazide groups, in order to facilitate enrichment of the 5' ends of the mRNAs. Molecules having reactive amine groups which are suitable for use in selecting mRNAs having intact 5' ends include avidin, proteins, antibodies, vitamins, ligands capable of specifically binding to receptor molecules, or oligonucleotides. Example 3 below describes the coupling of the resulting dialdehyde to biotin.

The oxidation product obtained in Example 2 was dissolved in 50 .mu.l of sodium acetate at a pH of between 5 and 5.2 and 50 .mu.l of freshly prepared 0.02 M solution of biotin hydrazide in a methoxyethanol/water mixture (1:1) of formula: ##STR1##

In the compound used in these experiments, n=5. However, it will be appreciated that other commercially available hydrazides may also be used, such as molecules of the formula above in which n varies from 0 to 5.

The mixture was then incubated for 2 hours at 37.degree. C. Following the incubation, the mixture was precipitated with ethanol and dialyzed against distilled water. Example 4 demonstrates the specificity of the biotinylation reaction.

The specificity of the biotinylation for capped mRNAs was evaluated by gel electrophoresis of the following samples:

Sample 1. The 46 nucleotide uncapped in vitro transcript prepared as in Example 2 and labeled with .sup.32 pCp as described in Example 1.

Sample 2. The 46 nucleotide uncapped in vitro transcript prepared as in Example 2, labeled with .sup.32 pCp as described in Example 1, treated with the oxidation reaction of Example 2, and subjected to the biotinylation conditions of Example 3.

Sample 3. The 47 nucleotide capped in vitro transcript prepared as in Example 2 and labeled with .sup.32 pCp as described in Example 1.

Sample 4. The 47 nucleotide capped in vitro transcript prepared as in Example 2, labeled with .sup.32 pCp as described in Example 1, treated with the oxidation reaction of Example 2, and subjected to the biotinylation conditions of Example 3.

Samples 1 and 2 had indentical migration rates, demonstrating that the uncapped RNAs were not oxidized and biotinylated. Sample 3 migrated more slowly than Samples 1 and 2, while Sample 4 exhibited the slowest migration. The difference in migration of the RNAs in Samples 3 and 4 demonstrates that the capped RNAs were specifically biotinylated.

In some cases, mRNAs having intact 5' ends may be enriched by binding the molecule containing a reactive amine group to a suitable solid phase substrate such as the inside of the vessel containing the mRNAs, magnetic beads, chromatography matrices, or nylon or nitrocellulose membranes. For example, where the molecule having a reactive amine group is biotin, the solid phase substrate may be coupled to avidin or streptavidin. Alternatively, where the molecule having the reactive amine group is an antibody or receptor ligand, the solid phase substrate may be coupled to the cognate antigen or receptor. Finally, where the molecule having a reactive amine group comprises an oligonucleotide, the solid phase substrate may comprise a complementary oligonucleotide.

The mRNAs having intact 5' ends may be released from the solid phase following the enrichment procedure. For example, where the dialdehyde is coupled to biotin hydrazide and the solid phase comprises streptavidin, the mRNAs may be released from the solid phase by simply heating to 95 degrees Celsius in 2% SDS. In some methods, the molecule having a reactive amine group may also be cleaved from the mRNAs having intact 5' ends following enrichment. Example 5 describes the capture of biotinylated mRNAs with streptavidin coated beads and the release of the biotinylated mRNAs from the beads following enrichment.

The streptavidin-coated magnetic beads were prepared according to the manufacturer's instructions (CPG Inc., USA). The biotinylated mRNAs were added to a hybridization buffer (1.5 M NaCl, pH 5-6). After incubating for 30 minutes, the unbound and nonbiotinylated material was removed. The beads were washed several times in water with 1% SDS. The beads obtained were incubated for 15 minutes at 95.degree. C. in water containing 2% SDS.

Example 6 demonstrates the efficiency with which biotinylated mRNAs were recovered from the streptavidin coated beads.

The efficiency of the recovery procedure was evaluated as follows. RNAs were labeled with .sup.32 pCp, oxidized, biotinylated and bound to streptavidin coated beads as described above. Subsequently, the bound RNAs were incubated for 5, 15 or 30 minutes at 95.degree. C. in the presence of 2% SDS.

The products of the reaction were analyzed by electrophoresis on 12% polyacrylamide gels under denaturing conditions (7 M urea). The gels were subjected to autoradiography. During this manipulation, the hydrazone bonds were not reduced.

Increasing amounts of nucleic acids were recovered as incubation times in 2% SDS increased, demonstrating that biotinylated mRNAs were efficiently recovered.

In an alternative method for obtaining mRNAs having intact 5' ends, an oligonucleotide which has been derivatized to contain a reactive amine group is specifically coupled to mRNAs having an intact cap. Preferably, the 3' end of the mRNA is blocked prior to the step in which the aldehyde groups are joined to the derivatized oligonucleotide, as described above, so as to prevent the derivatized oligonucleotide from being joined to the 3' end of the mRNA. For example, pCp may be attached to the 3' end of the mRNA using T4 RNA ligase. However, as discussed above, blocking the 3' end of the mRNA is an optional step. Derivatized oligonucleotides may be prepared as described below in Example 7.

An oligonucleotide phosphorylated at its 3' end was converted to a 3' hydrazide in 3' by treatment with an aqueous solution of hydrazine or of dihydrazide of the formula H.sub.2 N(R1)NH.sub.2 at about 1 to 3 M, and at pH 4.5, in the presence of a carbodiimide type agent soluble in water such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide at a final concentration of 0.3 M at a temperature of 8.degree. C. overnight.

The derivatized oligonucleotide was then separated from the other agents and products using a standard technique for isolating oligonucleotides.

As discussed above, the mRNAs to be enriched may be treated to eliminate the 3' OH groups which may be present thereon. This may be accomplished by enzymatic ligation of sequences lacking a 3' OH, such as pCp, as described above in Example 1. Alternatively, the 3' OH groups may be eliminated by alkaline hydrolysis as described in Example 8 below.

The mRNAs may be treated with alkaline hydrolysis as follows. In a total volume of 100 .mu.l of 0.1N sodium hydroxide, 1.5 .mu.g mRNA is incubated for 40 to 60 minutes at 4.degree. C. The solution is neutralized with acetic acid and precipitated with ethanol.

Following the optional elimination of the 3' OH groups, the diol groups at the 5' ends of the mRNAs are oxidized as described below in Example 9.

Up to 1 OD unit of RNA was dissolved in 9 .mu.l of buffer (0.1 M sodium acetate, pH 6-7 or water) and 3 .mu.l of freshly prepared 0.1 M sodium periodate solution. The reaction was incubated for 1 h in the dark at 4.degree. C. or room temperature. Following the incubation, the reaction was stopped by adding 4 .mu.l of 10% ethylene glycol. Thereafter the mixture was incubated at room temperature for 15 minutes. After ethanol precipitation, the product was resuspended in 10 .mu.l or more of water or appropriate buffer and dialyzed against water.

Following oxidation of the diol groups at the 5' ends of the mRNAs, the derivatized oligonucleotide was joined to the resulting aldehydes as described in Example 10.

The oxidized mRNA was dissolved in an acidic medium such as 50 .mu.l of sodium acetate pH 4-6. 50 .mu.l of a solution of the derivatized oligonucleotide was added such that an mRNA:derivatized oligonucleotide ratio of 1:20 was obtained and mixture was reduced with a borohydride. The mixture was allowed to incubate for 2 h at 37.degree. C. or overnight (14 h) at 10.degree. C. The mixture was ethanol precipitated, resuspended in 10 .mu.l or more of water or appropriate buffer and dialyzed against distilled water. If desired, the resulting product may be analyzed using acrylamide gel electrophoresis, HPLC analysis, or other conventional techniques.

Following the attachment of the derivatized oligonucleotide to the mRNAs, a reverse transcription reaction may be performed as described in Example 11 below.

An oligodeoxyribonucleotide was derivatized as follows. 3 OD units of an oligodeoxyribonucleotide of sequence ATCAAGAATTCGCACGAGACCATTA (SEQ ID NO:3) having 5'-OH and 3'-P ends were dissolved in 70 .mu.l of a 1.5 M hydroxybenzotriazole solution, pH 5.3, prepared in dimethylformamide/water (75:25) containing 2 .mu.g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide. The mixture was incubated for 2 h 30 min at 22.degree. C. The mixture was then precipitated twice in LiClO.sub.4 /acetone. The pellet was resuspended in 200 .mu.l of 0.25 M hydrazine and incubated at 8.degree. C. from 3 to 14 h. Following the hydrazine reaction, the mixture was precipitated twice in LiClO.sub.4 /acetone.

The messenger RNAs to be reverse transcribed were extracted from blocks of placenta having sides of 2 cm which had been stored at -80.degree. C. The mRNA was extracted using conventional acidic phenol techniques. Oligo-dT chromatography was used to purify the mRNAs. The integrity of the mRNAs was checked by Northern-blotting.

The diol groups on 7 .mu.g of the placental mRNAs were oxidized as described above in Example 9. The derivatized oligonucleotide was joined to the mRNAs as described in Example 10 above except that the precipitation step was replaced by an exclusion chromatography step to remove derivatized oligodeoxyribonucleotides which were not joined to mRNAs. Exclusion chromatography was performed as follows:

10 ml of AcA34 (BioSepra#230151) gel were equilibrated in 50 ml of a solution of 10 mM Tris pH 8.0, 300 mM NaCl, 1 mM EDTA, and 0.05% SDS. The mixture was allowed to sediment. The supernatant was eliminated and the gel was resuspended in 50 ml of buffer. This procedure was repeated 2 or 3 times.

A glass bead (diameter 3 mm) was introduced into a 2 ml disposable pipette (length 25 cm). The pipette was filled with the gel suspension until the height of the gel stabilized at 1 cm from the top of the pipette. The column was then equilibrated with 20 ml of equilibration buffer (10 mM Tris HCl pH 7.4, 20 mM NaCl).

10 .mu.l of the mRNA which had been reacted with the derivatized oligonucleotide were mixed in 39 .mu.l of 10 mM urea and 2 .mu.l of blue-glycerol buffer, which had been prepared by dissolving 5 mg of bromophenol blue in 60% glycerol (v/v), and passing the mixture through a filter with a filter of diameter 0.45 .mu.m.

The column was loaded. As soon as the sample had penetrated, equilibration buffer was added. 100 .mu.l fractions were collected. Derivatized oligonucleotide which had not been attached to mRNA appeared in fraction 16 and later fractions. Fractions 3 to 15 were combined and precipitated with ethanol.

The mRNAs which had been reacted with the derivatized oligonucleotide were spotted on a nylon membrane and hybridized to a radioactive probe using conventional techniques. The radioactive probe used in these hybridizations was an oligodeoxyribonucleotide of sequence TAATGGTCTCGTGCGAATTCTTGAT (SEQ ID NO:4) which was anticomplementary to the derivatized oligonucleotide and was labeled at its 5' end with .sup.32 P. 1/10th of the mRNAs which had been reacted with the derivatized oligonucleotide was spotted in two spots on the membrane and the membrane was visualized by autoradiography after hybridization of the probe. A signal was observed, indicating that the derivatized oligonucleotide had been joined to the mRNA.

The remaining 9/10 of the mRNAs which had been reacted with the derivatized oligonucleotide was reverse transcribed as follows. A reverse transcription reaction was carried out with the reverse transcriptase Superscript II (Gibco-BRL) following the manufacturer's instructions. To prime the reaction, 50 pmol of nonamers with random sequence were used.

A portion of the resulting cDNA was spotted on a positively charged nylon membrane using conventional methods. The cDNAs were spotted on the membrane after the cDNA:RNA heteroduplexes had been subjected to an alkaline hydrolysis in order to eliminate the RNAs. An oligonucleotide having a sequence identical to that of the derivatized oligonucleotide was labeled at its 5' end with .sup.32 P and hybridized to the cDNA blots using conventional techniques. Single-stranded cDNAs resulting from the reverse transcription reaction were spotted on the membrane. As controls, the blot contained 1 pmol, 100 fmol, 50 fmol, 10 fmol and 1 fmol respectively of a control oligodeoxyribonucleotide of sequence identical to that of the derivatized oligonucleotide. The signal observed in the spots containing the cDNA indicated that approximately 15 fmol of the derivatized oligonucleotide had been reverse transcribed.

These results demonstrate that the reverse transcription can be performed through the cap and, in particular, that reverse transcriptase crosses the 5'-P--P--P-5' bond of the cap of eukaryotic messenger RNAs.

The single stranded cDNAs obtained after the above first strand synthesis were used as template for PCR reactions. Two types of reactions were carried out. First, specific amplification of the mRNAs for the alpha globin, dehydrogenase, pp15 and elongation factor E4 were carried out using the following pairs of oligodeoxyribonucleotide primers.

Non specific amplifications were also carried out with the antisense (_As) oligodeoxyribonucleotides of the pairs described above and a primer chosen from the sequence of the derivatized oligodeoxyribonucleotide (ATCAAGAATTCGCACGAGACCATTA) (SEQ ID NO: 13).

A 1.5% agarose gel containing the following samples was stained with ethidium bromide of the PCR products of the reverse transcription (1/20th of the products of reverse transcription were used for each PCR reaction).

Sample 1: The products of a PCR reaction using the globin primers of SEQ ID NOs 5 and 6 in the presence of cDNA.

Sample 2: The products of a PCR reaction using the globin primers of SEQ ID NOs 5 and 6 in the the absence of added cDNA.

Sample 3: The products of a PCR reaction using the dehydrogenase primers of SEQ ID NOs 7 and 8 in the presence of cDNA.

Sample 4: The products of a PCR reaction using the dehydrogenase primers of SEQ ID NOs 7 and 8 in the absence of added cDNA.

Sample 5: The products of a PCR reaction using the pp15 primers of SEQ ID NOs 9 and 10 in the presence of cDNA.

Sample 6: The products of a PCR reaction using the pp15 primers of SEQ ID NOs 9 and 10 in the the absence of added cDNA.

Sample 7: The products of a PCR reaction using the EIE4 primers of SEQ ID NOs 11 and 12 in the presence of added cDNA.

Sample 8: The products of a PCR reaction using the EIE4 primers of SEQ ID NOs 11 and 12 in the absence of added cDNA.

In Samples 1, 3, 5 and 7, a band of the size expected for the PCR product was observed, indicating the presence of the corresponding sequence in the cDNA population.

PCR reactions were also carried out with the antisense oligonucleotides of the globin and dehydrogenase primers (SEQ ID NOs 6 and 8) and an oligonucleotide whose sequence corresponds to that of the derivatized oligonucleotide. The presence of PCR products of the expected size in the samples corresponding to samples 1 and 3 above indicated that the derivatized oligonucleotide had been incorporated.

The above examples summarize the chemical procedure for enriching mRNAs for those having intact 5' ends. Further detail regarding the chemical approaches for obtaining mRNAs having intact 5' ends are disclosed in International Application No. WO96/34981, published Nov. 7, 1996, which is incorporated herein by reference.

Strategies based on the above chemical modifications to the 5' cap structure may be utilized to generate cDNAs which have been selected to include the 5' ends of the mRNAs from which they are derived. In one version of such procedures, the 5' ends of the mRNAs are modified as described above. Thereafter, a reverse transcription reaction is conducted to extend a primer complementary to the mRNA to the 5' end of the mRNA. Single stranded RNAs are eliminated to obtain a population of cDNA/mRNA heteroduplexes in which the mRNA includes an intact 5' end. The resulting heteroduplexes may be captured on a solid phase coated with a molecule capable of interacting with the molecule used to derivative the 5' end of the mRNA. Thereafter, the strands of the heteroduplexes are separated to recover single stranded first cDNA strands which include the 5' end of the mRNA. Second strand cDNA synthesis may then proceed using conventional techniques. For example, the procedures disclosed in WO 96/34981 or in Carninci, P. et al. High-Efficiency Full-Length cDNA Cloning by Biotinylated CAP Trapper. Genomics 37:327-336 (1996), the disclosures of which are incorporated herein by reference, may be employed to select cDNAs which include the sequence derived from the 5' end of the coding sequence of the mRNA.

Following ligation of the oligonucleotide tag to the 5' cap of the mRNA, a reverse transcription reaction is conducted to extend a primer complementary to the mRNA to the 5' end of the mRNA. Following elimination of the RNA component of the resulting heteroduplex using standard techniques, second strand cDNA synthesis is conducted with a primer complementary to the oligonucleotide tag.

FIG. 1 summarizes the above procedures for obtaining cDNAs which have been selected to include the 5' ends of the mRNAs from which they are derived.

B. Enzymatic Methods for Obtaining mRNAs having Intact 5' Ends

Other techniques for selecting cDNAs extending to the 5' end of the mRNA from which they are derived are fully enzymatic. Some versions of these techniques are disclosed in Dumas Milne Edwards J. B. (Doctoral Thesis of Paris VI University, Le clonage des ADNc complets: difficultes et perspectives nouvelles. Apports pour l'etude de la regulation de l'expression de la tryptophane hydroxylase de rat, Dec. 20, 1993, EPO 625572 and Kato et al. Construction of a Human Full-Length cDNA Bank. Gene 150:243-250 (1994), the disclosures of which are incorporated herein by reference.

Briefly, in such approaches, isolated mRNA is treated with alkaline phosphatase to remove the phosphate groups present on the 5' ends of uncapped incomplete mRNAs. Following this procedure, the cap present on full length mRNAs is enzymatically removed with a decapping enzyme such as T4 polynucleotide kinase or tobacco acid pyrophosphatase. An oligonucleotide, which may be either a DNA oligonucleotide or a DNA-RNA hybrid oligonucleotide having RNA at its 3' end, is then ligated to the phosphate present at the 5' end of the decapped mRNA using T4 RNA ligase. The oligonucleotide may include a restriction site to facilitate cloning of the cDNAs following their synthesis. Example 12 below describes one enzymatic method based on the doctoral thesis of Dumas.

Twenty micrograms of PolyA+ RNA were dephosphorylated using Calf Intestinal Phosphatase (Biolabs). After a phenol chloroform extraction, the cap structure of mRNA was hydrolysed using the Tobacco Acid Pyrophosphatase (purified as described by Shinshi et al., Biochemistry 15: 2185-2190, 1976 and a hemi 5'DNA/RNA-3' oligonucleotide having an unphosphorylated 5' end, a stretch of adenosine ribophosphate at the 3' end, and an EcoRI site near the 5' end was ligated to the 5'P ends of mRNA using the T4 RNA ligase (Biolabs). Oligonucleotides suitable for use in this procedure are preferably 30-50 bases in length. Oligonucleotides having an unphosphorylated 5' end may be synthesized by adding a fluorochrome at the 5' end. The inclusion of a stretch of adenosine ribophosphates at the 3' end of the oligonucleotide increases ligation efficiency. It will be appreciated that the oligonucleotide may contain cloning sites other than EcoRI.

Following ligation of the oligonucleotide to the phosphate present at the 5' end of the decapped mRNA, first and second strand cDNA synthesis is carried out using conventional methods or those specified in EPO 625,572 and Kato et al. Construction of a Human Full-Length cDNA Bank. Gene 150:243-250 (1994), and Dumas Milne Edwards, supra, the disclosures of which are incorporated herein by reference. The resulting cDNA may then be ligated into vectors such as those disclosed in Kato et al. Construction of a Human Full-Length cDNA Bank. Gene 150:243-250 (1994) or other nucleic acid vectors known to those skilled in the art using techniques such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual 2d Ed., Cold Spring Harbor Laboratory Press, 1989, the disclosure of which is incorporated herein by reference.

The above chemical and enzymatic approaches for enriching mRNAs having intact 5' ends were employed to obtain 5' ESTs. First, mRNAs were prepared as described in Example 13 below.

Total human RNAs or PolyA+ RNAs derived from 29 different tissues were respectively purchased from LABIMO and CLONTECH and used to generate 44 cDNA libraries as described below. The purchased RNA had been isolated from cells or tissues using acid guanidium thiocyanate-phenol-chloroform extraction (Chomczyniski, P and Sacchi, N., Analytical Biochemistry 162:156-159, 1987). PolyA+ RNA was isolated from total RNA (LABIMO) by two passes of oligodT chromatography, as described by Aviv and Leder (Aviv, H. and Leder, P., Proc. Natl. Acad. Sci. USA 69:1408-1412, 1972) in order to eliminate ribosomal RNA.

The quality and the integrity of the poly A+ were checked. Northern blots hybridized with a globin probe were used to confirm that the mRNAs were not degraded. Contamination of the PolyA+ mRNAs by ribosomal sequences was checked using RNAs blots and a probe derived from the sequence of the 28S RNA. Preparations of mRNAs with less than 5% of ribosomal RNAs were used in library construction. To avoid constructing libraries with RNAs contaminated by exogenous sequences (prokaryotic or fungal), the presence of bacterial 16S ribosomal sequences or of two highly expressed mRNAs was examined using PCR.

Following preparation of the mRNAs, the above described chemical and/or the enzymatic procedures for enriching mRNAs having intact 5' ends discussed above were employed to obtain 5' ESTs from various tissues. In both approaches an oligonucleotide tag was attached to the cap at the 5' ends of the mRNAs. The oligonucleotide tag had an EcoRI site therein to facilitate later cloning procedures.

Following attachment of the oligonucleotide tag to the mRNA by either the chemical or enzymatic methods, the integrity of the mRNA was examined by performing a Northern blot with 200-500 ng of mRNA using a probe complementary to the oligonucleotide tag.

For the mRNAs joined to oligonucleotide tags using both the chemical and enzymatic methods, first strand cDNA synthesis was performed with Superscript II (Gibco BRL) using random nonamers as primers. In order to protect internal EcoRI sites in the cDNA from digestion at later steps in the procedure, methylated dCTP was used for first strand synthesis. After removal of RNA by an alkaline hydrolysis, the first strand of cDNA was precipitated using isopropanol in order to eliminate residual primers.

For both the chemical and the enzymatic methods, synthesis of the second strand of the cDNA was conducted as follows. After removal of RNA by alkaline hydrolysis, the first strand of cDNA was precipitated using isopropanol in order to eliminate residual primers. The second strand of the cDNA was synthesized with Klenow using a primer corresponding to the 5' end of the ligated oligonucleotide described in Example 12. Preferably, the primer is 20-25 bases in length. Methylated dCTP was also used for second strand synthesis in order to protect internal EcoRI sites in the cDNA from digestion during the cloning process.

Following cDNA synthesis, the cDNAs were cloned into pBlueScript as described in Example 15 below.

Following second strand synthesis, the ends of the cDNA were blunted with T4 DNA polymerase (Biolabs) and the cDNA was digested with EcoRI. Since methylated dCTP was used during cDNA synthesis, the EcoRI site present in the tag was the only site which was hemi-methylated. Consequently, only the EcoRI site in the oligonucleotide tag was susceptible to EcoRI digestion. The cDNA was then size fractionated using exclusion chromatography (AcA, Biosepra). Fractions corresponding to cDNAs of more than 150 bp were pooled and ethanol precipitated. The cDNA was directionally cloned into the SmaI and EcoRI ends of the phagemid pBlueScript vector (Stratagene). The ligation mixture was electroporated into bacteria and propagated under appropriate antibiotic selection.

Clones containing the oligonucleotide tag attached were selected as described in Example 16 below.

The plasmid DNAs containing 5' EST libraries made as described above were purified (Qiagen). A positive selection of the tagged clones was performed using the Gene Trapper kit (Gibco BRL). Briefly, in this selection procedure, the plasmid DNA was converted to single stranded DNA using the geneII product in combination with exonucleaseIII. The resulting single stranded DNA was then hybridized with a biotinylated oligonucleotide having a sequence corresponding to the 3' end of the oligonucleotide described in Example 12. Preferably, the primer has a length of 20-25 bases. Clones including a sequence complementary to the biotinylated oligonucleotide were captured by incubation with streptavidin coated magnetic beads followed by magnetic selection. After capture of the positive clones, the plasmid DNA was released from the magnetic beads and converted into double stranded DNA as recommended by the manufacture. The double stranded DNA was then electroporated into bacteria. The percentage of positive clones having the 5' tag oligonucleotide was estimated using dot blot analysis. Typically the percentage of positive clones was between 90 and 98%.

Following electroporation, the libraries were ordered in 384-microtiter plates (MTP). A copy of the MTP was stored for future needs. Then the libraries were transferred into 96 MTP and sequenced as described below.

Plasmid inserts were first amplified by PCR on PE 9600 thermocyclers (Perkin-Elmer), using standard SETA-A and SETA-B primers (Genset SA), AmpliTaqGold (Perkin-Elmer), dNTPs (Boehringer), buffer and cycling conditions as recommended by the Perkin-Elmer Corporation.

PCR products were then sequenced using automatic ABI Prism 377 sequencers (Perkin Elmer, Applied Biosystems Division, Foster City, Calif.). Sequencing reactions were performed using PE 9600 thermocyclers (Perkin Elmer) with standard dye-primer chemistry and ThermoSequenase (Amersham Life Science). The primers used were either T7 or 21M13 (available from Genset SA) as appropriate. The primers were labeled with the JOE, FAM, ROX and TAMRA dyes. The dNTPs and ddNTPs used in the sequencing reactions were purchased from Boehringer. Sequencing buffer, reagent concentrations and cycling conditions were as recommended by Amersham.

Following the sequencing reaction, the samples were precipitated with EtOH, resuspended in formamide loading buffer, and loaded on a standard 4% acrylamide gel. Electrophoresis was performed for 2.5 hours at 3000V on an ABI 377 sequencer, and the sequence data were collected and analyzed using the ABI Prism DNA Sequencing Analysis Software, version 2.1.2.

The sequence data from the 44 cDNA libraries made as described above were transferred to a proprietary database, where quality control and validation steps were performed. A proprietary base-caller ("Trace"), working using a Unix system automatically flagged suspect peaks, taking into account the shape of the peaks, the inter-peak resolution, and the noise level. The proprietary base-caller also performed an automatic trimming. Any stretch of 25 or fewer bases having more than 4 suspect peaks was considered unreliable and was discarded. Sequences corresponding to cloning vector or ligation oligonucleotides were automatically removed from the EST sequences. However, the resulting EST sequences may contain 1 to 5 bases belonging to the above mentioned sequences at their 5' end. If needed, these can easily be removed on a case by case basis.

Thereafter, the sequences were transferred to the proprietary NETGENE.TM. Database for further analysis as described below.

Following sequencing as described above, the sequences of the 5' ESTs were entered in a proprietary database called NETGENE.TM. for storage and manipulation. It will be appreciated by those skilled in the art that the data could be stored and manipulated on any medium which can be read and accessed by a computer. Computer readable media include magnetically readable media, optically readable media, or electronically readable media. For example, the computer readable media may be a hard disc, a floppy disc, a magnetic tape, CD-ROM, RAM, or ROM as well as other types of other media known to those skilled in the art.

In addition, the sequence data may be stored and manipulated in a variety of data processor programs in a variety of formats. For example, the sequence data may be stored as text in a word processing file, such as MicrosoftWORD or WORDPERFECT or as an ASCII file in a variety of database programs familiar to those of skill in the art, such as DB2, SYBASE, or ORACLE.

The computer readable media on which the sequence information is stored may be in a personal computer, a network, a server or other computer systems known to those skilled in the art. The computer or other system preferably includes the storage media described above, and a processor for accessing and manipulating the sequence data. Once the sequence data has been stored it may be manipulated and searched to locate those stored sequences which contain a desired nucleic acid sequence or which encode a protein having a particular functional domain. For example, the stored sequence information may be compared to other known sequences to identify homologies, motifs implicated in biological function, or structural motifs.

Programs which may be used to search or compare the stored sequences include the MacPattern (EMBL), BLAST, and BLAST2 program series (NCBI), basic local alignment search tool programs for nucleotide (BLASTN) and peptide (BLASTX) comparisons (Altschul et al, J. Mol. Biol. 215: 403 (1990)) and FASTA (Pearson and Lipman, Proc. Natl. Acad. Sci. USA, 85: 2444 (1988)). The BLAST programs then extend the alignments on the basis of defined match and mismatch criteria.

Motifs which may be detected using the above programs include sequences encoding leucine zippers, helix-turn-helix motifs, glycosylation sites, ubiquitination sites, alpha helices, and beta sheets, signal sequences encoding signal peptides which direct the secretion of the encoded proteins, sequences implicated in transcription regulation such as homeoboxes, acidic stretches, enzymatic active sites, substrate binding sites, and enzymatic cleavage sites.

Before searching the cDNAs in the NETGENE.TM. database for sequence motifs of interest, cDNAs derived from mRNAs which were not of interest were identified and eliminated from further consideration as described in Example 18 below.

5' ESTs in the NETGENE.TM. database which were derived from undesired sequences such as transfer RNAs, ribosomal RNAs, mitochondrial RNAs, procaryotic RNAs, fungal RNAs, Alu sequences, L1 sequences, or repeat sequences were identified using the FASTA and BLASTN programs with the parameters listed in Table I.

To eliminate 5' ESTs encoding tRNAs from further consideration, the 5' EST sequences were compared to the sequences of 1190 known tRNAs obtained from EMBL release 38, of which 100 were human. The comparison was performed using FASTA on both strands of the 5' ESTs. Sequences having more than 80% homology over more than 60 nucleotides were identified as tRNA. Of the 144,341 sequences screened, 26 were identified as tRNAs and eliminated from further consideration.

To eliminate 5' ESTs encoding rRNAs from further consideration, the 5' EST sequences were compared to the sequences of 2497 known rRNAs obtained from EMBL release 38, of which 73 were human. The comparison was performed using BLASTN on both strands of the 5' ESTs with the parameter S=108. Sequences having more than 80% homology over stretches longer than 40 nucleotides were identified as rRNAs. Of the 144,341 sequences screened, 3,312 were identified as rRNAs and eliminated from further consideration.

To eliminate 5' ESTs encoding mtRNAs from further consideration, the 5' EST sequences were compared to the sequences of the two known mitochondrial genomes for which the entire genomic sequences are available and all sequences transcribed from these mitochondrial genomes including tRNAs, rRNAs, and mRNAs for a total of 38 sequences. The comparison was performed using BLASTN on both strands of the 5' ESTs with the parameter S=108. Sequences having more than 80% homology over stretches longer than 40 nucleotides were identified as mtRNAs. Of the 144,341 sequences screened, 6,110 were identified as mtRNAs and eliminated from further consideration.

Sequences which might have resulted from exogenous contaminants were eliminated from further consideration by comparing the 5' EST sequences to release 46 of the EMBL bacterial and fungal divisions using BLASTN with the parameter S=144. All sequences having more than 90% homology over at least 40 nucleotides were identified as exogenous contaminants. Of the 42 cDNA libraries examined, the average percentages of procaryotic and fungal sequences contained therein were 0.2% and 0.5% respectively. Among these sequences, only one could be identified as a sequence specific to fungi. The others were either fungal or procaryotic sequences having homologies with vertebrate sequences or including repeat sequences which had not been masked during the electronic comparison.

In addition, the 5' ESTs were compared to 6093 Alu sequences and 1115 L1 sequences to mask 5' ESTs containing such repeat sequences from further consideration. 5' ESTs including THE and MER repeats, SSTR sequences or satellite, micro-satellite, or telomeric repeats were also eliminated from further consideration. On average, 11.5% of the sequences in the libraries contained repeat sequences. Of this 11.5%, 7% contained Alu repeats, 3.3% contained L1 repeats and the remaining 1.2% were derived from the other types of repetitive sequences which were screened. These percentages are consistent with those found in cDNA libraries prepared by other groups. For example, the cDNA libraries of Adams et al. contained between 0% and 7.4% Alu repeats depending on the source of the RNA which was used to prepare the cDNA library (Adams et al., Nature 377:174, 1996).

The sequences of those 5' ESTs remaining after the elimination of undesirable sequences were compared with the sequences of known human mRNAs to determine the accuracy of the sequencing procedures described above.

To further determine the accuracy of the sequencing procedure described above, the sequences of 5' ESTs derived from known sequences were identified and compared to the known sequences. First, a FASTA analysis with overhangs shorter than 5 bp on both ends was conducted on the 5' ESTs to identify those matching an entry in the public human mRNA database. The 6655 5' ESTs which matched a known human mRNA were then realigned with their cognate mRNA and dynamic programming was used to include substitutions, insertions, and deletions in the list of "errors" which would be recognized. Errors occurring in the last 10 bases of the 5' EST sequences were ignored to avoid the inclusion of spurious cloning sites in the analysis of sequencing accuracy.

This analysis revealed that the sequences incorporated in the NETGENE.TM. database had an accuracy of more than 99.5%.

To determine the efficiency with which the above selection procedures select cDNAs which include the 5' ends of their corresponding mRNAs, the following analysis was performed.

To determine the efficiency at which the above selection procedures isolated cDNAs which included sequences close to the 5' end of the mRNAs from which they were derived, the sequences of the ends of the 5' ESTs which were derived from the elongation factor 1 subunit .alpha. and ferritin heavy chain genes were compared to the known cDNA sequences for these genes. Since the transcription start sites for the elongation factor 1 subunit .alpha. and ferritin heavy chain are well characterized, they may be used to determine the percentage of 5' ESTs derived from these genes which included the authentic transcription start sites.

For both genes, more than 95% of the cDNAs included sequences close to or upstream of the 5' end of the corresponding mRNAs.

To extend the analysis of the reliability of the procedures for isolating 5' ESTs from cDNAs in the NETGENE.TM. database, a similar analysis was conducted using a database composed of human mRNA sequences extracted from GenBank database release 97 for comparison. For those 5' ESTs derived from mRNAs included in the GeneBank database, more than 85% had their 5' ends close to the 5' ends of the known sequence. As some of the mRNA sequences available in the GenBank database are deduced from genomic sequences, a 5' end matching with these sequences will be counted as an internal match. Thus, the method used here underestimates the yield of cDNAs including the authentic 5' ends of their corresponding mRNAs.

The cDNA libraries made above included multiple 5' ESTs derived from the same mRNA. The sequences of such 5' ESTs were compared to one another and the longest 5' ESTs for each mRNA were identified. Overlapping cDNAs were assembled into continuous sequences (contigs). The resulting continuous sequences were then compared to public databases to gauge their similarity to known sequences, as described in Example 21 below. Libraries

For each sequenced cDNA library, the sequences were clustered by the 5' end. Each sequence in the library was compared to the others with BLASTN2 (direct strand, parameters S=107). ESTs with High Scoring Segment Pairs (HSPs) at least 25 bp long, having 95% identical bases and beginning closer than 10 bp from each EST 5' end were grouped. The longest sequence found in the cluster was used as representative of the cluster. A global clustering between libraries was then performed leading to the definition of super-contigs.

To assess the yield of new sequences within the cDNA libraries, a novelty rate (NR) was defined as: NR=100 X (Number of new unique sequences found in the library/Total number of sequences from the library). Typically, novelty rating range between 10% and 41% depending on the tissue from which the cDNA library was obtained. For most of the libraries, the random sequencing of 5' EST libraries was pursued until the novelty rate reached 20%.

Following characterization as described above, the collection of 5' ESTs in NETGENE.TM. was screened to identify those 5' ESTs bearing potential signal sequences as described in Example 22 below.

The 5' ESTs in the NETGENE.TM. database were screened to identify those having an uninterrupted open reading frame (ORF) longer than 45 nucleotides beginning with an ATG codon and extending to the end of the EST. Approximately half of the cDNA sequences in NETGENE.TM. contained such an ORF. The ORFs of these 5' ESTs were searched to identify potential signal motifs using slight modifications of the procedures disclosed in Von Heijne, G. A New Method for Predicting Signal Sequence Cleavage Sites. Nucleic Acids Res. 14:4683-4690 (1986), the disclosure of which is incorporated herein by reference. Those 5' EST sequences encoding a 15 amino acid long stretch with a score of at least 3.5 in the Von Heijne signal peptide identification matrix were considered to possess a signal sequence. Those 5' ESTs which matched a known human mRNA or EST sequence and had a 5' end more than 20 nucleotides downstream of the known 5' end were excluded from further analysis. The remaining cDNAs having signal sequences therein were included in a database called SIGNALTAG.TM..

To confirm the accuracy of the above method for identifying signal sequences, the analysis of Example 23 was performed. 5' ESTs

The accuracy of the above procedure for identifying signal sequences encoding signal peptides was evaluated by applying the method to the 43 amino terminal amino acids of all human SwissProt proteins. The computed Von Heijne score for each protein was compared with the known characterization of the protein as being a secreted protein or a non-secreted protein. In this manner, the number of non-secreted proteins having a score higher than 3.5 (false positives) and the number of secreted proteins having a score lower than 3.5 (false negatives) could be calculated.

Using the results of the above analysis, the probability that a peptide encoded by the 5' region of the mRNA is in fact a genuine signal peptide based on its Von Heijne's score was calculated based on either the assumption that 10% of human proteins are secreted or the assumption that 20% of human proteins are secreted. The results of this analysis are shown in FIGS. 2 and 3.

Using the above method of identifying secretory proteins, 5' ESTs for human glucagon, gamma interferon induced monokine precursor, secreted cyclophilin-like protein, human pleiotropin, and human biotinidase precursor all of which are polypeptides which are known to be secreted, were obtained. Thus, the above method successfully identified those 5' ESTs which encode a signal peptide.

To confirm that the signal peptide encoded by the 5' ESTs actually functions as a signal peptide, the signal sequences from the 5' ESTs may be cloned into a vector designed for the identification of signal peptides. Some signal peptide identification vectors are designed to confer the ability to grow in selective medium on host cells which have a signal sequence operably inserted into the vector. For example, to confirm that a 5' EST encodes a genuine signal peptide, the signal sequence of the 5' EST may be inserted upstream and in frame with a non-secreted form of the yeast invertase gene in signal peptide selection vectors such as those described in U.S. Pat. No. 5,536,637, the disclosure of which is incorporated herein by reference. Growth of host cells containing signal sequence selection vectors having the signal sequence from the 5' EST inserted therein confirms that the 5' EST encodes a genuine signal peptide.

Those 5' ESTs which encoded a signal peptide, as determined by the method of Example 22 above, were further grouped into four categories based on their homology to known sequences. The categorization of the 5' ESTs is described in Example 24 below.

Those 5' ESTs having a sequence not matching any known vertebrate sequence nor any publicly available EST sequence were designated "new." Of the sequences in the SIGNALTAG.TM. database, 947 of the 5' ESTs having a Von Heijne's score of at least 3.5 fell into this category.

Those 5' ESTs having a sequence not matching any vertebrate sequence but matching a publicly known EST were designated "EST-ext", provided that the known EST sequence was extended by at least 40 nucleotides in the 5' direction. Of the sequences in the SIGNALTAG.TM. database, 150 of the 5' ESTs having a Von Heijne's score of at least 3.5 fell into this category.

Those ESTs not matching any vertebrate sequence but matching a publicly known EST without extending the known EST by at least 40 nucleotides in the 5' direction were designated "EST." Of the sequences in the SIGNALTAG.TM. database, 599 of the 5' ESTs having a Von Heijne's score of at least 3.5 fell into this category.

Those 5' ESTs matching a human mRNA sequence but extending the known sequence by at least 40 nucleotides in the 5' direction were designated "VERT-ext." Of the sequences in the SIGNALTAG.TM. database, 23 of the 5' ESTs having a Von Heijne's score of at least 3.5 fell into this category. Included in this category was a 5' EST which extended the known sequence of the human translocase mRNA by more than 200 bases in the 5' direction. A 5' EST which extended the sequence of a human tumor suppressor gene in the 5' direction was also identified.

FIG. 4 shows the distribution of 5' ESTs in each category and the number of 5' ESTs in each category having a given minimum von Heijne's score.

Each of the 5' ESTs was categorized based on the tissue from which its corresponding mRNA was obtained, as described below in Example 25.

FIG. 5 shows the tissues from which the mRNAs corresponding to the 5' ESTs in each of the above described categories were obtained.

Table II provides the sequence identification numbers of 5' EST sequences derived from brain, the categories in which these sequences fall, and the von Heijne's score of the signal peptides which they encode. The 5' EST sequences and the amino acid sequences they encode are provided in the appended sequence listings. Table III provides the sequence ID numbers of the 5' ESTs and the sequences of the signal peptides which they encode. The sequences of the 5' ESTs and the polypeptides they encode are provided in the sequence listing appended hereto.

The sequences of DNA SEQ ID NOs: 38-270 can readily be screened for any errors therein and any sequence ambiguities can be resolved by resequencing a fragment containing such errors or amibiguities on both strands. Such fragments may be obtained from the plasmids stored in the inventors' laboratory or can be isolated using the techniques described herein. Resolution of any such ambiguities or errors may be facilitated by using primers which hybridize to sequences located close to the ambiguous or erroneous sequences. For example, the primers may hybridize to sequences within 50-75 bases of the amibiguity or error. Upon resolution of an error or ambiguity, the corresponding corrections can be made in the protein sequences encoded by the DNA containing the error or amibiguity.

In addition to categorizing the 5' ESTs by the tissue from which the cDNA library in which they were first identified was obtained, the spatial and temporal expression patterns of the mRNAs corresponding to the 5' ESTs, as well as their expression levels, may be determined as described in Example 26 below. Characterization of the spatial and temporal expression patterns and expression levels of these mRNAs is useful for constructing expression vectors capable of producing a desired level of gene product in a desired spatial or temporal manner, as will be discussed in more detail below.

In addition, 5' ESTs whose corresponding mRNAs are associated with disease states may also be identified. For example, a particular disease may result from lack of expression, over expression, or under expression of an mRNA corresponding to a 5' EST. By comparing mRNA expression patterns and quantities in samples taken from healthy individuals with those from individuals suffering from a particular disease, 5' ESTs responsible for the disease may be identified. ESTs

Expression levels and patterns of mRNAs corresponding to 5' ESTs may be analyzed by solution hybridization with long probes as described in International Patent Application No. WO 97/05277, the entire contents of which are hereby incorporated by reference. Briefly, a 5' EST corresponding to a portion of a gene is inserted at a cloning site immediately downstream of a bacteriophage (T3, T7 or SP6) RNA polymerase promoter to produce antisense RNA. Preferably, the 5' EST has 100 or more nucleotides. The plasmid is linearized and transcribed in the presence of ribonucleotides comprising modified ribonucleotides (i.e. biotin-UTP and DIG-UTP). An excess of this doubly labeled RNA is hybridized in solution with mRNA isolated from cells or tissues of interest. The hybridizations are performed under standard stringent conditions (40-50.degree. C. for 16 hours in an 80% formamide, 0.4 M NaCl buffer, pH 7-8). The unhybridized probe is removed by digestion with ribonucleases specific for single-stranded RNA (i.e. RNases CL3, T1, Phy M, U2 or A). The presence of the biotin-UTP modification enables capture of the hybrid on a microtitration plate coated with streptavidin. The presence of the DIG modification enables the hybrid to be detected and quantified by ELISA using an anti-DIG antibody coupled to alkaline phosphatase.

The 5' ESTs may also be tagged with nucleotide sequences for the serial analysis of gene expression (SAGE) as disclosed in UK Patent Application No. 2 305 241 A, the entire contents of which are incorporated by reference. In this method, cDNAs are prepared from a cell, tissue, organism or other source of nucleic acid for which it is desired to determine gene expression patterns. The resulting cDNAs are separated into two pools. The cDNAs in each pool are cleaved with a first restriction endonuclease, called an "anchoring enzyme," having a recognition site which is likely to be present at least once in most cDNAs. The fragments which contain the 5' or 3' most region of the cleaved cDNA are isolated by binding to a capture medium such as streptavidin coated beads. A first oligonucleotide linker having a first sequence for hybridization of an amplification primer and an internal restriction site for a "tagging endonuclease" is ligated to the digested cDNAs in the first pool. Digestion with the second endonuclease produces short "tag" fragments from the cDNAs.

A second oligonucleotide having a second sequence for hybridization of an amplification primer and an internal restriction site is ligated to the digested cDNAs in the second pool. The cDNA fragments in the second pool are also digested with the "tagging endonuclease" to generate short "tag" fragments derived from the cDNAs in the second pool. The "tags" resulting from digestion of the first and second pools with the anchoring enzyme and the tagging endonuclease are ligated to one another to produce "ditags." In some embodiments, the ditags are concatamerized to produce ligation products containing from 2 to 200 ditags. The tag sequences are then determined and compared to the sequences of the 5' ESTs to determine which 5' ESTs are expressed in the cell, tissue, organism, or other source of nucleic acids from which the tags were derived. In this way, the expression pattern of the 5' ESTs in the cell, tissue, organism, or other source of nucleic acids is obtained.

Quantitative analysis of gene expression may also be performed using arrays. As used herein, the term array means a one dimensional, two dimensional, or multidimensional arrangement of full length cDNAs, 5' ESTs or fragments thereof of sufficient length to permit specific detection of gene expression. Preferably, the fragments are at least 15 nucleotides in length. More preferably, the fragments are at least 100 nucleotides in length. More preferably, the fragments are more than 100 nucleotides in length. In some embodiments the fragments may be more than 500 nucleotides in length.

For example, quantitative analysis of gene expression may be performed with full length cDNAs, 5' ESTs, or fragments thereof in a complementary DNA microarray as described by Schena et al. (Science 270:467-470, 1995; Proc. Natl. Acad Sci. U.S.A 93:10614-10619, 1996). cDNAs, 5' ESTs or fragments thereof are amplified by PCR and arrayed from 96-well microtiter plates onto silylated microscope slides using high-speed robotics. Printed arrays are incubated in a humid chamber to allow rehydration of the array elements and rinsed, once in 0.2% SDS for 1 min, twice in water for 1 min and once for 5 min in sodium borohydride solution. The arrays are submerged in water for 2 min at 95.degree. C., transferred into 0.2% SDS for 1 min, rinsed twice with water, air dried and stored in the dark at 25.degree. C.

Cell or tissue mRNA is isolated or commercially obtained and probes are prepared by a single round of reverse transcription. Probes are hybridized to 1 cm.sup.2 microarrays under a 14.times.14 mm glass coverslip for 6-12 hours at 60.degree. C. Arrays are washed for 5 min at 25.degree. C. in low stringency wash buffer (1.times. SSC/0.2% SDS), then for 10 min at room temperature in high stringency wash buffer (0.1.times. SSC/0.2% SDS). Arrays are scanned in 0.1.times. SSC using a fluorescence laser scanning device fitted with a custom filter set. Accurate differential expression measurements are obtained by taking the average of the ratios of two independent hybridizations.

Quantitative analysis of the expression of genes may also be performed with full length cDNAs, 5' ESTs, or fragments thereof in complementary DNA arrays as described by Pietu et al. (Genome Research 6:492-503, 1996). The cDNAs, 5' ESTs or fragments thereof are PCR amplified and spotted on membranes. Then, mRNAs originating from various tissues or cells are labeled with radioactive nucleotides. After hybridization and washing in controlled conditions, the hybridized mRNAs are detected by phospho-imaging or autoradiography. Duplicate experiments are performed and a quantitative analysis of differentially expressed mRNAs is then performed.

Alternatively, expression analysis of the 5' ESTs can be done through high density nucleotide arrays as described by Lockhart et al. (Nature Biotechnology 14: 1675-1680, 1996) and Sosnowsky et al. (Proc. Natl. Acad. Sci. 94:1119-1123, 1997). Oligonucleotides of 15-50 nucleotides corresponding to sequences of the 5' ESTs are synthesized directly on the chip (Lockhart et al., supra) or synthesized and then addressed to the chip (Sosnowski et al., supra). Preferably, the oligonucleotides are about 20 nucleotides in length.

cDNA probes labeled with an appropriate compound, such as biotin, digoxigenin or fluorescent dye, are synthesized from the appropriate mRNA population and then randomly fragmented to an average size of 50 to 100 nucleotides. The said probes are then hybridized to the chip. After washing as described in Lockhart et al., supra and application of different electric fields (Sosnowsky et al., Proc. Natl. Acad. Sci. 94:1119-1123), the dyes or labeling compounds are detected and quantified. Duplicate hybridizations are performed. Comparative analysis of the intensity of the signal originating from cDNA probes on the same target oligonucleotide in different cDNA samples indicates a differential expression of the mRNA corresponding to the 5' EST from which the oligonucleotide sequence has been designed. Corresponding mRNA As Well As the Entire Protein Coding Sequence of the Corresponding mRNA and to Clone the Corresponding Genomic DNAs

Once 5' ESTs which include the 5' end of the corresponding mRNAs have been selected using the procedures described above, they can be utilized to isolate cDNAs which include the entire coding sequence of the protein encoded by the corresponding mRNA, including the authentic translation start site, hereinafter referred to as "full length cDNAs". Example 27 below describes a general method for obtaining such cDNAs. Example 28 below describes the cloning and sequencing of a cDNA which includes the entire coding sequence and authentic 5' end of the corresponding mRNA for several secreted proteins.

The methods of Examples 27, 28, and 29 can also be used to obtain cDNAs which encode less than the entire coding sequence of the proteins encoded by the 5' ESTs. The cDNAs isolated using these methods encode at least 10 amino acids of the proteins encoded by the sequences of SEQ ID NOs: 38-270. Preferably, the cDNAs encode at least 20 amino acids of the proteins encoded by the sequences of SEQ ID NOs: 38-270. More preferably, the cDNAs encode at least 30 amino amino acids of the sequences of SEQ ID NOs: 38-270. In a preferred embodiment, the cDNAs encode a full length protein sequence, which includes the protein coding sequences of SEQ ID NOs: 38-270. the Entire Coding Region and the Authentic 5' End of the Corresponding mRNA

The following general method has been used to quickly and efficiently isolate cDNAs having the authentic 5' ends of their corresponding mRNAs as well as the full protein coding sequence. This method may be applied to obtain such cDNAs for any 5' EST in the NETGENE.TM. database, including those 5' ESTs encoding secreted proteins.

The method takes advantage of the known 5' sequence of the mRNA. An RTPCR reaction is conducted on purified mRNA using a poly 14dT primer containing a 49 nucleotide sequence at its 5' end which permits the addition of a known sequence at the end of the cDNA which corresponds to the 3' end of the mRNA. For example, the primer may have the following sequence: 5'-ATC GTT GAG ACT CGT ACC AGC AGA GTC ACG AGA GAG ACT ACA CGG TAC TGG TTT TTT TTT TTT TTVN-3' (SEQ ID NO:14). Those skilled in the art will appreciate that other sequences may also be added to the poly dT sequence and used to prime the first strand synthesis. Using this primer and an enzyme having reverse transcriptase activity, such as SuperScriptII (Gibco BRL), a reverse transcript which is anchored at the 3' polyA site of the RNAs is generated.

After removal of the mRNA hybridized to the first cDNA strand by alkaline hydrolysis, the products of the alkaline hydrolysis and the residual poly dT primer are eliminated with an exclusion column such as an Aca34 (Biosepra) matrix, a mix of agarose and acrylamide.

A pair of nested primers on each end is designed based on the known 5' sequence from the 5' EST and the known 3' end resulting from the primer used in the first strand synthesis. Preferably, the nested primers at the 5' end are separated from one another by four to nine bases. The 5' primer sequences may be selected to have melting temperatures and specificities suitable for use in PCR using formulas or software well known to those skilled in the art. If it is desired to obtain cDNAs containing the full length protein coding sequence, including the authentic translation initiation site, primers comprising sequences upstream of the translation initiation site are used. Alternatively, the PCR product is sequenced, the coding region is determined, and RTPCR is performed on an appropriate mRNA using primers at each end of the coding region.

Preferably, the nested primers at the 3' end are separated from one another by four to nine bases. For example, the nested 3' primers may have the following sequences: (5'-CCA GCA GAG TCA CGA GAG AGA CTA CAC GG-3' (SEQ ID NO:15), and 5'-CAC GAG AGA GAC TAC ACG GTA CTG G-3' (SEQ ID NO:16). These primers were selected because they have melting temperatures and specificities compatible with their use in PCR. However, those skilled in the art will appreciate that other sequences may also be used as primers.

The first PCR run of 25 cycles is performed using the Clontech Tth Polymerase Mix and the outer primer from each of the nested pairs. 1/2500 of the resulting PCR product is then used in a 20 cycle PCR using the same enzyme and the inner primer from each of the nested pairs. Thereafter, the primers and nucleotides are removed, and the final product is sequenced with a Die Terminator approach using the AmpliTaqFS kit available from Perkin Elmer. In addition, the double stranded cDNA produced by the above reactions is cloned into a vector capable of replicating in an appropriate host cell if it contains the full length protein coding sequence. If not, a cDNA product containing the full length protein coding sequence is obtained as described above and cloned into an appropriate vector.

In order to sequence long fragments primer walking is performed using automated computer software such as ASMG (Sutton, G. G. et al. TIGR Assembler: A New Tool for Assembling Large Shotgun Sequencing Projects. genome Science and Technology 1: 9-19 (1995)) to construct contigs and software such as OSP (Illier, L and Green, P. OSP: A Computer Program for Choosing PCR and DNA sequencing Primers. PCR Methods Appl. 1(2): 124-128 (1991) to choose primers.

cDNAs which include the entire coding sequence of secreted proteins may be obtained as described in Example 28 below.

Once a cDNA has been obtained, it can be sequenced to determine the amino acid sequence it encodes. Once the encoded amino acid sequence has been determined, one can create and identify any of the many conceivable cDNAs that will encode that protein by simply using the known genetic code.

In a preferred embodiment, the coding sequence may be selected using the known codon or codon pair preferences for the host organism in which the cDNA is to be expressed.

The procedure described in Example 27 above was used to obtain full length cDNAs. Using this approach, the full length cDNA of SEQ ID NO:17 (internal identification number 48-19-3-G1-FL1) was obtained. This cDNA falls into the "EST-ext" category described above and encodes the signal peptide MKKVLLLITAILAVAVG (SEQ ID NO: 18) having a von Heijne score of 8.2.

The full length cDNA of SEQ ID NO:19 (internal identification number 58-34-2-E7-FL2) was also obtained using this procedure. This cDNA falls into the "EST-ext" category described above and encodes the signal peptide MWWFQQGLSFLPSALVIWTSA (SEQ ID NO:20) having a von Heijne score of 5.5.

Another full length cDNA obtained using the procedure described above has the sequence of SEQ ID NO:21 (internal identification number 51-27-E8-FL1). This cDNA, falls into the "EST-ext" category described above and encodes the signal peptide MVLTTLPSANSANSPVNMPTTGPNSLSYASSALSPCLT (SEQ ID NO:22) having a von Heijne score of 5.9.

The above procedure was also used to obtain a full length cDNA having the sequence of SEQ ID NO:23 (internal identification number 76-4-1-G5-FL1). This cDNA falls into the "EST-ext" category described above and encodes the signal peptide ILSTVTALTFAXA (SEQ ID NO:24) having a von Heijne score of 5.5.

The full length cDNA of SEQ ID NO:25 (internal identification number 51-3-3-B10-FL3) was also obtained using this procedure. This cDNA falls into the "new" category described above and encodes a signal peptide LVLTLCTLPLAVA (SEQ ID NO:26) having a von Heijne score of 10.1.

The full length cDNA of SEQ ID NO:27 (internal identification number 58-35-2-F10-FL2) was also obtained using this procedure. This cDNA falls into the "new" category described above and encodes a signal peptide LWLLFFLVTAIHA (SEQ ID NO:28) having a von Heijne score of 10.7.

Bacterial clones containing plasmids containing the full length cDNAs described above are presently stored in the inventor's laboratories under the internal identification numbers provided above. The inserts may be recovered from the deposited materials by growing an aliquot of the appropriate bacterial clone in the appropriate medium. The plasmid DNA can then be isolated using plasmid isolation procedures familiar to those skilled in the art such as alkaline lysis minipreps or large scale alkaline lysis plasmid isolation procedures. If desired the plasmid DNA may be further enriched by centrifugation on a cesium chloride gradient, size exclusion chromatography, or anion exchange chromatography. The plasmid DNA obtained using these procedures may then be manipulated using standard cloning techniques familiar to those skilled in the art. Alternatively, a PCR can be done with primers designed at both ends of the EST insertion. The PCR product which corresponds to the 5' EST can then be manipulated using standard cloning techniques familiar to those skilled in the art.

In addition to PCR based methods for obtaining cDNAs which include the authentic 5' end of the corresponding mRNA as well as the full protein coding sequence of the corresponding mRNA, traditional hybridization based methods may also be employed. These methods may also be used to obtain the genomic DNAs which encode the mRNAs from which the 5' ESTs were derived. Example 29 below provides an example of such methods. Authentic 5' End of the Corresponding mRNA

A cDNA library or genomic DNA is obtained from a commercial source or made using techniques familiar to those skilled in the art. The library includes cDNAs which are derived from the mRNA corresponding to a 5' EST. The cDNA library or genomic DNA library is hybridized to a detectable probe comprising at least 10 consecutive nucleotides from the 5' EST using conventional techniques. Preferably, the probe comprises at least 12, 15, or 17 consecutive nucleotides from the 5' EST. More preferably, the probe comprises at least 20-30 consecutive nucleotides from the 5' EST. In some embodiments, the probe comprises more than 30 nucleotides from the 5' EST. Techniques for identifying cDNA clones in a cDNA library which hybridize to a given probe sequence are disclosed in Sambrook et al., Molecular Cloning: A Laboratory Manual 2d Ed., Cold Spring Harbor Laboratory Press, 1989, the disclosure of which is incorporated herein by reference. The same techniques may be used to isolate genomic DNAs.

Briefly, cDNA or genomic DNA clones which hybridize to the detectable probe are identified and isolated for further manipulation as follows. A probe comprising at least 10 consecutive nucleotides from the 5' EST is labeled with a detectable label such as a radioisotope or a fluorescent molecule. Preferably, the probe comprises at least 12, 15, or 17 consecutive nucleotides from the 5' EST. More preferably, the probe comprises 20-30 consecutive nucleotides from the 5' EST. In some embodiments, the probe comprises more than 30 nucleotides from the 5' EST.

Techniques for labeling the probe are well known and include phosphorylation with polynucleotide kinase, nick translation, and in vitro transcription. The cDNAs or genomic DNAs in the library are transferred to a nitrocellulose or nylon filter and denatured. After incubation of the filter with a blocking solution, the filter is contacted with the labeled probe and incubated for a sufficient amount of time for the probe to hybridize to cDNAs or genomic DNAs containing a sequence capable of hybridizing to the probe.

By varying the stringency of the hybridization conditions used to identify cDNAs or genomic DNAs which hybridize to the detectable probe, cDNAS having different levels of homology to the probe can be identified and isolated. To identify cDNAs or genomic DNAs having a high degree of homology to the probe sequence, the melting temperature of the probe may be calculated using the following formulas:

For probes between 14 and 70 nucleotides in length the melting temperature (Tm) is calculated using the formula: Tm=81.5+16.6(log [Na+])+0.41(fraction G+C)-(600/N) where N is the length of the probe.

If the hybridization is carried out in a solution containing formamide, the melting temperature may be calculated using the equation Tm=81.5+16.6(log [Na+])+0.41(fraction G+C)-(0.63% formamide)-(600/N) where N is the length of the probe.

Prehybridization may be carried out in 6.times. SSC, 5.times. Denhardt's reagent, 0.5% SDS, 100 .mu.g denatured fragmented salmon sperm DNA or 6.times. SSC, 5.times. Denhardt's reagent, 0.5% SDS, 100 .mu.g denatured fragmented salmon sperm DNA, 50% formamide. The formulas for SSC and Denhardt's solutions are listed in Sambrook et al., supra.

Hybridization is conducted by adding the detectable probe to the prehybridization solutions listed above. Where the probe comprised double stranded DNA, it is denatured before addition to the hybridization solution. The filter is contacted with the hybridization solution for a sufficient period of time to allow the probe to hybridize to cDNAs or genomic DNAs containing sequences complementary thereto. For probes over 200 nucleotides in length, the hybridization may be carried out at 15-25.degree. C. below the Tm. For shorter probes, such as oligonucleotide probes, the hybridization may be conducted at 15-25.degree. C. below the Tm. Preferably, for hybridizations in 6.times. SSC, the hybridization is conducted at approximately 68.degree. C. Preferably, for hybridizations in 50% formamide containing solutions, the hybridization is conducted at approximately 42.degree. C.

All of the foregoing hybridizations would be considerted to be under "stringent" conditions.

Following hybridization, the filter is washed in 2.times. SSC, 0.1% SDS at room temperature for 15 minutes. The filter is then washed with 0.1.times. SSC, 0.5% SDS at room temperature for 30 minutes to 1 hour. Thereafter, the solution is washed at the hybridization temperature in 0.1.times. SSC, 0.5% SDS. A final wash is conducted in 0.1.times.SSC at room temperature.

cDNAs or genomic DNAs which have hybridized to the probe are identified by autoradiography.

The above procedure may be modified to identify cDNAs or genomic DNAs having decreasing levels of homology to the probe sequence. For example, to obtain cDNAs or genomic DNAs of decreasing homology to the detectable probe, less stringent conditions may be used. For example, the hybridization temperature may be decreased in increments of 5.degree. C. from 68.degree. C. to 42.degree. C. in a hybridization buffer having a Na+ concentration of approximately 1 M. Following hybridization, the filter may be washed with 2.times. SSC, 0.5% SDS at the temperature of hybridization. These conditions are considered to be "moderate" conditions above 50.degree. C. and "low" conditions below 50.degree. C.

Alternatively, the hybridization may be carried out in buffers, such as 6.times. SSC, containing formamide at a temperature of 42.degree. C. In this case, the concentration of formamide in the hybridization buffer may be reduced in 5% increments from 50% to 0% to identify clones having decreasing levels of homology to the probe. Following hybridization, the filter may be washed with 6.times. SSC, 0.5% SDS at 50.degree. C. These conditions are considered to be "moderate" conditions above 25% formamide and "low" conditions below 25% formamide.

cDNAs or genomic DNAs which have hybridized to the probe are identified by autoradiography.

Alternatively, cDNAs may be prepared by obtaining mRNA from the tissue, cell, or organism of interest using mRNA preparation procedures utilizing poly A selection procedures or other techniques known to those skilled in the art. A first primer capable of hybridizing to the poly A tail of the mRNA is hybridized to the mRNA and a reverse transcription reaction is performed to generate a first cDNA strand.

The first cDNA strand is hybridized to a second primer containing at least 10 consecutive nucleotides of the sequences of SEQ ID NOs 38-270. Preferably, the primer comprises at least 12, 15, or 17 consecutive nucleotides from the sequences of SEQ ID NOs 38-270. More preferably, the primer comprises 20-30 consecutive nucleotides from the sequences of to SEQ ID NOs 38-270. In some embodiments, the primer comprises more than 30 nucleotides from the sequences of SEQ ID NOs 38-270. If it is desired to obtain cDNAs containing the full protein coding sequence, including the authentic translation initiation site, the second primer used contains sequences located upstream of the translation initiation site. The second primer is extended to generate a second cDNA strand complementary to the first cDNA strand. Alternatively, RTPCR may be performed as described above using primers from both ends of the cDNA to be obtained.

cDNAs containing 5' fragments of the mRNA may be prepared by contacting an mRNA comprising the sequences of SEQ ID NOs: 38-270 with a primer comprising at least 10 consecutive nucleotides of the sequences complementary to SEQ ID NOs: 38-270, hybridizing the primer to the mRNAs, and reverse transcribing the hybridized primer to make a first cDNA strand from the mRNAs. Preferably, the primer comprises at least 12, 15, or 17 consecutive nucleotides from the 5' EST. More preferably, the primer comprises 20-30 consecutive nucleotides from the 5' EST.

Thereafter, a second cDNA strand complementary to the first cDNA strand is synthesized. The second cDNA strand may be made by hybridizing a primer complementary to sequences in the first cDNA strand to the first cDNA strand and extending the primer to generate the second cDNA strand.

The resulting double stranded cDNA strand is isolated and cloned. The cDNA may be cloned into vectors such as plasmids or viral vectors capable of replicating in an appropriate host cell. For example, the host cell may be a bacterial, mammalian, avian, or insect cell.

Techniques for isolating mRNA, reverse transcribing a primer hybridized to mRNA to generate a first cDNA strand, extending a primer to make a second cDNA strand complementary to the first cDNA strand, isolating the double stranded cDNA and cloning the double stranded cDNA are well known to those skilled in the art and are described in Current Protocols in Molecular Biology, John Wiley 503 Sons, Inc. 1997 and Sambrook et al. Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, 1989, the entire disclosures of which are incorporated herein by reference.

Alternatively, kits for obtaining full length cDNAs, such as the GeneTrapper (Cat. No. 10356-020, Gibco, BRL), may be used for obtaining full length cDNAs. In this approach, cDNA inserts are cloned into double stranded phagemids. The cDNA library in the double stranded phagemids is then rendered single stranded by treatment with an endonuclease, such as the Gene II product of the phage F1, and Exonulease III as described in the manual accompanying the GeneTrapper kit, which is incorporated herein by reference. A biotinylated oligonucleotide comprising the sequence of a 5' EST, or a fragment containing at least 10 nucleotides thereof, is hybridized to the single stranded phagemids. Preferably, the fragment comprises at least 12, 15, or 17 consecutive nucleotides from the 5' EST. More preferably, the fragment comprises 20-30 consecutive nucleotides from the 5' EST. In some procedures, the fragment may comprise more than 30 consecutive nucleotides from the 5' EST.

Hybrids between the biotinylated oligonucleotide and phagemids having inserts containing the 5' EST sequence are isolated by incubating the hybrids with streptavidin coated paramagnetic beads and retrieving the beads with a magnet. Therafter, the resulting phagemids containing the 5' EST sequence are released from the beads and converted into doublestranded DNA using a primer specific for the 5' EST sequence. The resulting double stranded DNA is transformed into bacteria. cDNAs containing the 5' EST sequence are identified by colony PCR or colony hybridization.

A plurality of cDNAs containing full length protein coding sequences may be provided as cDNA libraries for subsequent evaluation of the encoded proteins or use in diagnostic assays as described below.

cDNAs containing the full protein coding sequences of their corresponding mRNAs may be used to express the secreted proteins which they encode as described in Example 30 below. If desired, the cDNAs may contain the sequences encoding the signal peptide to facilitate secretion of the expressed protein. It will be appreciated that a plurality of cDNAs containing the full protein coding sequences may be simultaneously cloned into expression vectors to create an expression library for analysis of the encoded proteins as described below. ESTs

To express the proteins encoded by the genes corresponding to 5' ESTs, cDNAs containing the entire protein coding region are obtained as described in Examples 27-29. If desired, the cDNAs may contain the sequences encoding the signal peptide to facilitate secretion of the expressed protein. The cDNAs may also contain sequences upstream of the sequences encoding the signal peptide, such as sequences which regulate expression levels or sequences which confer tissue specific expression. The cDNA is operably linked to a promoter in an expression vector using conventional cloning technology. The expression vector may be any of the mammalian, yeast, insect or bacterial expression systems known in the art. Commercially available vectors and expression systems are available from a variety of suppliers including Stratagene (La Jolla, Calif.), Promega (Madison, Wis.), and Invitrogen (San Diego, Calif.). If desired, to enhance expression and facilitate proper protein folding, the codon context and codon pairing of the sequence may be optimized for the particular expression organism in which the expression vector is introduced, as explained by Hatfield, et al., U.S. Pat. No. 5,082,767, incorporated herein by this reference.

The following is provided as one exemplary method to express the proteins encoded by the cDNAs corresponding to the 5' ESTs. First, the methionine initiation codon for the gene and the poly A sequence of the gene are identified. If the cDNA lacks a poly A sequence, this sequence can be added to the construct by, for example, splicing out the Poly A sequence from pSG5 (Stratagene) using BglI and SalI restriction endonuclease enzymes and incorporating it into the mammalian expression vector pXT1 (Stratagene). pXT1 contains the LTRs and a portion of the gag gene from Moloney Murine Leukemia Virus. The position of the LTRs in the construct allow efficient stable transfection. The vector includes the Herpes Simplex Thymidine Kinase promoter and the selectable neomycin gene. The cDNA is obtained by PCR from the bacterial vector using oligonucleotide primers complementary to the cDNA and containing restriction endonuclease sequences for Pst I incorporated into the 5' primer and BglII at the 5' end of the corresponding cDNA 3' primer, taking care to ensure that the cDNA is positioned in frame with the poly A sequence. The purified fragment obtained from the resulting PCR reaction is digested with PstI, blunt ended with an exonuclease, digested with Bgl II, purified and ligated to pXT1, now containing a poly A sequence and digested with BglII.

The ligated product is transfected into mouse NIH 3T3 cells using Lipofectin (Life Technologies, Inc., Grand Island, N.Y.) under conditions outlined in the product specification. Positive transfectants are selected after growing the transfected cells in 600 ug/ml G418 (Sigma, St. Louis, Mo.). Preferably the expressed protein is released into the culture medium, thereby facilitating purification.

Proteins in the culture medium are separated by gel electrophoresis. If desired, the proteins may be ammonium sulfate precipitated or separated based on size or charge prior to electrophoresis.

As a control, the expression vector lacking a cDNA insert is introduced into host cells or organisms and the proteins in the medium are harvested. The secreted proteins present in the medium are detected using techniques such as Coomassie or silver staining or using antibodies against the protein encoded by the cDNA. Coomassie and silver staining techniques are familiar to those skilled in the art.

Antibodies capable of specifically recognizing the protein of interest may be generated using synthetic 15-mer peptides having a sequence encoded by the appropriate 5' EST. The synthetic peptides are injected into mice to generate antibody to the polypeptide encoded by the cDNA.

Secreted proteins from the host cells or organisms containing an expression vector which contains the cDNA derived from a 5' EST are compared to those from the control cells or organism. The presence of a band in the medium from the cells containing the expression vector which is absent in the medium from the medium from the control cells indicates that the cDNA encodes a secreted protein. Generally, the band corresponding to the protein encoded by the cDNA will have a mobility near that expected based on the number of amino acids in the open reading frame of the cDNA. However, the band may have a mobility different than that expected as a result of modifications such as glycosylation, ubiquitination, or enzymatic cleavage.

The protein encoded by the cDNA may be purified using standard immunochromatography techniques. In such procedures, a solution containing the secreted protein, such as the culture medium or a cell extract, is applied to a column having antibodies against the secreted protein attached to the chromatography matrix. The secreted protein is allowed to bind the immunochromatography column. Thereafter, the column is washed to remove non-specifically bound proteins. The specifically bound secreted protein is then released from the column and recovered using standard techniques.

If antibody production is not possible, the cDNA sequence may be incorporated into expression vectors designed for use in purification schemes employing chimeric polypeptides. In such strategies the coding sequence of the cDNA is inserted in frame with the gene encoding the other half of the chimera. The other half of the chimera may be .beta.-globin or a nickel binding polypeptide encoding sequence. A chromatography matrix having antibody to .beta.-globin or nickel attached thereto is then used to purify the chimeric protein. Protease cleavage sites may be engineered between the .beta.-globin gene or the nickel binding polypeptide and the cDNA. Thus, the two polypeptides of the chimera may be separated from one another by protease digestion.

One useful expression vector for generating .beta.-globin chimerics is pSG5 (Stratagene), which encodes rabbit .beta.-globin. Intron II of the rabbit .beta.-globin gene facilitates splicing of the expressed transcript, and the polyadenylation signal incorporated into the construct increases the level of expression. These techniques as described are well known to those skilled in the art of molecular biology. Standard methods are published in methods texts such as Davis et al., (Basic Methods in Molecular Biology, L. G. Davis, M. D. Dibner, and J. F. Battey, ed., Elsevier Press, NY, 1986) and many of the methods are available from Stratagene, Life Technologies, Inc., or Promega. Polypeptide may additionally be produced from the construct using in vitro translation systems such as the In vitro Express.TM. Translation Kit (Stratagene).

Following expression and purification of the secreted proteins encoded by the 5' ESTs, the purified proteins may be tested for the ability to bind to the surface of various cell types as described in Example 31 below. It will be appreciated that a plurality of proteins expressed from these cDNAs may be included in a panel of proteins to be simultaneously evaluated for the activities specifically described below, as well as other biological roles for which assays for determining activity are available. Surface

The proteins encoded by the 5' ESTs are cloned into expression vectors such as those described in Example 30. The proteins are purified by size, charge, immunochromatography or other techniques familiar to those skilled in the art. Following purification, the proteins are labeled using techniques known to those skilled in the art. The labeled proteins are incubated with cells or cell lines derived from a variety of organs or tissues to allow the proteins to bind to any receptor present on the cell surface. Following the incubation, the cells are washed to remove non-specifically bound protein. The labeled proteins are detected by autoradiography. Alternatively, unlabeled proteins may be incubated with the cells and detected with antibodies having a detectable label, such as a fluorescent molecule, attached thereto.

Specificity of cell surface binding may be analyzed by conducting a competition analysis in which various amounts of unlabeled protein are incubated along with the labeled protein. The amount of labeled protein bound to the cell surface decreases as the amount of competitive unlabeled protein increases. As a control, various amounts of an unlabeled protein unrelated to the labeled protein is included in some binding reactions. The amount of labeled protein bound to the cell surface does not decrease in binding reactions containing increasing amounts of unrelated unlabeled protein, indicating that the protein encoded by the cDNA binds specifically to the cell surface.

As discussed above, secreted proteins have been shown to have a number of important physiological effects and, consequently, represent a valuable therapeutic resource. The secreted proteins encoded by the cDNAs made according to Examples 27-29 may be evaluated to determine their physiological activities as described below. or Cell Differentiation Activity

As discussed above, secreted proteins may act as cytokines or may affect cellular proliferation or differentiation. The proteins encoded by the above cDNAs may be evaluated for their ability to regulate T cell or thymocyte proliferation in assays such as those described in the following references, which are incorporated herein by reference: Current Protocols in Immunology, Ed. by J. E. Coligan et al., Greene Publishing Associates and Wiley-Interscience; Takai et al. J. Immunol. 137:3494-3500, 1986. Bertagnolli et al. J. Immunol. 145:1706-1712, 1990. Bertagnolli et al., Cellular Immunology 133:327-341, 1991. Bertagnolli, et al. J. Immunol. 149:3778-3783, 1992; Bowman et al., J. Immunol. 152:1756-1761, 1994.

In addition, numerous assays for cytokine production and/or the proliferation of spleen cells, lymph node cells and thymocytes are known. These include the techniques disclosed in Current Protocols in Immunology. J. E. Coligan et al. Eds., Vol 1 pp. 3.12.1-3.12.14 John Wiley and Sons, Toronto. 1994; and Schreiber, R. D. In Current Protocols in Immunology., supra Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto. 1994.

The proteins encoded by the cDNAs may also be assayed for the ability to regulate the proliferation and differentiation of hematopoietic or lymphopoietic cells. Many assays for such activity are familiar to those skilled in the art, including the assays in the following references, which are incorporated herein by reference: Bottomly, K., Davis, L. S. and Lipsky, P. E., Measurement of Human and Murine Interleukin 2 and Interleukin 4, In Current Protocols in Immunology., J. E. Coligan et al. Eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto. 1991; deVries et al., J. Exp. Med. 173:1205-1211, 1991; Moreau et al., Nature 36:690-692, 1988; Greenberger et al., Proc. Natl. Acad. Sci. U.S.A. 80:2931-2938, 1983; Nordan, R., Measurement of Mouse and Human Interleukin 6 In Current Protocols in Immunology. J. E. Coligan et al. Eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto. 1991; Smith et al., Proc. Natl. Acad. Sci. U.S.A. 83:1857-1861, 1986; Bennett, F., Giannotti, J., Clark, S. C. and Turner, K. J., Measurement of Human Interleukin 11 in Current Protocols in Immunology. J. E. Coligan et al. Eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto. 1991; Ciarletta, A., Giannotti, J., Clark, S. C. and Turner, K. J., Measurement of Mouse and Human Interleukin 9 In Current Protocols in Immunology. J. E. Coligan et al., Eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. 1991.

The proteins encoded by the cDNAs may also be assayed for their ability to regulate T-cell responses to antigens. Many assays for such activity are familiar to those skilled in the art, including the assays described in the following references, which are incorporated herein by reference: Chapter 3 (In Vitro Assays for Mouse Lymphocyte Function), Chapter 6 (Cytokines and Their Cellular Receptors) and Chapter 7, (Immunologic Studies in Humans) in Current Protocols in Immunology, J. E. Coligan et al. Eds. Greene Publishing Associates and Wiley-Interscience; Weinberger et al., Proc. Natl. Acad. Sci. USA 77:6091-6095, 1980; Weinberger et al., Eur. J. Immun. 11:405-411, 1981; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988.

Those proteins which exhibit cytokine, cell proliferation, or cell differentiation activity may then be formulated as pharmaceuticals and used to treat clinical conditions in which induction of cell proliferation or differentiation is beneficial. Alternatively, as described in more detail below, genes encoding these proteins or nucleic acids regulating the expression of these proteins may be introduced into appropriate host cells to increase or decrease the expression of the proteins as desired. Regulators

The proteins encoded by the cDNAs may also be evaluated for their effects as immune regulators. For example, the proteins may be evaluated for their activity to influence thymocyte or splenocyte cytotoxicity. Numerous assays for such activity are familiar to those skilled in the art including the assays described in the following references, which are incorporated herein by reference: Chapter 3 (In Vitro Assays for Mouse Lymphocyte Function 3.1-3.19) and Chapter 7 (Immunologic studies in Humans) in Current Protocols in Immunology, J. E. Coligan et al. Eds, Greene Publishing Associates and Wiley-Interscience; Herrmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Herrmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Bowman et al., J. Virology 61:1992-1998; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Brown et al., J. Immunol. 153:3079-3092, 1994.

The proteins encoded by the cDNAs may also be evaluated for their effects on T-cell dependent immunoglobulin responses and isotype switching. Numerous assays for such activity are familiar to those skilled in the art, including the assays disclosed in the following references, which are incorporated herein by reference: Maliszewski, J. Immunol. 144:3028-3033, 1990; Mond, J. J. and Brunswick, M Assays for B Cell Function: In vitro Antibody Production, Vol 1 pp. 3.8.1-3.8.16 in Current Protocols in Immunology. J. E. Coligan et al Eds., John Wiley and Sons, Toronto. 1994.

The proteins encoded by the cDNAs may also be evaluated for their effect on immune effector cells, including their effect on Th1 cells and cytotoxic lymphocytes. Numerous assays for such activity are familiar to those skilled in the art, including the assays disclosed in the following references, which are incorporated herein by reference: Chapter 3 (In Vitro Assays for Mouse Lymphocyte Function 3.1-3.19) and Chapter 7 (Immunologic Studies in Humans) in Current Protocols in Immunology, J. E. Coligan et al. Eds., Greene Publishing Associates and Wiley-Interscience; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al.; J. Immunol. 140:508-512, 1988; Bertagnolli et al., J. Immunol. 149:3778-3783, 1992.

The proteins encoded by the cDNAs may also be evaluated for their effect on dendritic cell mediated activation of naive T-cells. Numerous assays for such activity are familiar to those skilled in the art, including the assays disclosed in the following references, which are incorporated herein by reference: Guery et al., J. Immunol. 134:536-544, 1995; Inaba et al., Journal of Experimental Medicine 173:549-559, 1991; Macatonia et al., Journal of Immunology 154:5071-5079, 1995; Porgador et al., Journal of Experimental Medicine 182:255-260, 1995; Nair et al., Journal of Virology 67:4062-4069, 1993; Huang et al., Science 264:961-965, 1994; Macatonia et al., Journal of Experimental Medicine 169:1255-1264, 1989; Bhardwaj et al., Journal of Clinical Investigation 94:797-807, 1994; and Inaba et al., Journal of Experimental Medicine 172:631-640, 1990.

The proteins encoded by the cDNAs may also be evaluated for their influence on the lifetime of lymphocytes. Numerous assays for such activity are familiar to those skilled in the art, including the assays disclosed in the following references, which are incorporated herein by reference: Darzynkiewicz et al., Cytometry 13:795-808, 1992; Gorczyca et al., Leukemia 7:659-670, 1993; Gorczyca et al., Cancer Research 53:1945-1951, 1993; Itoh et al., Cell 66:233-243, 1991; Zacharchuk, Journal of Immunology 145:4037-4045, 1990; Zamai et al., Cytometry 14:891-897, 1993; Gorczyca et al., International Journal of Oncology 1:639-648, 1992.

Those proteins which exhibit activity as immune system regulators activity may then be formulated as pharmaceuticals and used to treat clinical conditions in which regulation of immune activity is beneficial. Alternatively, as described in more detail below, genes encoding these proteins or nucleic acids regulating the expression of these proteins may be introduced into appropriate host cells to increase or decrease the expression of the proteins as desired. Activity

The proteins encoded by the cDNAs may also be evaluated for their hematopoiesis regulating activity. For example, the effect of the proteins on embryonic stem cell differentiation may be evaluated. Numerous assays for such activity are familiar to those skilled in the art, including the assays disclosed in the following references, which are incorporated herein by reference: Johansson et al. Cellular Biology 15:141-151, 1995; Keller et al., Molecular and Cellular Biology 13:473-486, 1993; McClanahan et al., Blood 81:2903-2915, 1993.

The proteins encoded by the cDNAs may also be evaluated for their influence on the lifetime of stem cells and stem cell differentiation. Numerous assays for such activity are familiar to those skilled in the art, including the assays disclosed in the following references, which are incorporated herein by reference: Freshney, M. G. Methylcellulose Colony Forming Assays, in Culture of Hematopoietic Cells. R. I. Freshney, et al. Eds. pp. 265-268, Wiley-Liss, Inc., New York, N.Y. 1994; Hirayama et al., Proc. Natl. Acad. Sci. USA 89:5907-5911, 1992; McNiece, I. K. and Briddell, R. A. Primitive Hematopoietic Colony Forming Cells with High Proliferative Potential, in Culture of Hematopoietic Cells. R.I. Freshney, et al. eds. Vol pp. 23-39, Wiley-Liss, Inc., New York, N.Y. 1994; Neben et al., Experimental Hematology 22:353-359, 1994; Ploemacher, R. E. Cobblestone Area Forming Cell Assay, In Culture of Hematopoietic Cells. R. I. Freshney, et al. Eds. pp. 1-21, Wiley-Liss, Inc., New York, N.Y. 1994; Spooncer, E., Dexter, M. and Allen, T. Long Term Bone Marrow Cultures in the Presence of Stromal Cells, in Culture of Hematopoietic Cells. R. I. Freshney, et al. Eds. pp. 163-179, Wiley-Liss, Inc., New York, N.Y. 1994; Sutherland, H. J. Long Term Culture Initiating Cell Assay, in Culture of Hematopoietic Cells. R. I. Freshney, et al. Eds. pp. 139-162, Wiley-Liss, Inc., New York, N.Y. 1994.

Those proteins which exhibit hematopoiesis regulatory activity may then be formulated as pharmaceuticals and used to treat clinical conditions in which regulation of hematopoeisis is beneficial. Alternatively, as described in more detail below, genes encoding these proteins or nucleic acids regulating the expression of these proteins may be introduced into appropriate host cells to increase or decrease the expression of the proteins as desired.

The proteins encoded by the cDNAs may also be evaluated for their effect on tissue growth. Numerous assays for such activity are familiar to those skilled in the art, including the assays disclosed in International Patent Publication No. WO95/16035, International Patent Publication No. WO95/05846 and International Patent Publication No. WO91/07491, which are incorporated herein by reference.

Those proteins which are involved in the regulation of tissue growth may then be formulated as pharmaceuticals and used to treat clinical conditions in which regulation of tissue growth is beneficial. Alternatively, as described in more detail below, genes encoding these proteins or nucleic acids regulating the expression of these proteins may be introduced into appropriate host cells to increase or decrease the expression of the proteins as desired. Hormones or Cell Movement

The proteins encoded by the cDNAs may also be evaluated for their ability to regulate reproductive hormones, such as follicle stimulating hormone. Numerous assays for such activity are familiar to those skilled in the art, including the assays disclosed in the following references, which are incorporated herein by reference: Vale et al., Endocrinology 91:562-572, 1972; Ling et al., Nature 321:779-782, 1986; Vale et al., Nature 321:776-779, 1986; Mason et al., Nature 318:659-663, 1985; Forage et al., Proc. Natl. Acad. Sci. USA 83:3091-3095, 1986. Chapter 6.12 (Measurement of Alpha and Beta Chemokines) Current Protocols in Immunology, J. E. Coligan et al. Eds. Greene Publishing Associates and Wiley-Intersciece; Taub et al. J. Clin. Invest. 95:1370-1376, 1995; Lind et al. APMIS 103:140-146, 1995; Muller et al. Eur. J. Immunol. 25:1744-1748; Gruber et al. J. of Immunol. 152:5860-5867, 1994; Johnston et al. J. of Immunol. 153:1762-1768, 1994.

Those proteins which exhibit activity as reproductive hormones or regulators of cell movement may then be formulated as pharmaceuticals and used to treat clinical conditions in which regulation of reproductive hormones or cell movement are beneficial. Alternatively, as described in more detail below, genes encoding these proteins or nucleic acids regulating the expression of these proteins may be introduced into appropriate host cells to increase or decrease the expression of the proteins as desired.

The proteins encoded by the cDNAs may also be evaluated for their effects on blood clotting. Numerous assays for such activity are familiar to those skilled in the art, including the assays disclosed in the following references, which are incorporated herein by reference: Linet et al., J. Clin. Pharmacol. 26:131-140, 1986; Burdick et al., Thrombosis Res. 45:413-419, 1987; Humphrey et al., Fibrinolysis 5:71-79 (1991); Schaub, Prostaglandins 35:467-474, 1988.

Those proteins which are involved in the regulation of blood clotting may then be formulated as pharmaceuticals and used to treat clinical conditions in which regulation of blood clotting is beneficial. Alternatively, as described in more detail below, genes encoding these proteins or nucleic acids regulating the expression of these proteins may be introduced into appropriate host cells to increase or decrease the expression of the proteins as desired. Receptor/Ligand Interactions

The proteins encoded by the cDNAs may also be evaluated for their involvement in receptor/ligand interactions. Numerous assays for such involvement are familiar to those skilled in the art, including the assays disclosed in the following references, which are incorporated herein by reference: Chapter 7.28 (Measurement of Cellular Adhesion under Static Conditions 7.28.1-7.28.22) in Current Protocols in Immunology, J. E. Coligan et al. Eds. Greene Publishing Associates and Wiley-Interscience; Takai et al., Proc. Natl. Acad. Sci. USA 84:6864-6868, 1987; Bierer et al., J. Exp. Med. 168:1145-1156, 1988; Rosenstein et al., J. Exp. Med. 169:149-160, 1989; Stoltenborg et al., J. Immunol. Methods 175:59-68, 1994; Stitt et al., Cell 80:661-670, 1995; Gyuris et al., Cell 75:791-803, 1993. ESTs

Proteins which interact with the polypeptides encoded by full length cDNAs derived from the 5' ESTs or fragments thereof, such as receptor proteins, may be identified using two hybrid systems such as the Matchmaker Two Hybrid System 2 (Catalog No. K1604-1, Clontech). As described in the manual accompanying the Matchmaker Two Hybrid System 2 (Catalog No. K1604-1, Clontech), which is incorporated herein by reference, the full length cDNAs derived from 5' ESTs, or fragments thereof, are inserted into an expression vector such that they are in frame with DNA encoding the DNA binding domain of the yeast transcriptional activator GAL4. cDNAs in a cDNA library which encode proteins which might interact with the polypeptides encoded by full length cDNAs derived from the 5' ESTs or fragments thereof are inserted into a second expression vector such that they are in frame with DNA encoding the activation domain of GAL4. The two expression plasmids are transformed into yeast and the yeast are plated on selection medium which selects for expression of selectable markers on each of the expression vectors as well as GAL4 dependent expression of the HIS3 gene. Transformants capable of growing on medium lacking histidine are screened for GAL4 dependent lacZ expression. Those cells which are positive in both the histidine selection and the lacZ assay contain plasmids encoding proteins which interact with the polypeptide encoded by the full length cDNAs derived from the 5' ESTs or fragments thereof.

It will be appreciated by those skilled in the art that the proteins expressed from the cDNAs may be assayed for numerous activities in addition to those specifically enumerated above. For example, the expressed proteins may be evaluated for applications involving control and regulation of inflammation, tumor proliferation or metastasis, infection, or other clinical conditions. In addition, the proteins expressed from the cDNAs may be useful as nutritional agents or cosmetic agents.

The proteins expressed from the cDNAs may be used to generate antibodies capable of specifically binding to the expressed protein.

Substantially pure protein or polypeptide is isolated from the transfected or transformed cells as described in Example 30. The concentration of protein in the final preparation is adjusted, for example, by concentration on an Amicon filter device, to the level of a few micrograms/ml. Monoclonal or polyclonal antibody to the protein can then be prepared as follows:

A. Monoclonal Antibody Production by Hybridoma Fusion

Monoclonal antibody to epitopes of any of the peptides identified and isolated as described can be prepared from murine hybridomas according to the classical method of Kohler, G. and Milstein, C., Nature 256:495 (1975) or derivative methods thereof. Briefly, a mouse is repetitively inoculated with a few micrograms of the selected protein or peptides derived therefrom over a period of a few weeks. The mouse is then sacrificed, and the antibody producing cells of the spleen isolated. The spleen cells are fused by means of polyethylene glycol with mouse myeloma cells, and the excess unfused cells destroyed by growth of the system on selective media comprising aminopterin (HAT media). The successfully fused cells are diluted and aliquots of the dilution placed in wells of a microtiter plate where growth of the culture is continued. Antibody-producing clones are identified by detection of antibody in the supernatant fluid of the wells by immunoassay procedures, such as Elisa, as originally described by Engvall, E., Meth. Enzymol. 70:419 (1980), and derivative methods thereof. Selected positive clones can be expanded and their monoclonal antibody product harvested for use. Detailed procedures for monoclonal antibody production are described in Davis, L. et al. Basic Methods in Molecular Biology Elsevier, New York. Section 21-2.

B. Polyclonal Antibody Production by Immunization

Polyclonal antiserum containing antibodies to heterogenous epitopes of a single protein can be prepared by immunizing suitable animals with the expressed protein or peptides derived therefrom described above, which can be unmodified or modified to enhance immunogenicity. Effective polyclonal antibody production is affected by many factors related both to the antigen and the host species. For example, small molecules tend to be less immunogenic than others and may require the use of carriers and adjuvant. Also, host animals vary in response to site of inoculations and dose, with both inadequate or excessive doses of antigen resulting in low titer antisera. Small doses (ng level) of antigen administered at multiple intradermal sites appears to be most reliable. An effective immunization protocol for rabbits can be found in Vaitukaitis, J. et al. J. Clin. Endocrinol. Metab. 33:988-991 (1971).

Booster injections can be given at regular intervals, and antiserum harvested when antibody titer thereof, as determined semi-quantitatively, for example, by double immunodiffusion in agar against known concentrations of the antigen, begins to fall. See, for example, Ouchterlony, O. et al., Chap. 19 in: Handbook of Experimental Immunology D. Wier (ed) Blackwell (1973). Plateau concentration of antibody is usually in the range of 0.1 to 0.2 mg/ml of serum (about 12 .mu.M). Affinity of the antisera for the antigen is determined by preparing competitive binding curves, as described, for example, by Fisher, D., Chap. 42 in: Manual of Clinical Immunology, 2d Ed. (Rose and Friedman, Eds.) Amer. Soc. For Microbiol., Washington, D.C. (1980).

Antibody preparations prepared according to either protocol are useful in quantitative immunoassays which determine concentrations of antigen-bearing substances in biological samples; they are also used semi-quantitatively or qualitatively to identify the presence of antigen in a biological sample. The antibodies may also be used in therapeutic compositions for killing cells expressing the protein or reducing the levels of the protein in the body.

The 5' ESTs of the present invention (or cDNAs or genomic DNAs obtainable therefrom) therefrom may be used as reagents in isolation procedures, diagnostic assays, and forensic procedures. For example, sequences from the 5' ESTs (or cDNAs or genomic DNAs obtainable therefrom), may be detectably labeled and used as probes to isolate other sequences capable of hybridizing to them. In addition, sequences from the 5' ESTs (or cDNAs or genomic DNAs obtainable therefrom), may be used to design PCR primers to be used in isolation, diagnostic, or forensic procedures.

The 5' EST sequences (or cDNAs or genomic DNAs obtainable therefrom) may be used to prepare PCR primers for a variety of applications, including isolation procedures for cloning nucleic acids capable of hybridizing to such sequences, diagnostic techniques and forensic techniques. The PCR primers are at least 10 bases, and preferably at least 12, 15, or 17 bases in length. More preferably, the PCR primers are at least 20-30 bases in length. In some embodiments, the PCR primers may be more than 30 bases in length. It is preferred that the primer pairs have approximately the same G/C ratio, so that melting temperatures are approximately the same. A variety of PCR techniques are familiar to those skilled in the art. For a review of PCR technology, see Molecular Cloning to Genetic Engineering White, B. A. Ed. in Methods in Molecular Biology 67: Humana Press, Totowa 1997. In each of these PCR procedures, PCR primers on either side of the nucleic acid sequences to be amplified are added to a suitably prepared nucleic acid sample along with dNTPs and a thermostable polymerase such as Taq polymerase, Pfu polymerase, or Vent polymerase. The nucleic acid in the sample is denatured and the PCR primers are specifically hybridized to complementary nucleic acid sequences in the sample. The hybridized primers are extended. Thereafter, another cycle of denaturation, hybridization, and extension is initiated. The cycles are repeated multiple times to produce an amplified fragment containing the nucleic acid sequence between the primer sites.

Probes derived from 5' ESTs (or cDNAs or genomic DNAs obtainable therefrom), including full length cDNAs or genomic sequences, may be labeled with detectable labels familiar to those skilled in the art, including radioisotopes and non-radioactive labels, to provide a detectable probe. The detectable probe may be single stranded or double stranded and may be made using techniques known in the art, including in vitro transcription, nick translation, or kinase reactions.

A nucleic acid sample containing a sequence capable of hybridizing to the labeled probe is contacted with the labeled probe. If the nucleic acid in the sample is double stranded, it may be denatured prior to contacting the probe. In some applications, the nucleic acid sample may be immobilized on a surface such as a nitrocellulose or nylon membrane. The nucleic acid sample may comprise nucleic acids obtained from a variety of sources, including genomic DNA, cDNA libraries, RNA, or tissue samples.

Procedures used to detect the presence of nucleic acids capable of hybridizing to the detectable probe include well known techniques such as Southern blotting, Northern blotting, dot blotting, colony hybridization, and plaque hybridization. In some applications, the nucleic acid capable of hybridizing to the labeled probe may be cloned into vectors such as expression vectors, sequencing vectors, or in vitro transcription vectors to facilitate the characterization and expression of the hybridizing nucleic acids in the sample. For example, such techniques may be used to isolate and clone sequences in a genomic library or cDNA library which are capable of hybridizing to the detectable probe as described in Example 30 above.

PCR primers made as described in Example 41 above may be used in forensic analyses, such as the DNA fingerprinting techniques described in Examples 43-47 below. Such analyses may utilize detectable probes or primers based on the sequences of the 5' ESTs or of cDNAs or genomic DNAs isolated using the 5' ESTs.

In one exemplary method, DNA samples are isolated from forensic specimens of, for example, hair, semen, blood or skin cells by conventional methods. A panel of PCR primers based on a number of the 5' ESTs of Example 25, or cDNAs or genomic DNAs isolated therefrom as described above, is then utilized in accordance with Example 41 to amplify DNA of approximately 100-200 bases in length from the forensic specimen. Corresponding sequences are obtained from a test subject. Each of these identification DNAs is then sequenced using standard techniques, and a simple database comparison determines the differences, if any, between the sequences from the subject and those from the sample. Statistically significant differences between the suspect's DNA sequences and those from the sample conclusively prove a lack of identity. This lack of identity can be proven, for example, with only one sequence. Identity, on the other hand, should be demonstrated with a large number of sequences, all matching. Preferably, a minimum of 50 statistically identical sequences of 100 bases in length are used to prove identity between the suspect and the sample.

The technique outlined in the previous example may also be used on a larger scale to provide a unique fingerprint-type identification of any individual. In this technique, primers are prepared from a large number of sequences from Example 25, or cDNA or genomic DNA sequences obtainable therefrom. Preferably, 20 to 50 different primers are used. These primers are used to obtain a corresponding number of PCR-generated DNA segments from the individual in question in accordance with Example 41. Each of these DNA segments is sequenced, using the methods set forth in Example 43. The database of sequences generated through this procedure uniquely identifies the individual from whom the sequences were obtained. The same panel of primers may then be used at any later time to absolutely correlate tissue or other biological specimen with that individual.

The procedure of Example 44 is repeated to obtain a panel of at least 10 amplified sequences from an individual and a specimen. Preferably, the panel contains at least 50 amplified sequences. More preferably, the panel contains 100 amplified sequences. In some embodiments, the panel contains 200 amplified sequences. This PCR-generated DNA is then digested with one or a combination of, preferably, four base specific restriction enzymes. Such enzymes are commercially available and known to those of skill in the art. After digestion, the resultant gene fragments are size separated in multiple duplicate wells on an agarose gel and transferred to nitrocellulose using Southern blotting techniques well known to those with skill in the art. For a review of Southern blotting see Davis et al. (Basic Methods in Molecular Biology, 1986, Elsevier Press. pp 62-65).

A panel of probes based on the sequences of the 5' ESTs (or cDNAs or genomic DNAs obtainable therefrom), or fragments thereof of at least 10 bases, are radioactively or colorimetrically labeled using methods known in the art, such as nick translation or end labeling, and hybridized to the Southern blot using techniques known in the art (Davis et al., supra). Preferably, the probe comprises at least 12, 15, or 17 consecutive nucleotides from the 5' EST. More preferably, the probe comprises at least 20-30 consecutive nucleotides from the 5' EST. In some embodiments, the probe comprises more than 30 nucleotides from the 5' EST.

Preferably, at least 5 to 10 of these labeled probes are used, and more preferably at least about 20 or 30 are used to provide a unique pattern. The resultant bands appearing from the hybridization of a large sample of 5' ESTs will be a unique identifier. Since the restriction enzyme cleavage will be different for every individual, the band pattern on the Southern blot will also be unique. Increasing the number of 5' EST probes will provide a statistically higher level of confidence in the identification since there will be an increased number of sets of bands used for identification.

Another technique for identifying individuals using the 5' EST sequences disclosed herein utilizes a dot blot hybridization technique.

Genomic DNA is isolated from nuclei of subject to be identified. Oligonucleotide probes of approximately 30 bp in length are synthesized that correspond to at least 10, preferably 50 sequences from the 5' ESTs or cDNAs or genomic DNAs obtainable therefrom. The probes are used to hybridize to the genomic DNA through conditions known to those in the art. The oligonucleotides are end labeled with P.sup.32 using polynucleotide kinase (Pharmacia). Dot Blots are created by spotting the genomic DNA onto nitrocellulose or the like using a vacuum dot blot manifold (BioRad, Richmond Calif.). The nitrocellulose filter containing the genomic sequences is baked or UV linked to the filter, prehybridized and hybridized with labeled probe using techniques known in the art (Davis et al. supra). The .sup.32 P labeled DNA fragments are sequentially hybridized with successively stringent conditions to detect minimal differences between the 30 bp sequence and the DNA. Tetramethylammonium chloride is useful for identifying clones containing small numbers of nucleotide mismatches (Wood et al., Proc. Natl. Acad. Sci. USA 82(6):1585-1588 (1985)) which is hereby incorporated by reference. A unique pattern of dots distinguishes one individual from another individual.

5' EST sequences (or cDNAs or genomic DNAs obtainable therefrom) or oligonucleotides containing at least 10 consecutive bases from the preceding sequences can be used as probes in the following alternative fingerprinting technique. Preferably, the probe comprises at least 12, 15, or 17 consecutive nucleotides from the 5' EST. More preferably, the probe comprises at least 20-30 consecutive nucleotides from the 5' EST. In some embodiments, the probe comprises more than 30 nucleotides from the 5' EST. Preferably, a plurality of probes having sequences from different genes are used in the alternative fingerprinting technique. Example 47 below provides a representative alternative fingerprinting procedure in which the probes are derived from 5' ESTs. However, those skilled in the art will appreciate that the procedure of Example 47 may readily be implemented with probes containing sequences from cDNAs or genomic sequences obtainable from the 5' ESTs.

20-mer oligonucleotides are prepared from a large number, e.g. 50, 100, or 200, 5' EST sequences using commercially available oligonucleotide services such as Genset, Paris, France. Cell samples from the test subject are processed for DNA using techniques well known to those with skill in the art. The nucleic acid is digested with restriction enzymes such as EcoRI and XbaI. Following digestion, samples are applied to wells for electrophoresis. The procedure, as known in the art, may be modified to accommodate polyacrylamide electrophoresis, however in this example, samples containing 5 ug of DNA are loaded into wells and separated on 0.8% agarose gels. The gels are transferred onto nitrocellulose using standard Southern blotting techniques.

10 ng of each of the oligonucleotides are pooled and end-labeled with P.sup.32. The nitrocellulose is prehybridized with blocking solution and hybridized with the labeled probes. Following hybridization and washing, the nitrocellulose filter is exposed to X-Omat AR X-ray film. The resulting hybridization pattern will be unique for each individual.

It is additionally contemplated within this example that the number of probe sequences used can be varied for additional accuracy or clarity.

The antibodies generated in Examples 30 and 40 above may be used to identify the tissue type or cell species from which a sample is derived as described above. Specific Antibodies

Identification of specific tissues is accomplished by the visualization of tissue specific antigens by means of antibody preparations according to Examples 30 and 40 which are conjugated, directly or indirectly to a detectable marker. Selected labeled antibody species bind to their specific antigen binding partner in tissue sections, cell suspensions, or in extracts of soluble proteins from a tissue sample to provide a pattern for qualitative or semi-qualitative interpretation.

Antisera for these procedures must have a potency exceeding that of the native preparation, and for that reason, antibodies are concentrated to a mg/ml level by isolation of the gamma globulin fraction, for example, by ion-exchange chromatography or by ammonium sulfate fractionation. Also, to provide the most specific antisera, unwanted antibodies, for example to common proteins, must be removed from the gamma globulin fraction, for example by means of insoluble immunoabsorbents, before the antibodies are labeled with the marker. Either monoclonal or heterologous antisera is suitable for either procedure.

A. Immunohistochemical Techniques

Purified, high-titer antibodies, prepared as described above, are conjugated to a detectable marker, as described, for example, by Fudenberg, H., Chap. 26 in: Basic 503 Clinical Immunology, 3rd Ed. Lange, Los Altos, Calif. (1980) or Rose, N. et al., Chap. 12 in: Methods in Immunodiagnosis, 2d Ed. John Wiley 503 Sons, New York (1980).

A fluorescent marker, either fluorescein or rhodamine, is preferred, but antibodies can also be labeled with an enzyme that supports a color producing reaction with a substrate, such as horseradish peroxidase. Markers can be added to tissue-bound antibody in a second step, as described below. Alternatively, the specific antitissue antibodies can be labeled with ferritin or other electron dense particles, and localization of the ferritin coupled antigen-antibody complexes achieved by means of an electron microscope. In yet another approach, the antibodies are radiolabeled, with, for example .sup.125 I, and detected by overlaying the antibody treated preparation with photographic emulsion.

Preparations to carry out the procedures can comprise monoclonal or polyclonal antibodies to a single protein or peptide identified as specific to a tissue type, for example, brain tissue, or antibody preparations to several antigenically distinct tissue specific antigens can be used in panels, independently or in mixtures, as required.

Tissue sections and cell suspensions are prepared for immunohistochemical examination according to common histological techniques. Multiple cryostat sections (about 4 .mu.m, unfixed) of the unknown tissue and known control, are mounted and each slide covered with different dilutions of the antibody preparation. Sections of known and unknown tissues should also be treated with preparations to provide a positive control, a negative control, for example, pre-immune sera, and a control for non-specific staining, for example, buffer.

Treated sections are incubated in a humid chamber for 30 min at room temperature, rinsed, then washed in buffer for 30-45 min. Excess fluid is blotted away, and the marker developed.

If the tissue specific antibody was not labeled in the first incubation, it can be labeled at this time in a second antibody-antibody reaction, for example, by adding fluorescein- or enzyme-conjugated antibody against the immunoglobulin class of the antiserum-producing species, for example, fluorescein labeled antibody to mouse IgG. Such labeled sera are commercially available.

The antigen found in the tissues by the above procedure can be quantified by measuring the intensity of color or fluorescence on the tissue section, and calibrating that signal using appropriate standards.

B. Identification of Tissue Specific Soluble Proteins

The visualization of tissue specific proteins and identification of unknown tissues from that procedure is carried out using the labeled antibody reagents and detection strategy as described for immunohistochemistry; however the sample is prepared according to an electrophoretic technique to distribute the proteins extracted from the tissue in an orderly array on the basis of molecular weight for detection.

A tissue sample is homogenized using a Virtis apparatus; cell suspensions are disrupted by Dounce homogenization or osmotic lysis, using detergents in either case as required to disrupt cell membranes, as is the practice in the art. Insoluble cell components such as nuclei, microsomes, and membrane fragments are removed by ultracentrifugation, and the soluble protein-containing fraction concentrated if necessary and reserved for analysis.

A sample of the soluble protein solution is resolved into individual protein species by conventional SDS polyacrylamide electrophoresis as described, for example, by Davis, L. et al., Section 19-2 in: Basic Methods in Molecular Biology (P. Leder, ed), Elsevier, New York (1986), using a range of amounts of polyacrylamide in a set of gels to resolve the entire molecular weight range of proteins to be detected in the sample. A size marker is run in parallel for purposes of estimating molecular weights of the constituent proteins. Sample size for analysis is a convenient volume of from 5 to 55 .mu.l, and containing from about 1 to 100 .mu.g protein. An aliquot of each of the resolved proteins is transferred by blotting to a nitrocellulose filter paper, a process that maintains the pattern of resolution. Multiple copies are prepared. The procedure, known as Western Blot Analysis, is well described in Davis, L. et al., (above) Section 19-3. One set of nitrocellulose blots is stained with Coomassie Blue dye to visualize the entire set of proteins for comparison with the antibody bound proteins. The remaining nitrocellulose filters are then incubated with a solution of one or more specific antisera to tissue specific proteins prepared as described in Examples 30 and 40. In this procedure, as in procedure A above, appropriate positive and negative sample and reagent controls are run.

In either procedure A or B, a detectable label can be attached to the primary tissue antigen-primary antibody complex according to various strategies and permutations thereof. In a straightforward approach, the primary specific antibody can be labeled; alternatively, the unlabeled complex can be bound by a labeled secondary anti-IgG antibody. In other approaches, either the primary or secondary antibody is conjugated to a biotin molecule, which can, in a subsequent step, bind an avidin conjugated marker. According to yet another strategy, enzyme labeled or radioactive protein A, which has the property of binding to any IgG, is bound in a final step to either the primary or secondary antibody.

The visualization of tissue specific antigen binding at levels above those seen in control tissues to one or more tissue specific antibodies, prepared from the gene sequences identified from EST sequences, can identify tissues of unknown origin, for example, forensic samples, or differentiated tumor tissue that has metastasized to foreign bodily sites.

In addition to their applications in forensics and identification, 5' ESTs (or cDNAs or genomic DNAs obtainable therefrom) may be mapped to their chromosomal locations. Example 49 below describes radiation hybrid (RH) mapping of human chromosomal regions using 5' ESTs. Example 50 below describes a representative procedure for mapping a 5' EST to its location on a human chromosome. Example 51 below describes mapping of 5' ESTs on metaphase chromosomes by Fluorescence In Situ Hybridization (FISH). Those skilled in the art will appreciate that the method of Examples 49-51 may also be used to map cDNAs or genomic DNAs obtainable from the 5' ESTs to their chromosomal locations.

Radiation hybrid (RH) mapping is a somatic cell genetic approach that can be used for high resolution mapping of the human genome. In this approach, cell lines containing one or more human chromosomes are lethally irradiated, breaking each chromosome into fragments whose size depends on the radiation dose. These fragments are rescued by fusion with cultured rodent cells, yielding subclones containing different portions of the human genome. This technique is described by Benham et al. (Genomics 4:509-517, 1989) and Cox et al., (Science 250:245-250, 1990), the entire contents of which are hereby incorporated by reference. The random and independent nature of the subclones permits efficient mapping of any human genome marker. Human DNA isolated from a panel of 80-100 cell lines provides a mapping reagent for ordering 5' ESTs. In this approach, the frequency of breakage between markers is used to measure distance, allowing construction of fine resolution maps as has been done using conventional ESTs (Schuler et al., Science 274:540-546, 1996, hereby incorporated by reference).

RH mapping has been used to generate a high-resolution whole genome radiation hybrid map of human chromosome 17q22-q25.3 across the genes for growth hormone (GH) and thymidine kinase (TK) (Foster et al., Genomics 33:185-192, 1996), the region surrounding the Gorlin syndrome gene (Obermayr et al., Eur. J Hum. Genet. 4:242-245, 1996), 60 loci covering the entire short arm of chromosome 12 (Raeymaekers et al., Genomics 29:170-178, 1995), the region of human chromosome 22 containing the neurofibromatosis type 2 locus (Frazer et al., Genomics 14:574-584, 1992) and 13 loci on the long arm of chromosome 5 (Warrington et al., Genomics 11:701-708, 1991).

5' ESTs may be assigned to human chromosomes using PCR based methodologies. In such approaches, oligonucleotide primer pairs are designed from 5' EST sequences to minimize the chance of amplifying through an intron. Preferably, the oligonucleotide primers are 18-23 bp in length and are designed for PCR amplification. The creation of PCR primers from known sequences is well known to those with skill in the art. For a review of PCR technology see Erlich, H. A., PCR Technology: Principles and Applications for DNA Amplification. 1992. W. H. Freeman and Co., New York.

The primers are used in polymerase chain reactions (PCR) to amplify templates from total human genomic DNA. PCR conditions are as follows: 60 ng of genomic DNA is used as a template for PCR with 80 ng of each oligonucleotide primer, 0.6 unit of Taq polymerase, and 1 .mu.Cu of a .sup.32 P-labeled deoxycytidine triphosphate. The PCR is performed in a microplate thermocycler (Techne) under the following conditions: 30 cycles of 94.degree. C., 1.4 min; 55.degree. C., 2 min; and 72.degree. C., 2 min; with a final extension at 72.degree. C. for 10 min. The amplified products are analyzed on a 6% polyacrylamide sequencing gel and visualized by autoradiography. If the length of the resulting PCR product is identical to the distance between the ends of the primer sequences in the 5' EST from which the primers are derived, then the PCR reaction is repeated with DNA templates from two panels of human-rodent somatic cell hybrids, BIOS PCRable DNA (BIOS Corporation) and NIGMS Human-Rodent Somatic Cell Hybrid Mapping Panel Number 1 (NIGMS, Camden, N.J.).

PCR is used to screen a series of somatic cell hybrid cell lines containing defined sets of human chromosomes for the presence of a given 5' EST. DNA is isolated from the somatic hybrids and used as starting templates for PCR reactions using the primer pairs from the 5' ESTs. Only those somatic cell hybrids with chromosomes containing the human gene corresponding to the 5' EST will yield an amplified fragment. The 5' ESTs are assigned to a chromosome by analysis of the segregation pattern of PCR products from the somatic hybrid DNA templates. The single human chromosome present in all cell hybrids that give rise to an amplified fragment is the chromosome containing that 5' EST. For a review of techniques and analysis of results from somatic cell gene mapping experiments. (See Ledbetter et al., Genomics 6:475-481 (1990).)

Alternatively, the 5' ESTs (or cDNAs or genomic DNAs obtainable therefrom) may be mapped to individual chromosomes using FISH as described in Example 51 below.

Fluorescence in situ hybridization allows the 5' EST (or cDNAs or genomic DNAs obtainable therefrom) to be mapped to a particular location on a given chromosome. The chromosomes to be used for fluorescence in situ hybridization techniques may be obtained from a variety of sources including cell cultures, tissues, or whole blood.

In a preferred embodiment, chromosomal localization of a 5' EST (or cDNA or genomic DNAs obtained therefrom) are obtained by FISH as described by Cherif et al. (Proc. Natl. Acad Sci. U.S.A., 87:6639-6643, 1990). Metaphase chromosomes are prepared from phytohemagglutinin (PHA)-stimulated blood cell donors. PHA-stimulated lymphocytes from healthy males are cultured for 72 h in RPMI-1640 medium. For synchronization, methotrexate (10 .mu.M) is added for 17 h, followed by addition of 5-bromodeoxyuridine (5-BudR, 0.1 mM) for 6 h. Colcemid (1 .mu.g/ml) is added for the last 15 min before harvesting the cells. Cells are collected, washed in RPMI, incubated with a hypotonic solution of KCl (75 mM) at 37.degree. C. for 15 min and fixed in three changes of methanol:acetic acid (3:1). The cell suspension is dropped onto a glass slide and air dried. The 5' EST (or cDNA or genomic DNA obtainable therefrom) is labeled with biotin-16 dUTP by nick translation according to the manufacturer's instructions (Bethesda Research Laboratories, Bethesda, Md.), purified using a Sephadex G-50 column (Pharmacia, Upssala, Sweden) and precipitated. Just prior to hybridization, the DNA pellet is dissolved in hybridization buffer (50% formamide, 2.times. SSC, 10% dextran sulfate, 1 mg/ml sonicated salmon sperm DNA, pH 7) and the probe is denatured at 70.degree. C. for 5-10 min.

Slides kept at -20.degree. C. are treated for 1 h at 37.degree. C. with RNase A (100 .mu.g/ml), rinsed three times in 2.times. SSC and dehydrated in an ethanol series. Chromosome preparations are denatured in 70% formamide, 2.times. SSC for 2 min at 70.degree. C., then dehydrated at 4.degree. C. The slides are treated with proteinase K (10 .mu.g/100 ml in 20 mM Tris-HCl, 2 mM CaCl.sub.2) at 37.degree. C. for 8 min and dehydrated. The hybridization mixture containing the probe is placed on the slide, covered with a coverslip, sealed with rubber cement and incubated overnight in a humid chamber at 37.degree. C. After hybridization and post-hybridization washes, the biotinylated probe is detected by avidin-FITC and amplified with additional layers of biotinylated goat anti-avidin and avidin-FITC. For chromosomal localization, fluorescent R-bands are obtained as previously described (Cherif et al., supra.). The slides are observed under a LEICA fluorescence microscope (DMRXA). Chromosomes are counterstained with propidium iodide and the fluorescent signal of the probe appears as two symmetrical yellow-green spots on both chromatids of the fluorescent R-band chromosome (red). Thus, a particular 5' EST (or cDNA or genomic DNA obtainable therefrom) may be localized to a particular cytogenetic R-band on a given chromosome.

Once the 5' ESTs (or cDNAs or genomic DNAs obtainable therefrom) have been assigned to particular chromosomes using the techniques described in Examples 49-51 above, they may be utilized to construct a high resolution map of the chromosomes on which they are located or to identify the chromosomes in a sample.

Chromosome mapping involves assigning a given unique sequence to a particular chromosome as described above. Once the unique sequence has been mapped to a given chromosome, it is ordered relative to other unique sequences located on the same chromosome. One approach to chromosome mapping utilizes a series of yeast artificial chromosomes (YACs) bearing several thousand long inserts derived from the chromosomes of the organism from which the 5' ESTs are obtained. This approach is described in Ramaiah Nagaraja et al. Genome Research 7:210-222, March 1997. Briefly, in this approach each chromosome is broken into overlapping pieces which are inserted into the YAC vector. The YAC inserts are screened using PCR or other methods to determine whether they include the 5' EST whose position is to be determined. Once an insert has been found which includes the 5' EST, the insert can be analyzed by PCR or other methods to determine whether the insert also contains other sequences known to be on the chromosome or in the region from which the 5' EST was derived. This process can be repeated for each insert in the YAC library to determine the location of each of the 5' ESTs relative to one another and to other known chromosomal markers. In this way, a high resolution map of the distribution of numerous unique markers along each of the organisms chromosomes may be obtained.

As described in Example 53 below 5' ESTs (or cDNAs or genomic DNAs obtainable therefrom) may also be used to identify genes associated with a particular phenotype, such as hereditary disease or drug response. Response

This example illustrates an approach useful for the association of 5' EST sequences (or cDNAs or genomic DNAs obtainable therefrom) with particular phenotypic characteristics. In this example, a particular 5' EST (or cDNAs or genomic DNAs obtainable therefrom) is used as a test probe to associate that 5' EST (or cDNAs or genomic DNAs obtainable therefrom) with a particular phenotypic characteristic.

5' ESTs (or cDNAs or genomic DNAs obtainable therefrom) are mapped to a particular location on a human chromosome using techniques such as those described in Examples 49 and 50 or other techniques known in the art. A search of Mendelian Inheritance in Man (V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library) reveals the region of the human chromosome which contains the 5' EST (or cDNAs or genomic DNAs obtainable therefrom) to be a very gene rich region containing several known genes and several diseases or phenotypes for which genes have not been identified. The gene corresponding to this 5' EST (or cDNAs or genomic DNAs obtainable therefrom) thus becomes an immediate candidate for each of these genetic diseases.

Cells from patients with these diseases or phenotypes are isolated and expanded in culture. PCR primers from the 5' EST sequences (or cDNAs or genomic DNAs obtainable therefrom) are used to screen genomic DNA, mRNA or cDNA obtained from the patients. 5' ESTs (or cDNAs or genomic DNAs obtainable therefrom) that are not amplified in the patients can be positively associated with a particular disease by further analysis. Alternatively, the PCR analysis may yield fragments of different lengths when the samples are derived from an individual having the phenotype associated with the disease than when the sample is derived from a healthy individual, indicating that the gene containing the 5' EST may be responsible for the genetic disease. Construct Vectors

The present 5' ESTs (or cDNAs or genomic DNAs obtainable therefrom) may also be used to construct secretion vectors capable of directing the secretion of the proteins encoded by genes inserted in the vectors. Such secretion vectors may facilitate the purification or enrichment of the proteins encoded by genes inserted therein by reducing the number of background proteins from which the desired protein must be purified or enriched. Exemplary secretion vectors are described in Example 54 below.

The secretion vectors of the present invention include a promoter capable of directing gene expression in the host cell, tissue, or organism of interest. Such promoters include the Rous Sarcoma Virus promoter, the SV40 promoter, the human cytomegalovirus promoter, and other promoters familiar to those skilled in the art.

A signal sequence from a 5' EST (or cDNAs or genomic DNAs obtainable therefrom) is operably linked to the promoter such that the mRNA transcribed from the promoter will direct the translation of the signal peptide. The host cell, tissue, or organism may be any cell, tissue, or organism which recognizes the signal peptide encoded by the signal sequence in the 5' EST (or cDNAs or genomic DNAs obtainable therefrom). Suitable hosts include mammalian cells, tissues or organisms, avian cells, tissues, or organisms, insect cells, tissues or organisms, or yeast.

In addition, the secretion vector contains cloning sites for inserting genes encoding the proteins which are to be secreted. The cloning sites facilitate the cloning of the insert gene in frame with the signal sequence such that a fusion protein in which the signal peptide is fused to the protein encoded by the inserted gene is expressed from the mRNA transcribed from the promoter. The signal peptide directs the extracellular secretion of the fusion protein.

The secretion vector may be DNA or RNA and may integrate into the chromosome of the host, be stably maintained as an extrachromosomal replicon in the host, be an artificial chromosome, or be transiently present in the host. Many nucleic acid backbones suitable for use as secretion vectors are known to those skilled in the art, including retroviral vectors, SV40 vectors, Bovine Papilloma Virus vectors, yeast integrating plasmids, yeast episomal plasmids, yeast artificial chromosomes, human artificial chromosomes, P element vectors, baculovirus vectors, or bacterial plasmids capable of being transiently introduced into the host.

The secretion vector may also contain a polyA site such that the polyA site is located downstream of the gene inserted into the secretion vector.

After the gene encoding the protein for which secretion is desired is inserted into the secretion vector, the secretion vector is introduced into the host cell, tissue, or organism using calcium phosphate precipitation, DEAE-Dextran, electroporation, liposome-mediated transfection, viral particles or as naked DNA. The protein encoded by the inserted gene is then purified or enriched from the supernatant using conventional techniques such as ammonium sulfate precipitation, immunoprecipitation, immunochromatography, size exclusion chromatography, ion exchange chromatography, and hplc. Alternatively, the secreted protein may be in a sufficiently enriched or pure state in the supernatant or growth media of the host to permit it to be used for its intended purpose without further enrichment.

The signal sequences may also be inserted into vectors designed for gene therapy. In such vectors, the signal sequence is operably linked to a promoter such that mRNA transcribed from the promoter encodes the signal peptide. A cloning site is located downstream of the signal sequence such that a gene encoding a protein whose secretion is desired may readily be inserted into the vector and fused to the signal sequence. The vector is introduced into an appropriate host cell. The protein expressed from the promoter is secreted extracellularly, thereby producing a therapeutic effect.

The 5' ESTs may also be used to clone sequences located upstream of the 5' ESTs which are capable of regulating gene expression, including promoter sequences, enhancer sequences, and other upstream sequences which influence transcription or translation levels. Once identified and cloned, these upstream regulatory sequences may be used in expression vectors designed to direct the expression of an inserted gene in a desired spatial, temporal, developmental, or quantitative fashion. Example 55 describes a method for cloning sequences upstream of the 5' ESTs.

Sequences derived from 5' ESTs may be used to isolate the promoters of the corresponding genes using chromosome walking techniques. In one chromosome walking technique, which utilizes the GenomeWalker.TM. kit available from Clontech, five complete genomic DNA samples are each digested with a different restriction enzyme which has a 6 base recognition site and leaves a blunt end. Following digestion, oligonucleotide adapters are ligated to each end of the resulting genomic DNA fragments.

For each of the five genomic DNA libraries, a first PCR reaction is performed according to the manufacturer's instructions (which are incorporated herein by reference) using an outer adaptor primer provided in the kit and an outer gene specific primer. The gene specific primer should be selected to be specific for the 5' EST of interest and should have a melting temperature, length, and location in the 5' EST which is consistent with its use in PCR reactions. Each first PCR reaction contains 5 ng of genomic DNA, 5 .mu.l of 10.times. Tth reaction buffer, 0.2 mM of each dNTP, 0.2 .mu.M each of outer adaptor primer and outer gene specific primer, 1.1 mM of Mg(OAc).sub.2, and 1 .mu.l of the Tth polymerase 50.times. mix in a total volume of 50 .mu.l. The reaction cycle for the first PCR reaction is as follows: 1 min--94.degree. C./2 sec--94.degree. C., 3 min--72.degree. C. (7 cycles)/2 sec--94.degree. C., 3 min--67.degree. C. (32 cycles)/5 min--67.degree. C.

The product of the first PCR reaction is diluted and used as a template for a second PCR reaction according to the manufacturer's instructions using a pair of nested primers which are located internally on the amplicon resulting from the first PCR reaction For example, 5 .mu.l of the reaction product of the first PCR reaction mixture may be diluted 180 times. Reactions are made in a 50 .mu.l volume having a composition identical to that of the first PCR reaction except the nested primers are used. The first nested primer is specific for the adaptor, and is provided with the GenomeWalker.TM. kit. The second nested primer is specific for the particular 5' EST for which the promoter is to be cloned and should have a melting temperature, length, and location in the 5' EST which is consistent with its use in PCR reactions. The reaction parameters of the second PCR reaction are as follows: 1 min--94.degree. C./2 sec--94.degree. C., 3 min--72.degree. C. (6 cycles)/2 sec--94.degree. C., 3 min--67.degree. C. (25 cycles)/5 min--67.degree. C.

The product of the second PCR reaction is purified, cloned, and sequenced using standard techniques. Alternatively, tow or more human genomic DNA libraries can be constructed by using two or more restriction enzymes. The digested genomic DNA is cloned into vectors which can be converted into single stranded, circular, or linear DNA. A biotinylated oligonucleotide comprising at least 15 nucleotides from the 5' EST sequence is hybridized to the single stranded DNA. Hybrids between the biotinylated oligonucleotide and the single stranded DNA containing the EST sequence are isolated as described in Example 29 above. Thereafter, the single stranded DNA containing the EST sequence is released from the beas and converted into double stranded DNA using a primer specific for the 5' EST sequence or a primer corresponding to a sequence included in the cloning vector. The resulting double stranded DNA is transformed into bacteria. cDNAS containing the 5' sequence are identified by colony PCR or colony hybridization.

Once the upstream genomic sequences have been cloned and sequenced as described above, prospective promoters and transcription start sites within the upstream sequences may be identified by comparing the sequences upstream of the 5 ESTs with databases containing known transcription start sites, transcription factor binding sites, or promoter sequences.

In addition, promoters in the upstream sequences may be identified using promoter reporter vectors as described in Example 56.

The genomic sequences upstream of the 5' ESTs are cloned into a suitable promoter reporter vector, such as the pSEAP-Basic, pSEAP-Enhancer, p.beta.gal-Basic, p.beta.gal-Enhancer, or pEGFP-1 Promoter Reporter vectors available from Clontech. Briefly, each of these promoter reporter vectors include multiple cloning sites positioned upstream of a reporter gene encoding a readily assayable protein such as secreted alkaline phosphatase, .beta. galactosidase, or green fluorescent protein. The sequences upstream of the 5' ESTs are inserted into the cloning sites upstream of the reporter gene in both orientations and introduced into an appropriate host cell. The level of reporter protein is assayed and compared to the level obtained from a vector which lacks an insert in the cloning site. The presence of an elevated expression level in the vector containing the insert with respect to the control vector indicates the presence of a promoter in the insert. If necessary, the upstream sequences can be cloned into vectors which contain an enhancer for augmenting transcription levels from weak promoter sequences. A significant level of expression above that observed with the vector lacking an insert indicates that a promoter sequence is present in the inserted upstream sequence.

Appropriate host cells for the promoter reporter vectors may be chosen based on the results of the above described determination of expression patterns of the ESTs. For example, if the expression pattern analysis indicates that the mRNA corresponding to a particular 5' EST is expressed in fibroblasts, the promoter reporter vector may be introduced into a human fibroblast cell line.

Promoter sequences within the upstream genomic DNA may be further defined by constructing nested deletions in the upstream DNA using conventional techniques such as Exonuclease III digestion. The resulting deletion fragments can be inserted into the promoter reporter vector to determine whether the deletion has reduced or obliterated promoter activity. In this way, the boundaries of the promoters may be defined. If desired, potential individual regulatory sites within the promoter may be identified using site directed mutagenesis or linker scanning to obliterate potential transcription factor binding sites within the promoter individually or in combination. The effects of these mutations on transcription levels may be determined by inserting the mutations into the cloning sites in the promoter reporter vectors.

Using the method described in Example 55 above, sequences upstream of several genes were obtained. Using the primer pairs GGG AAG ATG GAG ATA GTA TTG CCT G (SEQ ID NO:29) and CTG CCA TGT ACA TGA TAG AGA GAT TC (SEQ ID NO:30), the promoter having the internal designation P13H2 (SEQ ID NO:31) was obtained.

Using the primer pairs GTA CCA GGGG ACT GTG ACC ATT GC (SEQ ID NO:32) and CTG TGA CCA TTG CTC CCA AGA GAG (SEQ ID NO:33), the promoter having the internal designation P15B4 (SEQ ID NO:34) was obtained.

Using the primer pairs CTG GGA TGG AAG GCA CGG TA (SEQ ID NO:35) and GAG ACC ACA CAG CTA GAC AA (SEQ ID NO:36), the promoter having the internal designation P29B6 (SEQ ID NO:37) was obtained.

FIG. 6 provides a schematic description of the promoters isolated and the way they are assembled with the corresponding 5' tags. The upstream sequences were screened for the presence of motifs resembling transcription factor binding sites or known transcription start sites using the computer program MatInspector release 2.0, August 1996.

FIG. 7 describes the transcription factor binding sites present in each of these promoters. The columns labeled matrice provides the name of the MatInspector matrix used. The column labeled position provides the 5' postion of the promoter site. Numeration of the sequence starts from the transcription site as determined by matching the genomic sequence with the 5' EST sequence. The column labeled "orientation" indicates the DNA strand on which the site is found, with the + strand bding the coding strand as determined by matching the genomic sequence with the sequence of the 5' EST. The column labeled "score" provides the MatInspector score found for this site. The column labeled "length" provides the length of the site in nucleotides. The column labeled "sequence" provides the sequence of the site found.

Bacterial clones containing plasmids containing the promoter sequences described above described above are presently stored in the inventor's laboratories under the internal identification numbers provided above. The inserts may be recovered from the deposited materials by growing an aliquot of the appropriate bacterial clone in the appropriate medium. The plasmid DNA can then be isolated using plasmid isolation procedures familiar to those skilled in the art such as alkaline lysis minipreps or large scale alkaline lysis plasmid isolation procedures. If desired the plasmid DNA may be further enriched by centrifugation on a cesium chloride gradient, size exclusion chromatography, or anion exchange chromatography. The plasmid DNA obtained using these procedures may then be manipulated using standard cloning techniques familiar to those skilled in the art. Alternatively, a PCR can be done with primers designed at both ends of the EST insertion. The PCR product which corresponds to the 5' EST can then be manipulated using standard cloning techniques familiar to those skilled in the art.

The promoters and other regulatory sequences located upstream of the 5' ESTs may be used to design expression vectors capable of directing the expression of an inserted gene in a desired spatial, temporal, developmental, or quantitative manner. A promoter capable of directing the desired spatial, temporal, developmental, and quantitative patterns may be selected using the results of the expression analysis described in Example 26 above. For example, if a promoter which confers a high level of expression in muscle is desired, the promoter sequence upstream of a 5' EST derived from an mRNA which is expressed at a high level in muscle, as determined by the method of Example 26, may be used in the expression vector.

Preferably, the desired promoter is placed near multiple restriction sites to facilitate the cloning of the desired insert downstream of the promoter, such that the promoter is able to drive expression of the inserted gene. The promoter may be inserted in conventional nucleic acid backbones designed for extrachromosomal replication, integration into the host chromosomes or transient expression. Suitable backbones for the present expression vectors include retroviral backbones, backbones from eukaryotic episomes such as SV40 or Bovine Papilloma Virus, backbones from bacterial episomes, or artificial chromosomes.

Preferably, the expression vectors also include a polyA site downstream of the multiple restriction sites for directing the polyadenylation of mRNA transcribed from the gene inserted into the expression vector.

Following the identification of promoter sequences using the procedures of Examples 55-57, proteins which interact with the promoter may be identified as described in Example 58 below. Regulatory Sequences, or mRNA

Sequences within the promoter region which are likely to bind transcription factors may be identified by homology to known transcription factor binding sites or through conventional mutagenesis or deletion analyses of reporter plasmids containing the promoter sequence. For example, deletions may be made in a reporter plasmid containing the promoter sequence of interest operably linked to an assayable reporter gene. The reporter plasmids carrying various deletions within the promoter region are transfected into an appropriate host cell and the effects of the deletions on expression levels is assessed. Transcription factor binding sites within the regions in which deletions reduce expression levels may be further localized using site directed mutagenesis, linker scanning analysis, or other techniques familiar to those skilled in the art.

Nucleic acids encoding proteins which interact with sequences in the promoter may be identified using one-hybrid systems such as those described in the manual accompanying the Matchmaker One-Hybrid System kit avalilabe from Clontech (Catalog No. K1603-1), the disclosure of which is incorporated herein by reference. Briefly, the Matchmaker One-hybrid system is used as follows. The target sequence for which it is desired to identify binding proteins is cloned upstream of a selectable reporter gene and integrated into the yeast genome. Preferably, multiple copies of the target sequences are inserted into the reporter plasmid in tandem.

A library comprised of fusions between cDNAs to be evaluated for the ability to bind to the promoter and the activation domain of a yeast transcription factor, such as GAL4, is transformed into the yeast strain containing the integrated reporter sequence. The yeast are plated on selective media to select cells expressing the selectable marker linked to the promoter sequence. The colonies which grow on the selective media contain genes encoding proteins which bind the target sequence. The inserts in the genes encoding the fusion proteins are further characterized by sequencing. In addition, the inserts may be inserted into expression vectors or in vitro transcription vectors. Binding of the polypeptides encoded by the inserts to the promoter DNA may be confirmed by techniques familiar to those skilled in the art, such as gel shift analysis or DNAse protection analysis. Therapy

The present invention also comprises the use of 5' ESTs (or cDNAs or genomic DNAs obtainable therefrom) in gene therapy strategies, including antisense and triple helix strategies as described in Examples 57 and 58 below. In antisense approaches, nucleic acid sequences complementary to an mRNA are hybridized to the mRNA intracellularly, thereby blocking the expression of the protein encoded by the mRNA. The antisense sequences may prevent gene expression through a variety of mechanisms. For example, the antisense sequences may inhibit the ability of ribosomes to translate the mRNA. Alternatively, the antisense sequences may block transport of the mRNA from the nucleus to the cytoplasm, thereby limiting the amount of mRNA available for translation. Another mechanism through which antisense sequences may inhibit gene expression is by interfering with mRNA splicing. In yet another strategy, the antisense nucleic acid may be incorporated in a ribozyme capable of specifically cleaving the target mRNA.

The antisense nucleic acid molecules to be used in gene therapy may be either DNA or RNA sequences. They may comprise a sequence complementary to the sequence of the 5' EST or cDNAs or genomic DNAs obtainable therefrom. The antisense nucleic acids should have a length and melting temperature sufficient to permit formation of an intracellular duplex having sufficient stability to inhibit the expression of the mRNA in the duplex. Strategies for designing antisense nucleic acids suitable for use in gene therapy are disclosed in Green et al., Ann. Rev. Biochem. 55:569-597 (1986) and Izant and Weintraub, Cell 36:1007-1015 (1984), which are hereby incorporated by reference.

In some strategies, antisense molecules are obtained from a nucleotide sequence encoding a protein by reversing the orientation of the coding region with respect to a promoter so as to transcribe the opposite strand from that which is normally transcribed in the cell. The antisense molecules may be transcribed using in vitro transcription systems such as those which employ T7 or SP6 polymerase to generate the transcript. Another approach involves transcription of the antisense nucleic acids in vivo by operably linking DNA containing the antisense sequence to a promoter in an expression vector.

Alternatively, oligonucleotides which are complementary to the strand normally transcribed in the cell may be synthesized in vitro. Thus, the antisense nucleic acids are complementary to the corresponding mRNA and are capable of hybridizing to the mRNA to create a duplex. In some embodiments, the antisense sequences may contain modified sugar phosphate backbones to increase stability and make them less sensitive to RNase activity. Examples of modifications suitable for use in antisense strategies are described by Rossi et al., Pharmacol. Ther. 50(2):245-254, (1991).

Various types of antisense oligonucleotides complementary to the sequence of the 5' EST or cDNAs or genomic DNAs obtainable therefrom may be used. In one preferred embodiment, stable and semi-stable antisense oligonucleotides described in International Application No. PCT WO94/23026, hereby incorporated by reference, are used. In these moleucles, the 3' end or both the 3' and 5' ends are engaged in intramolecular hydrogen bonding between complementary base pairs. These molecules are better able to withstand exonuclease attacks and exhibit increased stability compared to conventional antisense oligonucleotides.

In another preferred embodiment, the antisense oligodeoxynucleotides against herpes simplex virus types 1 and 2 described in International Application No. WO 95/04141, hereby incorporated by reference, are used.

In yet another preferred embodiment, the covalently cross-linked antisense oligonucleotides described in International Application No. WO 96/31523, hereby incorporated by reference, are used. These double- or single-stranded oligonucleotides comprise one or more, respectively, inter- or intra-oligonucleotide covalent cross-linkages, wherein the linkage consists of an amide bond between a primary amine group of one strand and a carboxyl group of the other strand or of the same strand, respectively, the primary amine group being directly substituted in the 2' position of the strand nucleotide monosaccharide ring, and the carboxyl group being carried by an aliphatic spacer group substituted on a nucleotide or nucleotide analog of the other strand or the same strand, respectively.

The antisense oligodeoxynucleotides and oligonucleotides disclosed in International Application No. WO 92/18522, incorporated by reference, may also be used. These molecules are stable to degradation and contain at least one transcription control recognition sequence which binds to control proteins and are effective as decoys therefor. These molecules may contain "hairpin" structures, "dumbbell" structures, "modified dumbbell" structures, "cross-linked" decoy structures and "loop" structures.

In another preferred embodiment, the cyclic double-stranded oligonucleotides described in European Patent Application No. 0 572 287 A2, hereby incorporated by reference are used. These ligated oligonucleotide "dumbbells" contain the binding site for a transcription factor and inhibit expression of the gene under control of the transcription factor by sequestering the factor.

Use of the closed antisense oligonucleotides disclosed in International Application No. WO 92/19732, hereby incorporated by reference, is also contemplated. Because these molecules have no free ends, they are more resistant to degradation by exonucleases than are conventional oligonucleotides. These oligonucleotides may be multifunctional, interacting with several regions which are not adjacent to the target mRNA.

The appropriate level of antisense nucleic acids required to inhibit gene expression may be determined using in vitro expression analysis. The antisense molecule may be introduced into the cells by diffusion, injection, infection or transfection using procedures known in the art. For example, the antisense nucleic acids can be introduced into the body as a bare or naked oligonucleotide, oligonucleotide encapsulated in lipid, oligonucleotide sequence encapsidated by viral protein, or as an oligonucleotide operably linked to a promoter contained in an expression vector. The expression vector may be any of a variety of expression vectors known in the art, including retroviral or viral vectors, vectors capable of extrachromosomal replication, or integrating vectors. The vectors may be DNA or RNA.

The antisense molecules are introduced onto cell samples at a number of different concentrations preferably between 1.times.10.sup.-10 M to 1.times.10.sup.-4 M. Once the minimum concentration that can adequately control gene expression is identified, the optimized dose is translated into a dosage suitable for use in vivo. For example, an inhibiting concentration in culture of 1.times.10.sup.-7 translates into a dose of approximately 0.6 mg/kg bodyweight. Levels of oligonucleotide approaching 100 mg/kg bodyweight or higher may be possible after testing the toxicity of the oligonucleotide in laboratory animals. It is additionally contemplated that cells from the vertebrate are removed, treated with the antisense oligonucleotide, and reintroduced into the vertebrate.

It is further contemplated that the antisense oligonucleotide sequence is incorporated into a ribozyme sequence to enable the antisense to specifically bind and cleave its target mRNA. For technical applications of ribozyme and antisense oligonucleotides see Rossi et al., supra.

In a preferred application of this invention, the polypeptide encoded by the gene is first identified, so that the effectiveness of antisense inhibition on translation can be monitored using techniques that include but are not limited to antibody-mediated tests such as RIAs and ELISA, functional assays, or radiolabeling.

The 5' ESTs of the present invention (or cDNAs or genomic DNAs obtainable therefrom) may also be used in gene therapy approaches based on intracellular triple helix formation. Triple helix oligonucleotides are used to inhibit transcription from a genome. They are particularly useful for studying alterations in cell activity as it is associated with a particular gene. The 5' EST sequences (or cDNAs or genomic DNAs obtainable therefrom) of the present invention or, more preferably, a portion of those sequences, can be used to inhibit gene expression in individuals having diseases associated with expression of a particular gene. Similarly, a portion of the 5' EST (or cDNAs or genomic DNAs obtainable therefrom) can be used to study the effect of inhibiting transcription of a particular gene within a cell. Traditionally, homopurine sequences were considered the most useful for triple helix strategies. However, homopyrimidine sequences can also inhibit gene expression. Such homopyrimidine oligonucleotides bind to the major groove at homopurine:homopyrimidine sequences. Thus, both types of sequences from either the 5' EST or from the gene corresponding to the 5' EST are contemplated within the scope of this invention.

The sequences of the 5' ESTs (or cDNAs or genomic DNAs obtainable therefrom) are scanned to identify 10-mer to 20-mer homopyrimidine or homopurine stretches which could be used in triple-helix based strategies for inhibiting gene expression. Following identification of candidate homopyrimidine or homopurine stretches, their efficiency in inhibiting gene expression is assessed by introducing varying amounts of oligonucleotides containing the candidate sequences into tissue culture cells which normally express the target gene. The oligonucleotides may be prepared on an oligonucleotide synthesizer or they may be purchased commercially from a company specializing in custom oligonucleotide synthesis, such as GENSET, Paris, France.

The oligonucleotides may be introduced into the cells using a variety of methods known to those skilled in the art, including but not limited to calcium phosphate precipitation, DEAE-Dextran, electroporation, liposome-mediated transfection or native uptake.

Treated cells are monitored for altered cell function or reduced gene expression using techniques such as Northern blotting, RNase protection assays, or PCR based strategies to monitor the transcription levels of the target gene in cells which have been treated with the oligonucleotide. The cell functions to be monitored are predicted based upon the homologies of the target gene corresponding to the 5' EST from which the oligonucleotide was derived with known gene sequences that have been associated with a particular function. The cell functions can also be predicted based on the presence of abnormal physiologies within cells derived from individuals with a particular inherited disease, particularly when the 5' EST is associated with the disease using techniques described in Example 53.

The oligonucleotides which are effective in inhibiting gene expression in tissue culture cells may then be introduced in vivo using the techniques described above and in Example 59 at a dosage calculated based on the in vitro results, as described in Example 59.

In some embodiments, the natural (beta) anomers of the oligonucleotide units can be replaced with alpha anomers to render the oligonucleotide more resistant to nucleases. Further, an intercalating agent such as ethidium bromide, or the like, can be attached to the 3' end of the alpha oligonucleotide to stabilize the triple helix. For information on the generation of oligonucleotides suitable for triple helix formation see Griffin et al. (Science 245:967-971 (1989), which is hereby incorporated by this reference).

Although this invention has been described in terms of certain preferred embodiments, other embodiments which will be apparent to those of ordinary skill in the art in view of the disclosure herein are also within the scope of this invention. Accordingly, the scope of the invention is intended to be defined only by reference to the appended claims. All documents cited herein are incorporated herein by reference in their entirety. Parameters used for each step of EST analysis Selection Characteristics Search Characteristics       Identity Length Step          Program   Strand  Parameters    (%)     (bp) Miscellaneous blastn    both    S = 61 X = 16 90      17 tRNA          fasta     both    --       80      60 rRNA          blastn    both    S = 108 80      40 mtRNA         blastn    both    S = 108 80      40 Procaryotic   blastn    both    S = 144 90      40 Fungal        blastn    both    S = 144 90      40 Alu           fasta*    both    --       70      40 L1            blastn    both    S = 72 70      40 Repeats       blastn    both    S = 72 70      40 Promoters     blastn    top     S = 54 X = 16 90      15.dagger. Vertebrate    fasta*    both    S = 108 90      30 ESTs          blastn    both    S = 108 X = 16 90      30 Proteins      blastx.star. top     E = 0.001 -- -- *use "Quick Fast" Database Scanner .dagger.alignement further constrained to begin closer than 10 bp to EST.backslash.5' end .star.using BLOSUM62 substitution matrix VON SEQ. ID                    HEIJNE  TISSUE    INTERNAL NO.       CATEGORY         SCORE   SOURCE    DESIGNATION ID38      new              10.8    Brain     33-19-2-H2-PU ID39      new              10.8    Brain     33-56-1-E8-PU ID40      new              10      Brain     33-79-3-D12-PU ID41      new              9.6     Brain     33-72-2-B2-PU ID42      new              9.5     Brain     33-13-2-B9-PU ID43      new              9.1     Brain     33-113-1-E9-PU ID44      new              9       Brain     33-28-4-E8-PU ID45      new              8.8     Brain     33-12-3-F2-PU ID46      new              8.8     Brain     33-70-1-C11-PU ID47      new              8.5     Brain     33-74-1-B2-PU ID48      new              8.5     Brain     33-29-3-F1-PU ID49      new              8.4     Brain     33-8-2-A1-PU ID50      new              8.3     Brain     17-17-3-A9-PU ID51      new              8.3     Brain     33-106-2-A8-PU ID52      new              8.3     Brain     33-112-4-E7-PU ID53      new              8.2     Brain     33-98-1-E6-PU ID54      new              8.2     Brain     33-76-1-B6-PU ID55      new              8       Brain     33-35-4-G8-PU ID56      new              7.9     Brain     33-17-3-E4-PU ID57      new              7.9     Brain     33-110-4-B5-PU ID58      new              7.8     Brain     33-40-1-A11-PU ID59      new              7.7     Brain     33-71-1-A8-PU ID60      new              7.7     Brain     33-96-3-G7-PU ID61      new              7.6     Brain     33-112-3-D12-PU ID62      new              7.6     Brain     33-62-2-B3-PU ID63      new              7.6     Brain     33-6-4-G6-PU ID64      new              7.5     Brain     33-82-4-E2-PU ID65      new              7.4     Brain     33-81-3-H11-PU ID66      new              7.3     Brain     33-64-1-B4-PU ID67      new              7.2     Brain     33-31-1-B12-PU ID68      new              7       Brain     33-24-4-F9-PU ID69      new              7       Brain     33-110-3-E9-PU ID70      new              7       Brain     33-4-2-G5-PU ID71      new              6.9     Brain     33-74-2-A4-PU ID72      new              6.9     Brain     33-52-4-F9-PU ID73      new              6.9     Brain     33-74-1-B11-PU ID74      new              6.8     Brain     33-10-4-D9-PU ID75      new              6.8     Brain     33-15-2-H3-PU ID76      new              6.7     Brain     33-38-2-D5-PU ID77      new              6.7     Brain     33-78-3-D2-PU ID78      new              6.7     Brain     33-96-3-D3-PU ID79      new              6.6     Brain     33-76-4-B11-PU ID80      new              6.3     Brain     33-39-1-C6-PU ID81      new              6.1     Brain     33-106-3-B12-PU ID82      new              6       Brain     33-4-2-B7-PU ID83      new              5.9     Brain     33-99-2-E4-PU ID84      new              5.9     Brain     33-34-1-B1-PU ID85      new              5.8     Brain     33-67-4-E9-PU ID86      new              5.7     Brain     33-11-3-H11-PU ID87      new              5.6     Brain     33-13-2-A8-PU ID88      new              5.6     Brain     33-83-4-B6-PU ID89      new              5.6     Brain     33-70-1-E4-PU ID90      new              5.6     Brain     33-5-3-H11-PU ID91      new              5.6     Brain     33-10-3-G5-PU ID92      new              5.5     Brain     33-97-4-G4-PU ID93      new              5.5     Brain     33-46-4-F4-PU ID94      new              5.4     Brain     33-4-1-G11-PU ID95      new              5.3     Brain     33-105-1-H5-PU ID96      new              5.3     Brain     33-74-2-B10-PU ID97      new              5.3     Brain     33-49-3-E5-PU ID98      new              5.3     Brain     33-114-2-A1-PU ID99      new              5.2     Brain     33-71-1-G12-PU ID100     new              5.2     Brain     33-47-3-E6-PU ID101     new              5.2     Brain     33-1-2-E8-PU ID102     new              5.2     Brain     33-93-4-E12-PU ID103     new              5.1     Brain     33-1-2-H1-PU ID104     new              5.1     Brain     17-10-1-H8-PU ID105     new              5       Brain     33-110-2-B8-PU ID106     new              5       Brain     33-104-3-D9-PU ID107     new              5       Brain     33-72-2-H11-PU ID108     new              4.9     Brain     33-7-4-D6-PU ID109     new              4.9     Brain     33-31-4-G2-PU ID110     new              4.9     Brain     33-109-1-E8-PU ID111     new              4.8     Brain     17-1-2-B11-PU ID112     new              4.8     Brain     33-19-4-H3-PU ID113     new              4.8     Brain     33-14-4-E1-PU ID114     new              4.8     Brain     33-70-3-H1-PU ID115     new              4.7     Brain     33-86-4-H10-PU ID116     new              4.7     Brain     33-107-3-D5-PU ID117     new              4.7     Brain     33-23-4-B9-PU ID118     new              4.7     Brain     33-82-4-H5-PU ID119     new              4.6     Brain     33-16-3-F4-PU ID120     new              4.6     Brain     33-97-4-C5-PU ID121     new              4.6     Brain     33-100-3-B10-PU ID122     new              4.6     Brain     33-59-3-E3-PU ID123     new              4.5     Brain     33-25-1-G2-PU ID124     new              4.5     Brain     17-16-3-B2-PU ID125     new              4.4     Brain     33-52-4-E7-PU ID126     new              4.4     Brain     33-91-1-D1-PU ID127     new              4.4     Brain     33-26-1-B9-PU ID128     new              4.4     Brain     33-97-3-H6-PU ID129     new              4.4     Brain     33-109-2-E8-PU ID130     new              4.3     Brain     33-59-2-B7-PU ID131     new              4.3     Brain     33-28-4-D1-PU ID132     new              4.3     Brain     33-29-4-E2-PU ID133     new              4.1     Brain     33-70-1-H6-PU ID134     new              4.1     Brain     33-7-1-B2-PU ID135     new              4.1     Brain     33-52-4-F8-PU ID136     new              4.1     Brain     33-23-2-A6-PU ID137     new              4.1     Brain     33-39-3-E5-PU ID138     new              4.1     Brain     33-81-4-H6-PU ID139     new              4.1     Brain     33-105-3-F5-PU ID140     new              4       Brain     33-35-2-H11-PU ID141     new              4       Brain     33-50-3-E12-PU ID142     new              4       Brain     33-16-3-H7-PU ID143     new              4       Brain     33-79-2-H4-PU ID144     new              3.9     Brain     33-32-4-B12-PU ID145     new              3.9     Brain     33-110-4-A5-PU ID146     new              3.9     Brain     33-109-2-H1-PU ID147     new              3.9     Brain     33-100-1-E6-PU ID148     new              3.9     Brain     33-78-2-E7-PU ID149     new              3.9     Brain     33-82-4-G3-PU ID150     new              3.9     Brain     17-1-1-A9-PU ID151     new              3.9     Brain     33-89-4-E1-PU ID152     new              3.9     Brain     33-89-1-B4-PU ID153     new              3.9     Brain     33-96-3-A3-PU ID154     new              3.8     Brain     33-92-3-D1-PU ID155     new              3.8     Brain     33-104-4-H4-PU ID156     new              3.8     Brain     33-106-1-B8-PU ID157     new              3.6     Brain     33-1-3-D1-PU ID158     new              3.6     Brain     33-40-2-F5-PU ID159     new              3.6     Brain     33-4-1-E8-PU ID160     new              3.6     Brain     33-36-3-E2-PU ID161     new              3.6     Brain     17-18-3-A6-PU ID162     new              3.6     Brain     33-12-1-B1-PU ID163     new              3.6     Brain     33-29-1-H1-PU ID164     new              3.6     Brain     33-103-1-E1-PU ID165     new              3.5     Brain     33-10-4-H2-PU ID166     new              3.5     Brain     33-25-1-H2-PU ID167     new              3.5     Brain     33-10-4-G2-PU ID168     new              3.5     Brain     33-67-1-F4-PU ID169     ext-est-not-vrt  12.5    Brain     33-77-4-E2-PU ID170     ext-est-not-vrt  10.1    Brain     33-31-3-C11-PU ID171     ext-est-not-vrt  9.8     Brain     33-28-2-H7-PU ID172     ext-est-not-vrt  9.2     Brain     33-112-3-C8-PU ID173     ext-est-not-vrt  7.9     Brain     33-23-3-A11-PU ID174     ext-est-not-vrt  7.9     Brain     33-29-2-E11-PU ID175     ext-est-not-vrt  7.9     Brain     33-66-4-C7-PU ID176     ext-est-not-vrt  7.1     Brain     33-78-1-D7-PU ID177     ext-est-not-vrt  6.6     Brain     33-31-3-D7-PU ID178     ext-est-not-vrt  6.3     Brain     33-19-1-C11-PU ID179     ext-est-not-vrt  6       Brain     33-67-1-A5-PU ID180     ext-est-not-vrt  5.9     Brain     33-58-3-C8-PU ID181     ext-est-not-vrt  4.9     Brain     33-107-4-C3-PU ID182     ext-est-not-vrt  4.9     Brain     33-7-2-G12-PU ID183     ext-est-not-vrt  4.8     Brain     33-11-1-G5-PU ID184     ext-est-not-vrt  4.7     Brain     33-31-4-D9-PU ID185     ext-est-not-vrt  4.6     Brain     33-26-4-E10-PU ID186     ext-est-not-vrt  4.5     Brain     33-70-4-F7-PU ID187     ext-est-not-vrt  4.5     Brain     33-19-2-D1-PU ID188     ext-est-not-vrt  4.4     Brain     33-48-4-F8-PU ID189     ext-est-not-vrt  4.3     Brain     33-109-3-B10-PU ID190     ext-est-not-vrt  4.1     Brain     33-30-2-A6-PU ID191     ext-est-not-vrt  3.8     Brain     33-75-3-D7-PU ID192     ext-est-not-vrt  3.7     Brain     33-109-4-C1-PU ID193     est-not-ext      10.5    Brain     33-97-3-D4-PU ID194     est-not-ext      10.1    Brain     33-61-2-F6-PU ID195     est-not-ext      9.5     Brain     33-54-1-B9-PU ID196     est-not-ext      9.3     Brain     33-39-4-D1-PU ID197     est-not-ext      9.1     Brain     33-57-4-H5-PU ID198     est-not-ext      9       Brain     33-60-2-B3-PU ID199     est-not-ext      8.6     Brain     33-52-1-A1-PU ID200     est-not-ext      8.4     Brain     33-82-2-H10-PU ID201     est-not-ext      7.5     Brain     33-79-4-B11-PU ID202     est-not-ext      7.5     Brain     33-18-3-H3-PU ID203     est-not-ext      7.5     Brain     33-21-1-D6-PU ID204     est-not-ext      7.4     Brain     33-17-3-F9-PU ID205     est-not-ext      7.4     Brain     33-70-2-G3-PU ID206     est-not-ext      7.4     Brain     33-89-3-H4-PU ID207     est-not-ext      7.4     Brain     33-46-3-E10-PU ID208     est-not-ext      7       Brain     33-36-2-F9-PU ID209     est-not-ext      6.8     Brain     33-39-1-C4-PU ID210     est-not-ext      6.8     Brain     33-65-4-C6-PU ID211     est-not-ext      6.4     Brain     33-18-2-G6-PU ID212     est-not-ext      6.4     Brain     33-36-3-C6-PU ID213     est-not-ext      6       Brain     33-79-2-B6-PU ID214     est-not-ext      5.9     Brain     33-71-4-D11-PU ID215     est-not-ext      5.9     Brain     17-12-2-A3-PU ID216     est-not-ext      5.9     Brain     33-95-1-A12-PU ID217     est-not-ext      5.8     Brain     33-5-3-E3-PU ID218     est-not-ext      5.8     Brain     33-74-2-D3-PU ID219     est-not-ext      5.7     Brain     33-50-3-H8-PU ID220     est-not-ext      5.6     Brain     33-19-1-A2-PU ID221     est-not-ext      5.5     Brain     33-22-1-D3-PU ID222     est-not-ext      5.5     Brain     33-97-1-G4-PU ID223     est-not-ext      5.4     Brain     33-65-4-D10-PU ID224     est-not-ext      5.4     Brain     33-79-4-C4-PU ID225     est-not-ext      5.3     Brain     33-20-2-C5-PU ID226     est-not-ext      5.2     Brain     33-34-4-A5-PU ID227     est-not-ext      5.2     Brain     33-6-2-F11-PU ID228     est-not-ext      5.2     Brain     33-2-2-G5-PU ID229     est-not-ext      5.1     Brain     33-98-1-G7-PU ID230     est-not-ext      5.1     Brain     33-20-3-B10-PU ID231     est-not-ext      5       Brain     33-106-2-D9-PU ID232     est-not-ext      4.9     Brain     33-72-2-A9-PU ID233     est-not-ext      4.9     Brain     33-83-3-G8-PU ID234     est-not-ext      4.8     Brain     33-31-3-E6-PU ID235     est-not-ext      4.7     Brain     33-28-4-E2-PU ID236     est-not-ext      4.6     Brain     33-101-3-F4-PU ID237     est-not-ext      4.6     Brain     33-98-4-C1-PU ID238     est-not-ext      4.5     Brain     33-31-2-E11-PU ID239     est-not-ext      4.5     Brain     33-26-2-B6-PU ID240     est-not-ext      4.4     Brain     33-75-4-H7-PU ID241     est-not-ext      4.3     Brain     33-13-1-C6-PU ID242     est-not-ext      4.3     Brain     33-35-4-G1-PU ID243     est-not-ext      4.3     Brain     33-76-3-G11-PU ID244     est-not-ext      4.2     Brain     33-72-1-A3-PU ID245     est-not-ext      4.2     Brain     33-71-2-A2-PU ID246     est-not-ext      4.2     Brain     33-23-3-H10-PU ID247     est-not-ext      4.2     Brain     33-13-1-C1-PU ID248     est-not-ext      4.2     Brain     33-43-2-G12-PU ID249     est-not-ext      4.2     Brain     33-91-4-E10-PU ID250     est-not-ext      4.1     Brain     33-113-2-B8-PU ID251     est-not-ext      4       Brain     33-104-3-G9-PU ID252     est-not-ext      3.9     Brain     33-66-2-B10-PU ID253     est-not-ext      3.9     Brain     33-1-2-E9-PU ID254     est-not-ext      3.9     Brain     33-51-1-G7-PU ID255     est-not-ext      3.9     Brain     33-32-3-D11-PU ID256     est-not-ext      3.8     Brain     33-43-2-H10-PU ID257     est-not-ext      3.8     Brain     33-48-4-H11-PU ID258     est-not-ext      3.8     Brain     33-8-4-C5-PU ID259     est-not-ext      3.8     Brain     33-24-1-F5-PU ID260     est-not-ext      3.8     Brain     33-70-1-A9-PU ID261     est-not-ext      3.8     Brain     33-30-4-C4-PU ID262     est-not-ext      3.8     Brain     33-10-2-G7-PU ID263     est-not-ext      3.6     Brain     33-18-4-E12-PU ID264     est-not-ext      3.6     Brain     33-52-1-G7-PU ID265     est-not-ext      3.6     Brain     33-57-1-H10-PU ID266     est-not-ext      3.5     Brain     33-80-3-E2-PU ID267     est-not-ext      3.5     Brain     33-36-1-D3-PU ID268     ext-vrt-not-genomic 11.3    Brain     33-101-1-A2-PU ID269     ext-vrt-not-genomic 6.6     Brain     33-55-2-E8-PU ID270     ext-vrt-not-genomic 4.8     Brain     33-14-2-H3-PU BRAIN-2.LIS 080197 SEQ. ID NO.       SIGNAL PEPTIDE ID38      MLLLLGLCLGLSLC (amino acids -14 through -1 of SEQ ID NO: 271) ID39      MENGGAGTLQIRQVLLFFVLLGMSQA (amino acids -26 through -1 of SEQ ID NO: 272) ID40      MRGPEPGPQPTMEGDVLDTLEALGYKGPLLEEQALTKAAEGGLSSPEFSELCIWLGSQIK SLCNLEESITSAGRDDLESFQLEISGFLKEMACPYSVLISGDIKDRLKKKEDCLKLLLFL STELQA (amino acids -126 through -1 of SEQ ID NO: 273) ID41      MEKSWMLWNFVERWLIALASWSWALC (amino acids -26 through -1 of SEQ ID NO: 274) ID42      MQQTRTEAVAGAFSHCLGFCGMRLGLLLLARHWCIA (amino acids -36 through -1 of SEQ ID NO: 275) ID43      MEKGNAFLKNRLVVFLLLPLASGP (amino acids -24 through -1 of SEQ ID NO: 276) ID44      MFPFNQAGLPTLLMLIVFHAASMA (amino acids -24 through -1 of SEQ ID NO: 277) ID45      MTSRSLRRCSCLRVTHNKEILASTVSLGVEGYMLGGGSRINSSNLNDGEEECSPDSLLVW KKKSLLLWMSSLPSLG (amino acids -76 through -1 of SEQ ID NO: 278) ID46      MWTASAMDFRTCIASXLPALCYVQACRALMIAASVLGLPAILLLLTVLPCIXM (amino acids -53 through -1 of SEQ ID NO: 279) ID47      MGPPPTHIKYLHLNIYCNCKSTAPGIRSHSLGFALLSLSHPTCQA (amino acids -45 through -1 of SEQ ID NO: 280) ID48      MFCLLTFLAFTTLLFA (amino acids -16 through -1 of SEQ ID NO: 281) ID49      MHCGSTPGLCPCWVPFLKCLLAVLSSLFA (amino acids -29 through -1 of SEQ ID NO: 282) ID50      MNLVCSALLLLGIVSS (amino acids -16 through -1 of SEQ ID NO: 283) ID51      MSVLDDRQRDILVVQKRHSSLEAAMLIGLLAWLQT (amino acids -35 through -1 of SEQ ID NO: 284) ID52      MGVNGRRLLIICHYLPLSLC (amino acids -20 through -1 of SEQ ID NO: 285) ID53      MKLRECPALRWSQLSQHKLECLLLYLAESSG (amino acids -31 through -1 of SEQ ID NO: 286) ID54      MDPRGILKAFPKRQKIHADASSKVLAKIPRREEGEEAEEWLSSLRAHVVRTGIGRARAEL FEKQIVQHGGQLCPAQGPGVTHIVVDEGMDYERALRLLRLPQLPPXCSA (amino acids -109 through -1 of SEQ ID NO: 287) ID55      MFWKLSLSLFLVAVLVKVAEA (amino acids -21 through -1 of SEQ ID NO: 288) ID56      MAFLGLFSLLVLQSMATG (amino acids -18 through -1 of SEQ ID NO: 289) ID57      MAFLGLFSLLVLQSMATG (amino acids -18 through -1 of SEQ ID NO: 290) ID58      MSFSLNFTLPANTTSSPVTGGKETDCGPSLGLAAGIPLLVATALLVALLFTLIHR (amino acids -55 through -1 of SEQ ID NO: 291) ID59      MSTWYLALNKSYKNKDSVRIYLSLCTVSIKFTYFHDIQTNCLTTWKHSRCRFYWAFGGSI LQHSVDPLVLFLSLALLVTP (amino acids -80 through -1 of SEQ ID NO: 292) ID60      MAIGISLQLLCCIFTLVLQ (amino acids -19 through -1 of SEQ ID NO: 293) ID61      MQATSNLLNLLLLSLFAGL (amino acids -19 through -1 of SEQ ID NO: 294) ID62      MMKWKPEDLGSVPCEAFSVTLLCGWPGSHWC (amino acids -31 through -1 of SEQ ID NO: 295) ID63      MQATSNLLNLLLLSLFAGL (amino acids -19 through -1 of SEQ ID NO: 296) ID64      MASSHWNETTTSVYQYLGFQVQKIYPFHDNWNTACFVILLLFIFTVVS (amino acids -48 through -1 of SEQ ID NO: 297) ID65      MLWFSGVGALAERYCRRSPGITCCVLLLLNCSG (amino acids -33 through -1 of SEQ ID NO: 298) ID66      MLFLQMGKQSWTLIFFLNVTQLVRG (amino acids -25 through -1 of SEQ ID NO: 299) ID67      MELRXXPPGGREVQLLLGLCSPPXXSL (amino acids -27 through -1 of SEQ ID NO: 300) ID68      MLWSLLSSSGSHFG (amino acids -14 through -1 of SEQ ID NO: 301) ID69      MDISGLIPGLVSTFILLSXSDHYGRKFPMILSSVGALATSVWLCLLCYFAFP (amino acids -52 through -1 of SEQ ID NO: 302) ID70      MXVFFSKNRFEMYFSLLLFVILLITSLIFC (amino acids -30 through -1 of SEQ ID NO: 303) ID71      MPVPACWISSSLSLLASHHSVSC (amino acids -23 through -1 of SEQ ID NO: 304) ID72      MCPVFSKQLLACGSLLPGLWQ (amino acids -21 through -1 of SEQ ID NO: 305) ID73      MALTIHGERMRPDWESPWITSSQAQSLSLGGSPSSRGPLVPRGEYLASCPEGVRSHSHLL PRSLLPLSAWPPWAWH (amino acids -76 through -1 of SEQ ID NO: 306) ID74      MAARFRCGHLCVPEVPRGPASHAEGGGGRLSRKAAHQAQLCWRAGGDGRGNFNPMNFLVA GTFASSCHSPPLLWSLPPRILIASSLPTLSHP (amino acids -92 through -1 of SEQ ID NO: 307) ID75      MASTISAYKEKMKELSVLSLICSCFYTQP (amino acids -29 through -1 of SEQ ID NO: 308) ID76      MLQVYGKPVYQGHRSTLKKGPYLRFNSPSPKSRPQRPKVIERVKGTKVKSIRTQTDFYAT KPKKMDSKMKHSVPVLPHGDQQYLFSPSREMPTFSGTLEGHLIPMAILLGQTQS (amino acids -114 through -1 of SEQ ID NO: 309) ID77      MSVLEISGMIMNRVNSHIPGIGYQIFGNAVSLILGLTPFVFRLSQATDLEQLTAHSASEL YVIAFGSNEDVIVLSMVIISFVVRVSLVWIFFFLLCVAERTYKQRLLFAKLFGHLTSA (amino acids -118 through -1 of SEQ ID NO: 310) ID78      MCKGIKAGDTCEKLVGYSAVYRVCFGMACFFFIFCLLTLKINNSKSCRAHIHNGFWFFKL LLLGAMCSG (amino acids -69 through -1 of SEQ ID NO: 311) ID79      MSDSAGGRAGLRRYPKLPVWVVEDHQEVLPFIYRAIGSKHLPASNVSFLHFDSHPDLLIP VNMPADTVFDKETLFGELSIENWIMPAVYAGHFSHVVWFHPTWA (amino acids -104 through -1 of SEQ ID NO: 312) ID80      MSSCRGQKVAGGLRVVSPFPLCQPAGEPSRGKMRSSCVLLTALVALA (amino acids -47 through -1 of SEQ ID NO: 313) ID81      MIIPFKIKNLGGRVLLSGREMFPASVRAPDLAVALSLLPAWT (amino acids -42 through -1 of SEQ ID NO: 314) ID82      MVCSAPRKIVVRAFITIIFIYYAIKKRANEPAAYLMLKPEALILLLLAQKGPS (amino acids -53 through -1 of SEQ ID NO: 315) ID83      MTESSMKKLASTLLDAITDKDPLVQEQVCSALCSLGEVRP (amino acids -40 through -1 of SEQ ID NO: 316) ID84      MQETDCNKRWGRGLGGLWSETGRRFHCKSFVFLFHCTSGLSSC (amino acids -43 through -1 of SEQ ID NO: 317) ID85      MLLEVPWLSSTVSCAQG (amino acids -17 through -1 of SEQ ID NO: 318) ID86      MSGGRMQARCSQQSTWSPAFLAVAGPGWA (amino acids -29 through -1 of SEQ ID NO: 319) ID87      MLQMLWHFLASFFPRAGC (amino acids -18 through -1 of SEQ ID NO: 320) ID88      MYSHPVSSLVCLLAMGKGLG (amino acids -20 through -1 of SEQ ID NO: 321) ID89      MGRKEEDDCSXWKKQTTNIRKTFIFMEVLGSGAFS (amino acids -35 through -1 of SEQ ID NO: 322) ID90      MMIAVFGNANDRNVLTLLPNQSLFSLARA (amino acids -29 through -1 of SEQ ID NO: 323) ID91      MFFELPLVVTAWFFGMCRS (amino acids -19 through -1 of SEQ ID NO: 324) ID92      MNHNIIICVMYIVPFLMTKCLYFCHSCKRGSFLLIVANVHFSQT (amino acids -44 through -1 of SEQ ID NO: 325) ID93      MSCGSAASLTGLCXCCLQALG (amino acids -21 through -1 of SEQ ID NO: 326) ID94      MQAVDNLTSAPGNTSLCTRDYKITQVLFPLLYTVLFFVGLITNGLA (amino acids -46 through -1 of SEQ ID NO: 327) ID95      MAAAMXLLCSSCCSWGPAAG (amino acids -20 through -1 of SEQ ID NO: 328) ID96      MDFIKDQSLSHRSVVKVLSLRKAQA (amino acids -25 through -1 of SEQ ID NO: 329) ID97      MTRPFWASCSTWATSRISCAFSLASSTA (amino acids -28 through -1 of SEQ ID NO: 330) ID98      MKSCAVSLTTAAVAFG (amino acids -16 through -1 of SEQ ID NO: 331) ID99      MSIHECACLSLSLICLRMSLS (amino acids -21 through -1 of SEQ ID NO: 332) ID100     MLSGLSFLSVFSLWC (amino acids -15 through -1 of SEQ ID NO: 333) ID101     MGLKDKSQAPASGLGVLRGQRSGSFISMPAPASGQXPEESRSPAPPVASRSQNRGYRPWH GPLWVHQSVRFGLYSILHFPFWVHG (amino acids -65 through -1 of SEQ ID NO: 334) ID102     MSDQIKFIMDSLNKEPFRKNYNLITFDSLEPMQLLQVLSDVLA (amino acids -43 through -1 of SEQ ID NO: 335) ID103     MSPSCLHPDLWSMCLEVPSFTATDSVNCGCCLELATEPARNIRSTTRASLLRCSSFTSTR NSTGISALPPAAPMAWPFSASLSTLPVPLTHSSVASLTATPSLA (amino acids -104 through -1 of SEQ ID NO: 336) ID104     MDLSFHLLLDPSSTQS (amino acids -16 through -1 of SEQ ID NO: 337) ID105     MPHFLDWFVXVYLVISVLILVGFGAC (amino acids -26 through -1 of SEQ ID NO: 338) TD106     MSKLKVIPEKSLTNNSRIVGLLAQLEKINA (amino acids -30 through -1 of SEQ ID NO: 339) ID107     MMSASRLAGTLIPAMAFLSCVRP (amino acids -23 through -1 of SEQ ID NO: 340) ID108     MVDGTQLRGLTRMYQVPLXLDRDETLVRLRFTMVALVTVCCXLVAFLFC (amino acids -49 through -1 of SEQ ID NO: 341) ID109     MKQNFLVLNSVWYLISMLQMLAVIIT (amino acids -26 through -1 of SEQ ID NO: 342) ID110     MECQNSSLKKCLLVEKSLVKASYLIAFQTAASKKPFSIAEELIKPYLVEMCLEVLGSSA (amino acids -59 through -1 of SEQ ID NO: 343) ID111     MHSSIKTKGSVMWLVALLEMCVC (amino acids -23 through -1 of SEQ ID NO: 344) ID112     MTVLPLEAISSLSSFVLG (amino acids -18 through -1 of SEQ ID NO: 345) ID113     MGTASRSNIARHLQTNLILFCVGAVGACTL (amino acids -30 through -1 of SEQ ID NO: 346) ID114     MNSSKEEMRELAALFYSVVVSTVSG (amino acids -25 through -1 of SEQ ID NO: 347) ID115     MSQDGGXGELKHMVMSFRVSELQVLLGFAGRNKSGRKHELLAKALHLLKSSC (amino acids -52 through -1 of SEQ ID NO: 348) ID116     MPCISLLGLLYNFVQVLCYLSIFCLGVLF (amino acids -29 through -1 of SEQ ID NO: 349) ID117     MKIAVLFCFFLLIIF (amino acids -15 through -1 of SEQ ID NO: 350) ID118     MAKQKPHVLGSRVMPASCVSERRRKPSFQVSTWSSASLRGSWQ (amino acids -43 through -1 of SEQ ID NO: 351) ID119     MGFLYLKSVFDVSLG (amino acids -15 through -1 of SEQ ID NO: 352) ID120     MRMGPGRKRDFSPVPWSQYFESMEDVEVENETGKDTFRVYKSGSEGPVLLLLHGGGHSAL S (amino acids -61 through -1 of SEQ ID NO: 353) ID121     MIFLLYLLPSSEE (amino acids -13 through -1 of SEQ ID NO: 354) ID122     MRMGPGRKRDFSPVPWSQYFESMEDVEVENETGKDTFRVYKSGSEGPVLLLLHGGGHSAL S (amino acids -61 through -1 of SEQ ID NO: 355) ID123     MLSLLNLISILASIPS (amino acids -16 through -1 of SEQ ID NO: 356) ID124     MGTTSNMVTTIHLMLLWPVHPLLVG (amino acids -25 through -1 of SEQ ID NO: 357) ID125     MGDPERPEAAGLDQDERSSSDTNESEIKSNEEPLLRKSSRRFVTFPIQYPDIWKMYKQAQ ASFWTAEEVDLSKDLPHWNKLKADEKYFISHILAFFAASDG (amino acids -101 through -1 of SEQ ID NO: 358) ID126     MDAGLFSLLPHPPCVG (amino acids -16 through -1 of SEQ ID NO: 359) ID127     MLITLTYLIQGESA (amino acids -14 through -1 of SEQ ID NO: 360) ID128     MYTGFRIEATLLTRVQCLCAIPFAFS (amino acids -26 through -1 of SEQ ID NO: 361) ID129     MYKQAQASFWTAEEVDLSKDLPHWNKLKADEKYFISHILAFFAASDG (amino acids -47 through -1 of SEQ ID NO: 362) ID130     MLLHLCSVKNLYQNRFLGLAAMASPSRN (amino acids -28 through -1 of SEQ ID NO: 363) ID131     MPCPTWTCLKSFPSPTSS (amino acids -18 through -1 of SEQ ID NO: 364) ID132     MEDLFSPSIXPPAPNISVPILLGWGLNLTLGQG (amino acids -33 through -1 of SEQ ID NO: 365) ID133     MAETKDAAQMLVTFKDVAVTFTREEWRQLDLAQRTLYREVMLETCGLLVSLG (amino acids -52 through -1 of SEQ ID NO: 366) ID134     MLILSQNIAQLEA (amino acids -13 through -1 of SEQ ID NO: 367) ID135     MLLGASAQGLWAHSWTCSCSA (amino acids -21 through -1 of SEQ ID NO: 368) ID136     MAAPLELSCWGGGWG (amino acids -15 through -1 of SEQ ID NO: 369) ID137     MSXVGIDLGFLNCYIAVARS (amino acids -20 through -1 of SEQ ID NO: 370) ID138     MEYSTKXFVVFSTMFTASSP (amino acids -19 through -1 of SEQ ID NO: 371) ID139     MPMASSPPPSPHPQEPAPLLPSLPRLSLPFRLPWASTATA (amino acids -40 through -1 of SEQ ID NO: 372) ID140     MQHVXGHXPDPIAIMYVCPPCGHTTWALGLKFLSSSSQ (amino acids -38 through -1 of SEQ ID NO: 373) ID141     MGWEMTCIKSFFWARSHAGFLKCLLLSSLQ (amino acids -30 through -1 of SEQ ID NO: 374) ID142     MVFGGVCPSVTSIIAESLQGWNLVQLSFAATTPVLA (amino acids -36 through -1 of SEQ ID NO: 375) ID143     MHFITWSLLFLYQCSL (amino acids -16 through -1 of SEQ ID NO: 376) ID144     MSGASPIERTPMEEAPSSCPTSSCWFSVASPSSSWS (amino acids -36 through -1 of SEQ ID NO: 377) ID145     MEWAGKQRDFQVRAAPGWDHLASFPGPSLRLFSGSQA (amino acids -37 through -1 of SEQ ID NO: 378) ID146     MIAFFDEDNPRKRRSYSFTQSAGILCQETTYSTPHTKLEKAKSPTADAKVVSLSLQTSSA (amino acids -60 through -1 of SEQ ID NO: 379) ID147     MGKSIXSLCSVXLKARLKGXLEAVHLCLRAQKRRTALFCTLPCPVERG (amino acids -48 through -1 of SEQ ID NO: 380) ID148     MCLHMTLFRVPFTFS (amino acids -15 through -1 of SEQ ID NO: 381) ID149     MLNILKTLTSAALP (amino acids -14 through -1 of SEQ ID NO: 382) ID150     MRARVWPRSHGIPVPSFLSKSSLSHTPSPLLCLYHPPVYT (amino acids -40 through -1 of SEQ ID NO: 383) ID151     MWNAVAIICNGSWCQTXSTSGLESLCLSLLIPGPKP (amino acids -36 through -1 of SEQ ID NO: 384) ID152     MLRLGLFKISWARC (amino acids -14 through -1 of SEQ ID NO: 385) ID153     MPFAEDKTYKYICRNFSNFCNVDVVEILPYLPCLTA (amino acids -36 through -1 of SEQ ID NO: 386) ID154     MPGSSGLRFICKSRNHPQFGSFSGTDSLSFLPPCPC (amino acids -36 through -1 of SEQ ID NO: 387) ID155     MDVTGDEEEEIKQEINMLKKYSHHRNIATYYGAFIKKNPPGMDDQLXLVMEFCGAGS (amino acids -57 through -1 of SEQ ID NO: 388) ID156     MIFGLYFVLAVKLFLVFLLNICKG (amino acids -24 through -1 of SEQ ID NO: 389) ID157     MRKKRVEELIVFPGEVTSFSSIKCSSWISSLASG (amino acids -34 through -1 of SEQ ID NO: 390) ID158     MPSSSLAELCLMQQDACLFSXFLAVSRH (amino acids -26 through -1 of SEQ ID NO: 391) ID159     MDLWSCLFPVMLMEPSKGLEDSEWKMALQMRMQLPCLVLG (amino acids -40 through -1 of SEQ ID NO: 392) ID160     MSGKGKCRPIALRRAVPLPTTSTLTSA (amino acids -27 through -1 of SEQ ID NO: 393) ID161     MTPKAIQKSSGLFCPSQA (amino acids -18 through -1 of SEQ ID NO: 394) ID162     MPDQFDQAVVLNQLRYSGMLETVRIRKAGYAVRRPFQDFYKRYKVLMRNLALPEDVRGKC TSLLQLYDASNS (amino acids -72 through -1 of SEQ ID NO: 395) ID163     MCLVSFFLELNVLQQ (amino acids -15 through -1 of SEQ ID NO: 396) ID164     MRSLACLTPCGHA (amino acids -13 through -1 of SEQ ID NO: 397) ID165     MHLLSNWANPASS (amino acids -13 through -1 of SEQ ID NO: 398) ID166     MWSGKWALVSPFAMLHSVWRLIPA (amino acids -24 through -1 of SEQ ID NO: 399) ID167     MKVHMHTKFCLICLLTFIFH (amino acids -20 through -1 of SEQ ID NO: 400) ID168     MGRRHWVLTHSALSLFYTADTSHG (amino acids -24 through -1 of SEQ ID NO: 401) ID169     MAVFVVLLALVAGVLG (amino acids -16 through -1 of SEQ ID NO: 402) ID170     MAPLLLQLAVLGAALA (amino acids -16 through -1 of SEQ ID NO: 403) ID171     MPVTVTRTTITTTTTSSSGLGSPMIVGSPRALTQPLGLLRLLQLVSTCVA (amino acids -50 through -1 of SEQ ID NO: 404) ID172     MELVLVFLCSLLAPMVLA (amino acids -18 through -1 of SEQ ID NO: 405) ID173     MGPIWSSYYGNCRSLLFVMDASDPTQLSASCVQLLGLLSAEQLAEA (amino acids -46 through -1 of SEQ ID NO: 406) ID174     MSGGRAPAVLLGGVASLLLSFVWMPALLPVASRLLLLPRVLLTMASG (amino acids -47 through -1 of SEQ ID NO: 407) ID175     MALSCTLNRYLLLMAQEHLEFRLPEIXSLLLLFGGQFASS (amino acids -40 through -1 of SEQ ID NO: 408) ID176     MAARGVIAPVGESLRYAEYLQPSAKRPDADVDQQRLVRSLIAVGLGVAALAFA (amino acids -53 through -1 of SEQ ID NO: 409) ID177     MRMCAGSIYKSATQAVLGXLFLGGLCRG (amino acids -28 through -1 of SEQ ID NO: 410) ID178     MAERRRPLSPIPSXRRPSEPSRPRPAAAGXRSLPRPGDEELQLPCAVHDLIFWRDVKKTG FVFGTTLIMLLSWQLSVS (amino acids -78 through -1 of SEQ ID NO: 411) ID179     MAAPVLLRVSVPRWERVARYAVCAAGILLSIYAYHVEREKERDPEHRALCDLGPWVKCSA ALASRWGRGFGLLGSIFGKDGVLNQPNSVFGLIFYILQLLLGMTASAVA (amino acids -109 through -1 of SEQ ID NO: 412) ID180     MSFLQDPSFFTMGMWSIGAGALGAAALALLLANT (amino acids -34 through -1 of SEQ ID NO: 413) ID181     MASLLCCGPKLAACGIVLSAWGVIMLIMLGIFFNVHS (amino acids -37 through -1 of SEQ ID NO: 414) ID182     MILPYRMXSLFLHAVSSSFT (amino acids -20 through -1 of SEQ ID NO: 415) ID183     MATLVELPDSVLLEIFSYLPVRDRIRISRVCHRWKRLVDDRWLWRHVDLTLYTVRALAGR AWA (amino acids -63 through -1 of SEQ ID NO: 416) ID184     MKNACIVLPPTPPPSLQPSASLLAPNRFLFSCFCFLSHKFG (amino acids -41 through -1 of SEQ ID NO: 417) ID185     MAFGLQMFIQRKFPYPLQWSLLVAVVAG (amino acids -28 through -1 of SEQ ID NO: 418) ID186     MYCKILVLMLHTELIRTDYSSVDQLLLNYPAEEGLGRERSLLWTPLLSPGSLR (amino acids -53 through -1 of SEQ ID NO: 419) ID187     MAVSHSVKERTISENSLIILLQGLQG (amino acids -26 through -1 of SEQ ID NO: 420) ID188     MESGGRPSLCQFILLGTTSVVTA (amino acids -23 through -1 of SEQ ID NO: 421) ID189     MAALDLRAXWIRWSCSCLGXLXGAGGETNGVERPGGGGLALARQGSLRDGRQVGRAPAVC FPHGAPGLPPRQRXXGGXPEVQGGESWCPRPRGGGASRTGLRRRKGFTKTPEPESSEAPQ DPLNWFGILVPHSLRQAQA (amino acids -139 through -1 of SEQ ID NO: 422) ID190     MAFLPSPAWWISLLPSLLSIC (amino acids -21 through -1 of SEQ ID NO: 423) ID191     MEPKVAELKQKIEDTLCPFGFEVYPFQVAWYNELLPPAFHLPLPGPTLA (amino acids -49 through -1 of SEQ ID NO: 424) ID192     MLVLRSGLTKALA (amino acids -13 through -1 of SEQ ID NO: 425) ID193     MSGGHLADLTLLFVLLLFSLLPA (amino acids -23 through -1 of SEQ ID NO: 426) ID194     MKPSRTPARLWMLPQQQAGAVVVAAPTERHPTHHMAGWLLGALTLLGLVTS (amino acids -51 through -1 of SEQ ID NO: 427) ID195     MGESIPLAAPVPVEQAVLETFFSHLGIFSYDKAKDNVEKEREANKSAGGSWLSLLAALAH LAAA (amino acids -64 through -1 of SEQ ID NO: 428) ID196     MQMSYAIRCAFYQLLLAALMLVAMLQLLYLSLLSGLHG (amino acids -38 through -1 of SEQ ID NO: 429) ID197     MLRAELKIAVVLFAFHLLLSFILG (amino acids -24 through -1 of SEQ ID NO: 430) ID198     MNHQQTLIGRLLCDLHGLSLSPPVANNVQALFRMLTPEAYSCLLILLLRTFLCSA (amino acids -55 through -1 of SEQ ID NO: 431) ID199     MIITAVVSISVTIFCFQTKVDFTSCTGLFCVLGIVLLVTG (amino acids -40 through -1 of SEQ ID NO: 432) ID200     MAAGGRMEDGSLDITQSIEDDPLLDAQLLPHHSLQAHFRPRFHPLPTVIIVNLLWFIHLV FVVLX (amino acids -65 through -1 of SEQ ID NO: 433) ID201     MSPGCMLLFVFGFVGG (amino acids -16 through -1 of SEQ ID NO: 434) ID202     MKLLLGIALLAYVAS (amino acids -15 through -1 of SEQ ID NO: 435) ID203     MDILVPLLQLLVLLLTLPLHLHA (amino acids -23 through -1 of SEQ ID NO: 436) ID204     MEAASPSNSTGVERXADLMDADSLLLSLELASGSG (amino acids -35 through -1 of SEQ ID NO: 437) ID205     MIRQERSTSYQEAVRPALPSSKPCLLTSPAVLVKLLSSSASTS (amino acids -43 through -1 of SEQ ID NO: 438) ID206     MKLIDYGLSGYQEESAEVKAMDFITSTAILPLLFGCLGVFG (amino acids -41 through '1 of SEQ ID NO: 439) ID207     MRCLTTPMLLRALAQAARA (amino acids -19 through -1 of SEQ ID NO: 440) ID208     MSRFLNVLRSWLVMVSIIAMGNTLQSFRDHTFLYEKLYTGKPNLVNGLQARTFGIWTLLS SVIRCLC (amino acids -67 through -1 of SEQ ID NO: 441) ID209     MIFLTLSLDSRVSA (amino acids -14 through -1 of SEQ ID NO: 442) ID210     MQCFSFIKTMMILFNLLIFLCGAALLXVG (amino acids -29 through -1 of SEQ ID NO: 443) ID211     MAEAALEAVRXSYENSRPLQGSSACLLLCPTWTNP (amino acids -35 through -1 of SEQ ID NO: 444) ID212     MATASPSVFLLMVNGQVES (amino acids -19 through -1 of SEQ ID NO: 445) ID213     MAGIKALISLSFGGAIGLMFLMLGCALP (amino acids -28 through -1 of SEQ ID NO: 446) ID214     MIGDILLFGTLLMNAGA (amino acids -17 through -1 of SEQ ID NO: 447) ID215     MKTMILTLSLFGSCIS (amino acids -16 through -1 of SEQ ID NO: 448) ID216     MDWRVPPSXXDPGHQDIPLPVTXXFISVSVLSSLGIVLA (amino acids -39 through -1 of SEQ ID NO: 449) ID217     MAAAALPAWLSLQSRA (amino acids -16 through -1 of SEQ ID NO: 450) ID218     MAMVSAMSWVLYLWISACAMLLCHG (amino acids -25 through -1 of SEQ ID NO: 451) ID219     MGKEWGWQEMENGGAAPAWGAGPFVHPAPPPVEKTLSWGCGFGLHSGFGGSGGGVGLCRL LCLVRLFCC (amino acids -69 through -1 of SEQ ID NO: 452) ID220     MLQTSNYSLVLSLQFLLLSYD (amino acids -21 through -1 of SEQ ID NO: 453) ID221     MWFEILPGLSVMGVCLLIPGLATA (amino acids -24 through -1 of SEQ ID NO: 454) ID222     MRPSPLSGILADPLXLFPFSEG (amino acids -22 through -1 of SEQ ID NO: 455) ID223     MRESLSXRSWHLPASLMMAQXFIPAVA (amino acids -27 through -1 of SEQ ID NO: 456) ID224     MSGVVPTAPEQPAXEMENQTKPPDPRPDAPPEYSSHXFTRTPWKQLSLHLLATPACYG (amino acids -58 through -1 of SEQ ID NO: 457) ID225     MWRYQFGWGVITRGPREIPFPPSLLASESLLPPLPDLVLTCTSLGFVTRVWMSLNLNELS LYSRTWVFTCLVFFCFG (amino acids -77 through -1 of SEQ ID NO: 458) ID226     MVKLLVAKILCMVGVFFFMLLGSLLPVKI (amino acids -29 through -1 of SEQ ID NO: 459) ID227     MPVSIMCLIGLKANASS (amino acids -17 through -1 of SEQ ID NO: 460) ID228     MKVILLYLVLEKLVSRA (amino acids -17 through -1 of SEQ ID NO: 461) ID229     MAVTLSLLLGGRVCXPSLA (amino acids -19 through -1 of SEQ ID NO: 462) ID230     MLNQTSGRTSLLPELGVVTPAQG (amino acids -23 through -1 of SEQ ID NO: 463) ID231     MTSENLVQTAPKKKKNKGKKGLEPSQSTAAKVPKKAKTWIPEVHDQKADVSAWKDLFVPR PVLRALSFLGFSAPTPIQA (amino acids -79 through -1 of SEQ ID NO: 464) ID232     MAAFGRQXXXWHXLIPLTWACMA (amino acids -23 through -1 of SEQ ID NO: 465) ID233     MSLTSSPKKRRSICFDRFLMFQSQSGPSSLGESYRTGVGFLIPEGWFLSGCPHGSSA (amino acids -57 through -1 of SEQ ID NO: 466) ID234     MGELGNRSRCILFLSENPCLSESIFQSLXFCLSPPPSPS (amino acids -39 through -1 of SEQ ID NO: 467) ID235     MAELGLNEHHQNEVINYMRFARSKRGLRLKTVDSCFQDLKESRLVEDTFTIDEVSEVLNG LQAVVHSEVESELINTAYTNVLLLRQXFAQAEK (amino acids -93 through -1 of SEQ ID NO: 468) ID236     MVTLPSGTWAFSCPYLALVDGGMLGSAREDAHASVVSWAVGLLYAVAQG (amino acids -49 through -1 of SEQ ID NO: 469) ID237     MASASARGNQDKDAHFPPPSKQSLLFCPKXXLHIHRAEISKIMRECQEESFWKRALPFSL VSMLVTQG (amino acids -68 through -1 of SEQ ID NO: 470) ID238     MLLMKSILLKVVCVLCIYLKFKLMALIYVPDKNNTNNNILRYNHNEISIGISVQCHFILS LCVLCIVLT (amino acids -69 through -1 of SEQ ID NO: 471) ID239     MAQRLLLRRFLASVIS (amino acids -16 through -1 of SEQ ID NO: 472) ID240     MAASKVKQDMPPXGGYGPIDYKRNLPRRGLSGYSMLAIGIGTLIYGHWSIMKWNRERRRL QIEDFEARIALLPLLQA (amino acids -77 through -1 of SEQ ID NO: 473) ID241     MRHLVTEELFPCSNLEDVVEDNSHSYFTLRITMACKGVPSTLLSLAILSHISTP (amino acids -54 through -1 of SEQ ID NO: 474) ID242     MSAEVKVTGQNQEQFLLLAKSAKGAALATLIHQVLEAPGVYVFGELLDMPNVRELAESXF ASTFRLLXVFAYGTYA (amino acids -76 through -1 of SEQ ID NO: 475) ID243     MLLSIGMLMLSATQVXTILXVQLFAFLNLLPVEA (amino acids -34 through -1 of SEQ ID NO: 476) ID244     MGWEVVSLSYCGVSWG (amino acids -16 through -1 of SEQ ID NO: 477) ID245     MRECISVHVGQAGVQIGNACWELFCLEHGIQA (amino acids -32 through -1 of SEQ ID NO: 478) ID246     MAGPLQGGGARALDLLRGLPRVSLA (amino acids -25 through -1 of SEQ ID NO: 479) ID247     MPAGVPMSTYLKMFAASXLAMCAGA (amino acids -25 through -1 of SEQ ID NO: 480) ID248     MAVQCVRLARRSLPALALSLRASP (amino acids -24 through -1 of SEQ ID NO: 481) ID249     MFSIISRSRACSMYFKENAKPSQLRLMHHYLSTPTSA (amino acids -37 through -1 of SEQ ID NO: 482) ID250     MKRLLPATSLAGPVLS (amino acids -16 through -1 of SEQ ID NO: 483) ID251     MLIITNPWPKYFDAAGRLTPEFSQRLTNKIRELLQQMERGLKSADXXDGTGYTGWAGIAV LYLHLYDVFG (amino acids -70 through -1 of SEQ ID NO: 494) ID252     MCATETVRAWLAQGSSSAGWG (amino acids -21 through -1 of SEQ ID NO: 485) ID253     MLLLATHPETVGQVTLRVXPVSLEVSIQMCAAAAAAFCLKXXGANT (amino acids -46 through -1 of SEQ ID NO: 486) ID254     MAASSATPAPXXSQRCGADAGSAARIVFRWGRGRRGARSPEGSGHHGRANSGLGGAQLQG GAXG (amino acids -64 through -1 of SEQ ID NO: 487) ID255     MLRRPLAGLAAAALGRA (amino acids -17 through -1 of SEQ ID NO: 488) ID256     MDRPGFVAALVAGGVAG (amino acids -17 through -1 of SEQ ID NO: 489) ID257     MIVWFEGISMDLLTLLFQRRS (amino acids -21 through -1 of SEQ ID NO: 490) ID258     MRTFVHFALDALMFPARRRA (amino acids -20 through -1 of SEQ ID NO: 491) ID259     MAAPPQLRALLVVVNALLRKRRYHAALAVLKGFRNGAVYGAKIRAPHALVMTFLFRNGSL Q (amino acids -61 through -1 of SEQ ID NO: 492) ID260     MPVDLGXALGLLPSLAKA (amino acids -18 through -1 of SEQ ID NO: 493) ID261     MNLFIMYMAGNTISIFPTMMVCMMAWRPIQALMAISATFKMLESSSQKFLQGLVYLIGNL MGLALAVYKCQS (amino acids -72 through -1 of SEQ ID NO: 494) ID262     MISLTDTQKIGMGLTGFGVFFLFFGMILFFDKALLAIGNVLFVAGLAFVIG (amino acids -51 through -1 of SEQ ID NO: 495) ID263     MAASGAPRILVDLLKLXVAPLAVFQMLKSMCAG (amino acids -33 through -1 of SEQ ID NO: 496) ID264     MASVSSATFSGHGARSLLQFLRLVGQ (amino acids -26 through -1 of SEQ ID NO: 497) ID265     MWYLAVLLVLFTLNIL (amino acids -16 through -1 of SEQ ID NO: 498) ID266     MFTFGRLFQIITVVTCLQFIQDCCIHSRQINSLLEXSSLSRC (amino acids -42 through -1 of SEQ ID NO: 499) ID267     MIQDRDRCAQAAAVAAVGNLEPRGTPGPEDEAFCLPGCVGTLCQLDWWIWG (amino acids -51 through -1 of SEQ ID NO: 500) ID268     MKIIFPILSNPVFRRTVKLLLCLLWIGYSQG (amino acids -31 through -1 of SEQ ID NO: 501) ID269     MVSRMVSTMLSGLLFWLASGWTPAFA (amino acids -26 through -1 of SEQ ID NO: 502) ID270     MTATLAAAADIATMVSGSSGLAXA (amino acids -24 through -1 of SEQ ID NO: 503)

## Claims

1. A purified polynucleotide encoding a polypeptide comprising: ID NO: 271 or a fragment of SEQ ID NO: 271 which comprises amino acids -14 to -1; and the polypeptide encoded by the gene corresponding to SEQ ID NO: 38, said second nucleic acid being fused in frame to the nucleic acid sequence of (a).

2. The purified polynucleotide of claim 1 wherein the nucleic acid sequence of (a) is a nucleic acid sequence encoding amino acids -14 to -1 of SEQ ID NO: 271.

3. A purified polynucleotide encoding a polypeptide comprising: ID NO: 273 or a fragment of SEQ ID NO: 273 which comprises amino acids -126 to -1; and the polypeptide encoded by the gene corresponding to SEQ ID NO: 40, said second nucleic acid being fused in frame to the nucleic acid sequence of (a).

4. The purified polynucleotide of claim 3 wherein the nucleic acid sequence of (a) is a nucleic acid sequence encoding amino acids -126 to -1 of SEQ ID NO: 273.

5. A purified polynucleotide encoding a polypeptide comprising: ID NO: 276 or a fragment of SEQ ID NO: 276 which comprises amino acids -24 to -1; and the polypeptide encoded by the gene corresponding to SEQ ID NO: 43, said second nucleic acid being fused in frame to the nucleic acid sequence of (a).

6. The purified polynucleotide of claim 5 wherein the nucleic acid sequence of (a) is a nucleic acid sequence encoding amino acids -24 to -1 of SEQ ID NO: 276.

7. A purified polynucleotide encoding a polypeptide comprising: ID NO: 283 or a fragment of SEQ ID NO: 283 which comprises amino acids -16 to -1; and the polypeptide encoded by the gene corresponding to SEQ ID NO: 50, said second nucleic acid being fused in frame to the nucleic acid sequence of (a).

8. The purified polynucleotide of claim 7, wherein the nucleic acid sequence of (a) is a nucleic acid sequence encoding amino acids -16 to -1 of SEQ ID NO: 283.

9. A purified polynucleotide encoding a polypeptide comprising: ID NO: 292 or a fragment of SEQ ID NO: 292 which comprises amino acids -80 to -1; and the polypeptide encoded by the gene corresponding to SEQ ID NO: 59, said second nucleic acid being fused in frame to the nucleic acid sequence of (a).

10. The purified polynucleotide of claim 9 wherein the nucleic acid sequence of (a) is a nucleic acid sequence encoding amino acids -80 to -1 of SEQ ID NO: 292.

11. A purified polynucleotide encoding a polypeptide comprising: ID NO: 305 or a fragment of SEQ ID NO: 305 which comprises amino acids -21 to -1; and the polypeptide encoded by the gene corresponding to SEQ ID NO: 72, said second nucleic acid being fused in frame to the nucleic acid sequence of (a).

12. The purified polynucleotide of claim 11 wherein the nucleic acid sequence of (a) is a nucleic acid sequence encoding amino acids -21 to -1 of SEQ ID NO: 305.

13. A purified polynucleotide encoding a polypeptide comprising: ID NO: 318 or a fragment of SEQ ID NO: 318 which comprises amino acids -17 to -1; and the polypeptide encoded by the gene corresponding to SEQ ID NO: 85, said second nucleic acid being fused in frame to the nucleic acid sequence of (a).

14. The purified polynucleotide of claim 13 wherein the nucleic acid sequence of (a) is a nucleic acid sequence encoding amino acids -17 to -1 of SEQ ID NO: 318.

15. A purified polynucleotide encoding a polypeptide comprising: ID NO: 337 or a fragment of SEQ ID NO: 337 which comprises amino acids -16 to -1; and the polypeptide encoded by the gene corresponding to SEQ ID NO: 104, said second nucleic acid being fused in frame to the nucleic acid sequence of (a).

16. The purified polynucleotide of claim 15 wherein the nucleic acid sequence of (a) is a nucleic acid sequence encoding amino acids -16 to -1 of SEQ ID NO: 337.

17. A purified polynucleotide encoding a polypeptide comprising: ID NO: 364 or a fragment of SEQ ID NO: 364 which comprises amino acids -18 to -1; and the polypeptide encoded by the gene corresponding to SEQ ID NO: 131, said second nucleic acid being fused in frame to the nucleic acid sequence of (a).

18. The purified polynucleotide of claim 17 wherein the nucleic acid sequence of (a) is a nucleic acid sequence encoding amino acids -18 to -1 of SEQ ID NO: 364.

19. A purified polynucleotide encoding a polypeptide comprising: ID NO: 399 or a fragment of SEQ ID NO: 399 which comprises amino acids -24 to -1; and the polypeptide encoded by the gene corresponding to SEQ ID NO: 166, said second nucleic acid being fused in frame to the nucleic acid sequence of (a).

20. The purified polynucleotide of claim 19 wherein the nucleic acid sequence of (a) is a nucleic acid sequence encoding amino acids -24 to -1 of SEQ ID NO: 399.